<SEC-DOCUMENT>0001615219-21-000093.txt : 20211104
<SEC-HEADER>0001615219-21-000093.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104164306
ACCESSION NUMBER:		0001615219-21-000093
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		211380566

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>flks-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:933be885-fec0-4346-88e3-96fdb95628e8,g:3a038917-b4df-486f-8fdf-f41d10c2cf87,d:3735967cc9cb41008b6e1b6e77b8d64e--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:flks="http://www.flex-pharma.com/20210930" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>flks-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF80LTEtMS0xLTE_4025973f-e0da-4325-a644-3a27c4ec2da0">0001615219</ix:nonNumeric><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF81LTEtMS0xLTE_c0a6294f-a111-4cfa-9222-04e9befd5f99">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF84LTEtMS0xLTE_16f24709-68dc-4801-b7bc-0716cc878d56">2021</ix:nonNumeric><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF85LTEtMS0xLTE_9a429455-fa23-46e9-ac67-bd8b3fc0b1c1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF8xMC0xLTEtMS0x_e852ef06-8d37-4dca-a1e2-9f7f6563e92b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_364a1241-d7a9-4e7c-98c2-25b02fba3fdb">http://fasb.org/us-gaap/2021-01-31#GrantMember</ix:nonNumeric><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_407c59a9-1a55-41e6-8ea4-62a5380e3581">http://fasb.org/us-gaap/2021-01-31#GrantMember</ix:nonNumeric><ix:nonNumeric contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_54ac70d5-5fa9-4988-b93c-d343cc9752bd">http://fasb.org/us-gaap/2021-01-31#GrantMember</ix:nonNumeric><ix:nonNumeric contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_7f901995-a856-4b16-b7c1-84ec51666bd0">http://fasb.org/us-gaap/2021-01-31#GrantMember</ix:nonNumeric><ix:nonNumeric contextRef="i7e25a08a7b8243698baceb726d714709_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI0NA_14cf129a-350a-4324-b668-9e3a5073d911">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="flks-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ieb85bd86da7243f5aa57922b11eff1e9_I20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc576fa0a40d46a09cde34e4add1d831_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d20dc51e5fe4ea99139098eb7f83411_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91ac971072f1418a89a4376f024276cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0024786ef67540f7ac2c0db72574744a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d2ac1c7ee44444cb491532bc41f23f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18254c89c4564a21a71a20589bc53179_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb03da10c8aa48f08dc0254a264659dd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdadb645f0404a4d95746cc2ba5ff395_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72958b2722c44979991d7838b0e41c5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879f0c3963444b66916504729b1e3d17_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf5af0205ac648a5a2afbfdf5f6e3274_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d5e105e076d46699489e811c97d2199_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ef3be74ccc4ed780f60aaea7b84cd6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id883671275ee47f29805bc8d421e6c30_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b959c132384760adfcad6637c903e0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cb73c0bc694074878b0432e6f254cf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6b4d878dea4f218fc2f35d89ffb0c3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4078d2163404318a25c07dba8baec76_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e80edb414d4a79ae54153572f0e6eb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56344979fde94e63aa913f4a5e8723d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a378992dd7b49d9a157ab15eab9f3ed_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i494e149e02d3480995871fe3ca7e8497_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i008da512d397437a9cba8e4395f8379c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad60589c9a6a4dd7b40672b0faa48107_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i103946fb0b22442b9d8a5266ee347645_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b7745f01faa466f876bdd522070c58d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db0f3b8635a4838b6ac72d40a6ecc06_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f8c31eb4f14036be3bc5ad4af88834_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11266e19063543088c03f4b86e4beca8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i177696ed3c044d74afa4d317d038fb4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecdeccc9f1f44bff859e3f3fcc5cbdb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f542a0e98d4604a00099497a1f1804_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib552ff1dbb674586b246269a7598461d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4246855be8574284a65e3d4eba29df11_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b30b72e16c34ba3a2db567ae552cea6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88143d34f36d418e965adf2e6fd1ec52_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84baeb8b40334043b2e851612655fc30_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58585740081444529b94b6645f75a15f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bdd980a35274061bc26ccaccf9623a7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic29d1e6d22804c40b7c53ce44db787ec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d02fc8d1b514c81839144c985474d09_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c23cfd88914796ae8bcfbb6182d920_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb593881ffd4b39a7166b73ba48fad3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f8c9fa71354fb58629cf1202290260_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia256a575bccf481fa61288d8f7b235d1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4486746847a436886263055e53f87f8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2408113d2df34fd08dad1aad2b45fc4d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf11851802384bfcb427ad4bdb517f9d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80c8dcc9ab0b4b0ebdfe09ad48ecb9fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adff28f56e841a08e131253d1872d50_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64588aad3ec4f21aae0e0cd7fb960cf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c667283927432092625abe5f346269_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc81e334348d4c79b3f31451ed65c6b1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0a506d355e4b78bb7008211cbfe661_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f38b06e4284e2dad48030ae167ccec_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8bf301820e43f0bbc64c6954a84ac1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3365ee0645e1428a8bf15e40c57c905e_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc107ab4ba649ca943e231ca67e264f_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i75439519a47a4f6989cd2cd3b40b5195_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">flks:UniversityOfUtahResearchFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12375731a1584f5db3722367e5d44b8b_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ae7eac7ac445aebc542f0429384d0a_D20160701-20160701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f1fbc10f714bacb40851d5e79f0484_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509e2e173464488a8d80584086100e5c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice74598ecb934cd4a025ee4792e6670d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8980e464358d45fabde2cb82b652df91_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4f1866e1f849c489daf2e3e0a10e39_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03bc59929da24395880307913e87fb66_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6026e2ea63474bb6b5241d862bf6c303_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3725d493747d4bbe83005958d3ac6d23_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f88e0cf88b84bf9854e0bedf0607dd1_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507cbbf0634340df95b758b92062fb43_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb060d868e36408ebdd36e2a2fe2658d_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa8c9f6d7934dcaa6197a4ab35db643_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9309e3d556bc49209dff4d4ae28bffc9_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ba6b78c05f44859360da199a2f4d38_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154dce57782f49a0b2407f5f8b6c7819_I20201211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc44ad82e29143268254f26cd0b201a3_I20201211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d324e00fd0449ada9306d7820e7650a_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637b5066c13e46c8ad5054fcf7d9db91_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97060a95644a4253a9d97d1b2c868b7e_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1455af2bd3e48fbab07d23af33ccf27_D20210205-20210205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e0f9788dcba480c96b8fa31f68fb351_D20210702-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22aba5a3e90e4e95a276ef89efe1ac98_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ae6026c59f4ec38c6949b4bef8d233_D20210308-20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-08</xbrli:startDate><xbrli:endDate>2021-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4075aa174dd346ae968ca14c8a84ba8a_I20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ec404e1c2a4fa19e8f881a89360a33_D20210308-20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-08</xbrli:startDate><xbrli:endDate>2021-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d6648d8528478096111949d12cd28f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f29b4bffdb04060b79c90b287ec75ee_I20190718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>flks:day</xbrli:measure></xbrli:unit><xbrli:context id="i7b06abcc4a3c4d32837217db39cf0e29_D20190718-20190718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-18</xbrli:startDate><xbrli:endDate>2019-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b4f85b5e2f4b0da127ab2e310c28a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe55d006aa740d7bdb83434769e6cec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1e7939df33476493958c5474f1ec12_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20fa72ce8b44760a27f5514b956d6a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3767d63d21841febd91f1664b87398c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27743a41234488c94ecdbae56d5030e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de1973dc957478cb0bc2d769059d427_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id806215bb22c4a6bbb84c72994b31e52_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd9bebb5d234611a3707cb6f311df80_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e25a08a7b8243698baceb726d714709_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618536f8debf473cb0710a7c02b3140f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b2f8b8184949889f3aa6bcf52f8836_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-10</xbrli:startDate><xbrli:endDate>2021-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-02</xbrli:startDate><xbrli:endDate>2021-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id634fbf36df7473db3bb7e070c784cad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6f2c50c3e144b5b8f013949d188cfd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if61674fa0744426bad5a356d5af164c9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01803b42cf2b4af6b7b175622f3970f8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_1"></div><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTI1_a59fd105-be6e-4873-a4c4-198e9064115c">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark&#160;One)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjcxODdkNGZjZDU1NGNiMDhjYzVmZTFiMGI1MDlmOGQvdGFibGVyYW5nZTo2NzE4N2Q0ZmNkNTU0Y2IwOGNjNWZlMWIwYjUwOWY4ZF8xLTAtMS0xLTE_08ef18e5-f6e7-4357-90ff-d61ef24614e6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjcxODdkNGZjZDU1NGNiMDhjYzVmZTFiMGI1MDlmOGQvdGFibGVyYW5nZTo2NzE4N2Q0ZmNkNTU0Y2IwOGNjNWZlMWIwYjUwOWY4ZF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjo2YmQxNTZiNmUzNDI0MTg4ODE1NWFlYWMxOWVlODYwNF8zNQ_a1383c0a-308f-4686-859c-12359fc9ff3f">September&#160;30, 2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjcxODdkNGZjZDU1NGNiMDhjYzVmZTFiMGI1MDlmOGQvdGFibGVyYW5nZTo2NzE4N2Q0ZmNkNTU0Y2IwOGNjNWZlMWIwYjUwOWY4ZF80LTAtMS0xLTE_94d6cdf5-9770-4a06-a731-803f38d4f0ea">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Transition Period from      to</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xMTY_29f7b27a-855f-443f-a565-09f6960c1103">001-36812</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xMjA_a8d574ce-3f63-4b7a-a5db-859c2596bf42">SALARIUS PHARMACEUTICALS,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:15.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjA0Njc2MThkMmExNDgxYTgwOGVhNjIzMDNmOTM4ZTkvdGFibGVyYW5nZTo2MDQ2NzYxOGQyYTE0ODFhODA4ZWE2MjMwM2Y5MzhlOV8wLTEtMS0xLTE_2079826a-fdf5-451b-b1de-a945231c925c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjA0Njc2MThkMmExNDgxYTgwOGVhNjIzMDNmOTM4ZTkvdGFibGVyYW5nZTo2MDQ2NzYxOGQyYTE0ODFhODA4ZWE2MjMwM2Y5MzhlOV8wLTMtMS0xLTE_f4632101-a23f-474d-95d4-d8d2ce0f805b">46-5087339</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xODA_462f63ac-923d-4506-a4c9-9d90b608cda0">2450 Holcombe Blvd</ix:nonNumeric>., <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTI3_d8430af1-f29a-404a-8339-b5dc2b5d781a">Suite X</ix:nonNumeric>, <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTQ_b6af9f43-5592-4136-9359-47c12e6a1a25">Houston</ix:nonNumeric>, <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTg_58989376-290b-49dd-bed0-f34a07da851d">TX</ix:nonNumeric> <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8yMDE_62fdae51-3254-4216-a9a2-5810ac9fac8c">77021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8yNTg_d173e16f-8547-49eb-975a-9f03ccc24a41">832</ix:nonNumeric>)<ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTI4_b0c0c426-b6fa-46c0-aad5-e2913d1a621e">834-6992</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, If changed since last report)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of  each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MzQwMjZkZmExMTA3NGM3MWFiZGU0ZjFlYTY2NmQwNzQvdGFibGVyYW5nZTozNDAyNmRmYTExMDc0YzcxYWJkZTRmMWVhNjY2ZDA3NF8xLTAtMS0xLTE_78e4750a-0fa3-413b-9147-56e9638ed991">Common Stock, $ 0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MzQwMjZkZmExMTA3NGM3MWFiZGU0ZjFlYTY2NmQwNzQvdGFibGVyYW5nZTozNDAyNmRmYTExMDc0YzcxYWJkZTRmMWVhNjY2ZDA3NF8xLTItMS0xLTE_fc1b6fef-41eb-4e90-a116-b9bdb0b539a0">SLRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MzQwMjZkZmExMTA3NGM3MWFiZGU0ZjFlYTY2NmQwNzQvdGFibGVyYW5nZTozNDAyNmRmYTExMDc0YzcxYWJkZTRmMWVhNjY2ZDA3NF8xLTQtMS0xLTE_019879f4-4441-48a5-be81-7bb42b9bfeb5">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to the filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV84MTI_c9a5aa9d-2ed3-4069-b173-62e317ca5b8c">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xMTMy_33965841-ee95-4d57-a701-34589ce750d0">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:16.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated Filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MGVmZTVlMzk4YzI2NDE2MDljNjAzMTJiMTQ4MDM0YWEvdGFibGVyYW5nZTowZWZlNWUzOThjMjY0MTYwOWM2MDMxMmIxNDgwMzRhYV8wLTQtMS0xLTE_b9c77f3f-7e01-4171-a8e1-75230d8d245a">Non-accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MGVmZTVlMzk4YzI2NDE2MDljNjAzMTJiMTQ4MDM0YWEvdGFibGVyYW5nZTowZWZlNWUzOThjMjY0MTYwOWM2MDMxMmIxNDgwMzRhYV8wLTctMS0xLTE_3273534b-2598-466d-aa6f-5ec874e0d8d0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Emerging Growth Company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MGVmZTVlMzk4YzI2NDE2MDljNjAzMTJiMTQ4MDM0YWEvdGFibGVyYW5nZTowZWZlNWUzOThjMjY0MTYwOWM2MDMxMmIxNDgwMzRhYV8wLTktMS0xLTE_c2db8700-9630-4618-876e-a71c7d79d048">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act.)&#160;Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xODU2_90a1e407-7577-4066-82c4-c0e81bccea88">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As of November&#160;1, 2021, there were  <ix:nonFraction unitRef="shares" contextRef="ieb85bd86da7243f5aa57922b11eff1e9_I20211101" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8yMTk5MDIzMjU3NTE2_dd16b589-65cd-4b8f-a6ce-e22d350c1ce4">45,206,135</ix:nonFraction>  shares of common stock outstanding.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:12.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_13">PART I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_13">Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_19">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_19">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_22">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_22">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_25">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_25">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_28">Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_28">Consolidated Statement</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_28">s</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_28"> of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_31">Notes to</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_31"> Condensed </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_31">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_64">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_64">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_73">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_73">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_73">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_76">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_76">22</a></span></div></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_79">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_79">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_82">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_82">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_85">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_85">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_88">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_88">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_88">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_91">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_91">26</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The information in this Quarterly Report on Form 10-Q, including the information and exhibits incorporated herein by reference, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Statements other than statements of historical fact constitute forward-looking statements. These are statements that include, but are not limited to, statements about:  future periods; the Company's strategy and ongoing development programs; the Company's clinical trials, including status, costs, goals, timing and other expectations related thereto; the Company&#8217;s belief as to the potential of its lead compound, SP-2577; the Company's strategic collaborations and license agreements, and intellectual property; the potential for seclidemstat to target the epigenetic dysregulation underlying Ewing sarcoma and advanced solid tumors including, but not limited to, prostate, breast, ovarian, melanoma, colorectal and other cancers; expected timing and results of clinical studies; the ability of seclidemstat to demonstrate drug activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">the nature, strategy and focus of the Company; the development and commercial potential of any product candidates; the Company's ability and plan to regain and maintain compliance with Nasdaq's continued listing standards; the Company&#8217;s expectations as to revenue, cash flow, and expenses;  the potential impact of the COVID-19 pandemic on the Company&#8217;s business, operations, cash flow and ability to obtain additional financing; the Company's liquidity position, the expected sufficiency of such position for anticipated  operating and capital requirements; future capital requirements, and need for, and ability to secure, additional financing; the ability of the Company to access additional financing under the Grant Contract with Cancer Prevention and Research Institute of Texas; the Company's operating losses and ability to continue as a going concern ; and the Company's decision to engage in any new collaborations or selectively partnering its technology to improve the Company's ability to continue as a going concern. These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties, including those discussed under &#8220;Part I &#8212; Item 1A &#8212; Risk Factors,&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2020, and under Part II &#8212;  Item 1A &#8212; Risk Factors in this Quarterly Report on Form 10-Q. These risks and uncertainties that could cause actual results to differ materially from expectations or those expressed in these forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. When used in this report, the words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;indicate,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221;  &#8220;target&#8221;,  &#8220;potential,&#8221; &#8220;evaluate,&#8221; &#8220;proceeding&#8221;  and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, our results could differ materially from the forward-looking statements in this report. All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events. </span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_16"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td></tr></table></div><div><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNC0xLTEtMS0x_e99ccaf8-7dbf-49ff-8f04-7f0373e036ea">31,903,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNC0zLTEtMS0x_3066ca21-7f91-4e4d-be0f-b0970b1bacbe">11,118,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants receivable from CPRIT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNS0xLTEtMS0x_502b14f0-2a0d-4f48-9d97-154ccb211544">2,086,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNS0zLTEtMS0x_2698fa6d-6cd7-40df-9c48-bf61281979c1">3,855,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNy0xLTEtMS0x_75f750ef-bf31-4745-bc41-67572114ea1c">1,194,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNy0zLTEtMS0x_3c2041ab-42e3-459b-b4f8-af0888ab42b2">822,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOC0xLTEtMS0x_67a3f123-ddfa-4a3e-bec2-2b6b90740e9f">35,184,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOC0zLTEtMS0x_abf84753-7f62-4391-95c2-daf7ed5db39f">15,796,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOS0xLTEtMS0x_d11a6958-209d-4f99-9727-2321c03d5350">11,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOS0zLTEtMS0x_091522da-4c6c-4ebe-afe5-23509c88b9ce">22,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTAtMS0xLTEtMQ_c78b909f-ec2a-441e-9ce2-10e693f55370">201,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTAtMy0xLTEtMQ_d5eafff6-0a10-4a1f-9f81-85e86f4c232c">247,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTEtMS0xLTEtMQ_0bcf99fb-9c5c-4424-90dd-3b9e150cdf0c">8,865,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTEtMy0xLTEtMQ_f23511b2-a2e2-4e20-9fda-f94aef30dec0">8,865,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTItMS0xLTEtMQ_5eebdb60-3a69-427c-806e-a74c608e7f3f">44,263,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTItMy0xLTEtMQ_c79540e3-0bf1-48fc-97a1-73976c48ff79">24,932,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTUtMS0xLTEtMQ_8269b532-4fac-45cf-88cc-c2b980ee74ad">1,234,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTUtMy0xLTEtMQ_a189649a-d710-415c-a9ef-64b46048c051">1,853,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="flks:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTYtMS0xLTEtMQ_b91b854e-5f91-43e6-aab4-ae852608f0fa">323,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="flks:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTYtMy0xLTEtMQ_c6e5fc8e-5d56-4fc3-b71b-8495b08cdc92">383,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTktMS0xLTEtMQ_c43f24be-05e6-469f-8109-36ad889e59c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTktMy0xLTEtMQ_cfd559a3-1f97-47e9-a282-539496f0ae53">477,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjAtMS0xLTEtMQ_4799be75-5c8b-4136-a18f-d93761c1ef53">54,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjAtMy0xLTEtMQ_6b4b87cd-9f0d-4171-8f92-72f8b75c15fb">59,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjEtMS0xLTEtMQ_8c93edae-d084-4868-b8ae-a8eecb87c97f">1,612,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjEtMy0xLTEtMQ_0ad7e3d2-bc31-4eaf-a77e-7627517b927a">2,773,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjUtMS0xLTEtMQ_2ba92ac0-29ff-46af-b621-e10a28d37196"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjUtMy0xLTEtMQ_9762ba0d-0348-43eb-bb98-34d04f0c9891"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzIx_2fd5d993-af4a-4948-ac55-a29ad6ad6553"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzIx_ecae1d18-bda6-4a0b-8e19-5564047a23b9">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzM1_23b6b0fb-7a39-48d3-9fe8-883af56900c2"><ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzM1_c6ad3893-4551-43cd-82be-ccc3dbe2b6c5">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_000e87e6-ecee-4230-84e4-69e5c1a30226"><ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_02432825-ac4d-4b41-87c6-e53899cf6e8a"><ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_78b859bc-cc06-45a9-b4ee-3732e132f517"><ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_e00e4d6b-8ca5-4a79-8eb3-75225a316fb0">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMS0xLTEtMQ_58617722-566f-470c-ba63-fe728feffe4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMy0xLTEtMQ_b1156c20-f8c9-4b7c-aef6-066786e46929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzE4_2720fa02-99a6-49d6-a6a3-363f94d281f2"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzE4_97b55338-a671-44e3-b335-bcae772b3917">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzMy_282bd815-735a-490a-a9b7-26b7c9411f0b"><ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzMy_519baf24-9c0d-4887-bb64-9e5e9427aabd">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzU0_7cdbc24d-c838-4671-8ddf-359ebaee68c0">45,172,535</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzYx_0bfefd06-532e-4238-a278-3160d6075940">23,810,541</ix:nonFraction> shares issued at September&#160;30, 2021 and December&#160;31, 2020, and <ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzk2_f178f781-ea02-45c8-b64e-ec0a9c092889">45,172,535</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzEwMw_0892232d-d145-4db8-94e7-ff178008ecd9">23,808,546</ix:nonFraction> shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMS0xLTEtMQ_6251525d-78a7-4d08-9825-8bc3a2953318">4,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMy0xLTEtMQ_f797052f-cb4a-4445-975c-1d26abc9d280">2,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzAtMS0xLTEtMQ_d40bc5ea-7d95-4848-9fa3-aab929cca333">70,738,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzAtMy0xLTEtMQ_76805f9d-91c8-4d86-866e-6a5951b17a9a">41,585,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzItMS0xLTEtMQ_fb7a2e2a-6e99-46e0-816c-581bf89c1a1b">28,092,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzItMy0xLTEtMQ_dbac701e-8a0f-4bee-9193-9482cc66b64b">19,428,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzMtMS0xLTEtMQ_639d7f63-77e6-4f01-8c26-2a5aac35dcde">42,650,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzMtMy0xLTEtMQ_db0ef43a-e33e-4361-a15d-9c9683c26c8b">22,159,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzQtMS0xLTEtMQ_e7b1a8f0-53e4-48d5-85cd-8d38819f8e81">44,263,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzQtMy0xLTEtMQ_0ce77dd9-a565-4dba-adbd-c1a93f1abf04">24,932,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_364a1241-d7a9-4e7c-98c2-25b02fba3fdb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_407c59a9-1a55-41e6-8ea4-62a5380e3581"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_54ac70d5-5fa9-4988-b93c-d343cc9752bd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_7f901995-a856-4b16-b7c1-84ec51666bd0">Grant revenue</span></span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0xLTEtMS0x_fa8f1209-f73e-45ac-82a6-2e022871b54a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0zLTEtMS0x_f4fd9689-d1e7-4d5e-bdc9-3ea00d023156">1,378,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy01LTEtMS0x_d53fefeb-43e2-4b0f-9412-c376f08f5cad">1,840,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy03LTEtMS0x_b3832c5b-d720-40ff-9944-91f78d89548e">3,754,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS0xLTEtMS0x_30ea4270-c93e-4ef1-8eb9-04305ae7723b">2,015,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS0zLTEtMS0x_9299adb6-ad5d-4b9b-9b2d-84630370b65e">1,803,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS01LTEtMS0x_47b00c7f-1f4b-4bc2-897e-793dd2e6742a">5,852,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS03LTEtMS0x_25c16507-e50e-4d91-bf55-5b46a017f7cc">4,890,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi0xLTEtMS0x_78301076-17d3-4da0-b0c4-e7bfc3188fa4">1,730,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi0zLTEtMS0x_8949f42a-051b-4668-957f-1ee2fbd877f9">1,333,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi01LTEtMS0x_535ce011-46a9-4485-aa08-52f95bb2b1ee">4,655,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi03LTEtMS0x_9091e74a-a1fa-4a13-af3c-02ba395f4770">4,893,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy0xLTEtMS0x_badd8366-a770-46de-82c2-d5e57dc288d8">3,746,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy0zLTEtMS0x_2408af8b-53ef-463a-bf4f-2b63e0864940">3,136,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy01LTEtMS0x_4694a1e7-f450-4f69-b3fb-b9594f0a4cba">10,508,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy03LTEtMS0x_e6def2f2-d229-436a-a4c4-979f6dc8306b">9,783,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC0xLTEtMS0x_cf3d42e7-82c2-4f06-be8c-e98b68c3d894">3,746,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC0zLTEtMS0x_610497fa-233b-4335-b723-2bf9fa23d334">1,758,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC01LTEtMS0x_519bbcb8-b32c-4952-a257-869a0594256a">8,668,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC03LTEtMS0x_4bebdf7e-c689-45e2-9d5e-e5ead9e69667">6,029,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS0xLTEtMS0x_d9a00ff3-f61e-4592-bf98-6a6131b88f27">9,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS0zLTEtMS0x_24f914a0-4061-49eb-b24a-f97d5b699446">45,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS01LTEtMS0x_c32a9839-1d7c-470b-a979-50590ee085b8">5,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS03LTEtMS0x_b45f8446-a4c9-4e59-85d1-c0f18cbe73c7">265,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grants and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtMS0xLTEtMQ_7447cada-d19c-4041-b72d-23fcf213ccfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtMy0xLTEtMQ_bdc0f3c1-46da-4ca8-afd4-3bd9437411f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtNS0xLTEtMQ_84f67498-6b5e-49f1-83bd-f0e3c2a3952c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtNy0xLTEtMQ_3599b3e1-39ea-4cca-afeb-9a10005d267b">179,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtMS0xLTEtMQ_358ee2e7-6b81-4175-bccf-87c38cedcef0">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtMy0xLTEtMQ_2bed848e-12e1-49eb-9ae5-931a4b5aab9c">3,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtNS0xLTEtMQ_7114096a-f9d0-4ee4-a481-dd75647adbbb">495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtNy0xLTEtMQ_4405cc4e-96eb-470a-8e2f-07819801e907">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItMS0xLTEtMQ_ddc39591-2ad6-4738-a3a6-1e50c1f15431">3,737,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItMy0xLTEtMQ_9f817d8d-f911-4a6b-9c49-4be27b0a186f">1,716,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItNS0xLTEtMQ_50d9d937-02ce-4a88-8332-418743692638">8,663,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItNy0xLTEtMQ_6c1c2868-3a63-4996-ad46-332b5463eac0">5,584,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtMS0xLTEtMQ_b07246b8-8e9f-48e0-80af-8a1776e74341">3,737,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtMy0xLTEtMQ_277c38bf-3b6b-4104-9c92-dde951b5113a">1,716,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtNS0xLTEtMQ_8c10e984-ac89-4beb-b26c-79fca0d4fcc4">8,663,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtNy0xLTEtMQ_0cc84983-4565-40bf-a298-631c35e66838">5,584,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share&#160;&#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMS0xLTEtMQ_09c0bb82-e3b4-4423-808a-d38c5bc34156"><ix:nonFraction unitRef="usdPerShare" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMS0xLTEtMQ_4e5254fb-79c7-45d8-b052-acd646e912c7">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMy0xLTEtMQ_d43e3f27-59e2-4b6c-8c2c-1be3ea99e610"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMy0xLTEtMQ_fc1fec73-0f61-46e5-ba41-fc35587e44e9">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNS0xLTEtMQ_47a14ada-f84b-4539-b981-2e0511728b17"><ix:nonFraction unitRef="usdPerShare" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNS0xLTEtMQ_ac182478-c61b-46be-bf10-3a7b3d7642ab">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNy0xLTEtMQ_4c2ab2b7-bdba-4a9b-b794-0890f016ce6e"><ix:nonFraction unitRef="usdPerShare" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNy0xLTEtMQ_9fadea1c-c0e3-4871-8b5f-cdceedc583c0">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMS0xLTEtMQ_7254fdcd-4b82-47f3-b78b-c6bac9e8a979"><ix:nonFraction unitRef="shares" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMS0xLTEtMQ_eb38ae60-d079-4d48-81d4-b3356647e172">44,804,741</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMy0xLTEtMQ_9e62452d-72a3-4725-9d13-28524cfd6010"><ix:nonFraction unitRef="shares" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMy0xLTEtMQ_d203ea4b-88f2-4193-96f1-2b63c07179a2">17,968,664</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNS0xLTEtMQ_33675986-0f75-48df-aef8-0ab8e6e98abc"><ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNS0xLTEtMQ_f25f91ec-2bfa-4e6c-8928-492c0476c1df">40,064,119</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNy0xLTEtMQ_8377a8db-edcb-445a-9eb3-ba957d77af6b"><ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNy0xLTEtMQ_fd312662-cb3a-4095-80ad-9c06c39841e2">13,833,410</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended&#160;<br/>September 30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMy0xLTEtMS0x_752a6126-2f98-4728-b3f7-6e5db243e849">8,663,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMy0zLTEtMS0x_88cb9062-7aec-4b6f-bc69-71317bcf8b1f">5,584,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNS0xLTEtMS0x_bb1b3636-5c24-4cdc-922f-3dff1451645c">14,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNS0zLTEtMS0x_443a5226-e0b9-4ea4-86ca-1e479578afe3">12,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNi0xLTEtMS0x_d7fa0ea5-9385-4279-85c8-0dc2681c74ba">413,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNi0zLTEtMS0x_11084c7a-3df4-438e-b683-3906111b2ad5">149,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for services </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOC0xLTEtMS0x_083efb46-2d7c-431c-9624-8534d3d81adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOC0zLTEtMS0x_1f53c67e-5a06-43f4-8def-54e3ceac932e">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOS0xLTEtMS0x_a8eb16a9-9eb7-47d7-9ff7-119e00cce94f">5,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOS0zLTEtMS0x_0a01995b-7d9a-4fcf-b7af-3b2fd290d22f">265,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTEtMS0xLTEtMQ_be57c212-dae8-41a6-b7ec-3e91ff456d37">1,769,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTEtMy0xLTEtMQ_34004fe2-1895-4238-8d20-6a5e3fb99fee">3,212,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTItMS0xLTEtMQ_1dae9e60-d238-44be-a4e7-8a279e5c3e3f">329,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTItMy0xLTEtMQ_eae0ec15-8a0b-4f99-b604-179d6e97c815">799,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTQtMS0xLTEtMQ_61acfc11-ae61-4af6-a707-9950bdba37f0">618,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTQtMy0xLTEtMQ_1ba58c1e-d2da-4029-a7e8-60ab8c0ac4e4">607,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTUtMS0xLTEtMQ_2d6dfd96-d4b8-4166-9b72-1dcd000ae708">59,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTUtMy0xLTEtMQ_5ce5a233-2683-4f72-b902-3e82d0b9a2ba">288,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTYtMS0xLTEtMQ_9c23f398-b938-426d-bdb8-0e2c30499abb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTYtMy0xLTEtMQ_d56e5517-bac7-4f2a-b7d7-26cbf02f0ec9">541,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTctMS0xLTEtMQ_f709d8bb-4932-4176-abd9-e2c9acf0e4ef">7,479,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTctMy0xLTEtMQ_4808eaee-4aa5-41b8-acf5-8a0d4dcb9b2a">8,937,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjEtMS0xLTEtMQ_5f19b8f4-a8a6-4696-b9cc-2fec5cc15e31">27,256,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjEtMy0xLTEtMQ_1c1cd086-666f-4387-97af-e75b0015dd17">14,810,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from warrants exercised for cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjItMS0xLTEtMQ_f225f7e3-191a-4235-a2cb-3fc3c5462d47">1,485,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjItMy0xLTEtMQ_d8abd9e9-0418-41e1-b484-7cef7296a2fc">636,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjMtMS0xLTEtMQ_d1b0ea19-6a0b-4ba7-a19b-946ae47b7481">477,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjMtMy0xLTEtMQ_4ace17aa-f0d9-483f-b8f0-09670304fd61">690,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjUtMS0xLTEtMQ_b059a7b4-ded0-4aec-9bf8-7a38f3c5d03c">28,264,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjUtMy0xLTEtMQ_ed600fd6-aa79-488f-a142-293f8137c4ec">14,756,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjctMS0xLTEtMQ_11aad131-acd4-42ac-9297-daa9ba6cc0d4">20,785,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjctMy0xLTEtMQ_ad8d9561-c71b-4c2b-9a71-525df5d6197a">5,818,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjgtMS0xLTEtMQ_513acd17-1884-4edf-b4e2-ff349297107f">11,118,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjgtMy0xLTEtMQ_080a7ab6-8ccf-4a32-ac22-f380c311cd7b">3,738,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjktMS0xLTEtMQ_ef0f4482-f579-454d-a863-82e13cbcb31e">31,903,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjktMy0xLTEtMQ_bc99b819-2652-41f0-88d6-8023d2072679">9,557,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzItMS0xLTEtMQ_ee077215-c427-43a5-baad-a67afdfec2f4">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzItMy0xLTEtMQ_9fe0a7c2-148f-45ce-a826-0655a38a2cb5">6,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued issuance costs for public offering </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="flks:StockIssuanceCostsAccruedAndAmortized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzQtMS0xLTEtMQ_a72330b3-e8d8-47ea-af15-6943e770975a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuanceCostsAccruedAndAmortized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzQtMy0xLTEtMQ_c15fcb44-b8dc-4d44-920d-0db72c5a7536">12,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense financed by note payable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" xsi:nil="true" name="flks:PrepaidExpenseFinancedByNotePayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzUtMS0xLTEtMTAzNTg_8dab33ef-9ea1-49de-98f7-cc665d99af1d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="flks:PrepaidExpenseFinancedByNotePayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzUtMy0xLTEtMTAzNTg_9b816508-a762-4a7c-b4be-1bdd1a3616b2">949,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.967%"><tr><td style="width:1.0%"></td><td style="width:32.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.760%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.572%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d20dc51e5fe4ea99139098eb7f83411_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0xLTEtMS0x_45862565-145c-45cf-9989-ff410f2f9b7e">4,511,174</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d20dc51e5fe4ea99139098eb7f83411_I20191231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0zLTEtMS0x_86dbed16-4d72-42a8-a832-2dde8537ef81">451</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91ac971072f1418a89a4376f024276cd_I20191231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy01LTEtMS0x_b6b5e172-c0e6-4e94-86f8-1982bd279de8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ac971072f1418a89a4376f024276cd_I20191231" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy03LTEtMS0x_77f909da-38a7-4d3f-8dce-01c8af682f35">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0024786ef67540f7ac2c0db72574744a_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy05LTEtMS0x_9f45ad52-3edd-4ced-9c71-a9941d2eb265">22,657,103</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d2ac1c7ee44444cb491532bc41f23f5_I20191231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0xMS0xLTEtMQ_4372b99d-baaa-4343-9524-ab26dbf0bdba">12,076,700</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0xMy0xLTEtMQ_1a1f265e-0b6e-4745-84ac-bac62949b4e2">10,580,854</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity securities, net</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC0xLTEtMS0x_b7480d57-6c80-4dcb-b399-fd8509340a88">8,353,480</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC0zLTEtMS0x_0438ebbc-2f34-4a03-b164-278c25db20fc">835</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC01LTEtMS0x_4c6afe06-db06-49d0-b0f6-7d7a367ebd0d">1,246,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC03LTEtMS0x_208aee17-5db6-4966-a96a-86e059842744">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC05LTEtMS0x_a9393e5b-aac6-4520-af01-49c5ba203c0d">9,466,206</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC0xMy0xLTEtMQ_2a316a09-d224-4d43-af3c-988cdc833380">9,467,166</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares  converted to common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS0xLTEtMS0x_91455171-807d-466a-8269-bac6cf217fb6">777,825</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS0zLTEtMS0x_a70b7e87-9baa-4f49-9d96-44291e38b5b4">78</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS01LTEtMS0x_d345ffc1-8ab8-4c3d-a06f-c6a385baeb9c">777,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS03LTEtMS0x_fab3a20d-8f05-4bb3-b03a-922649935c5c">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS0xMy0xLTEtMQ_cbb144b2-32cd-4331-89cb-e5767283ee4c">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNi0xLTEtMS0x_e6876e9a-2f10-415c-ad22-5a626fb25209">3,198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNi05LTEtMS0x_b2fb1ecb-e0c3-4ca3-8947-2ade607e805c">38,409</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNi0xMy0xLTEtMQ_5d17a589-c342-4d7e-a357-3bb7e0176c71">38,409</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb03da10c8aa48f08dc0254a264659dd_D20200101-20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNy0xMS0xLTEtMQ_08c0bdfc-17e8-4f1b-ab46-4a9440d5bf35">2,083,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNy0xMy0xLTEtMQ_e97bf535-facc-46a1-ae58-14d0b3f2b7c0">2,083,816</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdadb645f0404a4d95746cc2ba5ff395_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0xLTEtMS0x_dd7731be-861f-4486-a24d-7463a0cb5bf4">13,645,677</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdadb645f0404a4d95746cc2ba5ff395_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0zLTEtMS0x_6702704d-0568-4326-a1cd-e4f8525dc410">1,364</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id72958b2722c44979991d7838b0e41c5_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC01LTEtMS0x_242bfa5e-a2b1-44ea-a6b2-8f6eeb249a82">468,694</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72958b2722c44979991d7838b0e41c5_I20200331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC03LTEtMS0x_a2e30bea-8d00-44ba-a07e-722401ffdcf0">47</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879f0c3963444b66916504729b1e3d17_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC05LTEtMS0x_04c421a9-3e96-43e8-9c72-85800835ffab">32,161,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf5af0205ac648a5a2afbfdf5f6e3274_I20200331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0xMS0xLTEtMQ_30f4978e-fb7c-478e-9476-089623b8da48">14,160,516</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5e105e076d46699489e811c97d2199_I20200331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0xMy0xLTEtMQ_4b2ad82b-230b-4c7c-b7e5-f4b20b155183">18,002,613</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised for cash, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS0xLTEtMS0x_2a53ddf9-5346-4747-8a43-bb652a11e921">503,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630" decimals="0" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS0zLTEtMS0x_c583864a-a4f6-4ec6-8718-bfe89f0ed8e6">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ef3be74ccc4ed780f60aaea7b84cd6_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS05LTEtMS0x_1f34489a-3dcf-4048-b371-a16c750faea9">578,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS0xMy0xLTEtMQ_5ab1a259-3121-4c57-a6ef-6168a0e51d7c">578,714</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares converted to common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtMS0xLTEtMQ_a4ec229b-9173-4fd3-a6e1-1f5273c6800e">468,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtMy0xLTEtMQ_519dd97f-7159-4ae3-ad9e-440affa64b9d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id883671275ee47f29805bc8d421e6c30_D20200401-20200630" decimals="INF" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtNS0xLTEtMQ_00b6aa82-f06d-4b23-9977-16ebac93dde1">468,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id883671275ee47f29805bc8d421e6c30_D20200401-20200630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtNy0xLTEtMQ_38a03942-b9a2-45c5-b224-05dbc635f03c">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtMTMtMS0xLTE_954d543a-02d9-4ea7-a1ce-87847e2454f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTEtMS0xLTEtMQ_3b1e0028-5889-41db-954e-d19f3d8916aa">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ef3be74ccc4ed780f60aaea7b84cd6_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTEtOS0xLTEtMQ_d51029ba-aedc-4a29-a468-c19dba3d6523">32,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTEtMTMtMS0xLTE_50a6f730-f5ea-4170-a891-cb6dd1b06982">32,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89b959c132384760adfcad6637c903e0_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItMS0xLTEtMQ_da7555dd-6055-4fa1-a6ac-c1df5e32bec4">18,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b959c132384760adfcad6637c903e0_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItMy0xLTEtMQ_f336641b-c6ed-48b8-a431-94dd8f076c72">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cb73c0bc694074878b0432e6f254cf_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItOS0xLTEtMQ_30a02517-981b-4e3a-a35c-a190b29cf938">24,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6b4d878dea4f218fc2f35d89ffb0c3_D20200401-20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItMTMtMS0xLTE_a71e00a4-8849-4e2b-996b-edf4a9b47f96">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4078d2163404318a25c07dba8baec76_D20200401-20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTMtMTEtMS0xLTE_b1d715b0-ddeb-4585-b7f1-cce9785b3bfa">1,784,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTMtMTMtMS0xLTE_709815f7-fa57-42cb-859d-a38d631cfc58">1,784,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38e80edb414d4a79ae54153572f0e6eb_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMS0xLTEtMQ_085f0706-2665-4d18-97b2-b949f03ab89b">14,638,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e80edb414d4a79ae54153572f0e6eb_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMy0xLTEtMQ_b248b767-09c4-42c8-8856-8a8ddd7b2e53">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56344979fde94e63aa913f4a5e8723d0_I20200630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtNS0xLTEtMQ_2ab6813f-e950-430a-8966-057c779c5dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56344979fde94e63aa913f4a5e8723d0_I20200630" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtNy0xLTEtMQ_26169be0-6086-43bd-aa54-732a0b31eb66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a378992dd7b49d9a157ab15eab9f3ed_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtOS0xLTEtMQ_292669be-05c3-41e3-a6bc-9f5f2cb85a7e">32,798,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i494e149e02d3480995871fe3ca7e8497_I20200630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMTEtMS0xLTE_46f9c00a-112f-40c7-8eac-416a0c197b5a">15,944,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008da512d397437a9cba8e4395f8379c_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMTMtMS0xLTE_1eafae7c-567c-4a92-947a-6598104f5d72">16,854,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised for cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtMS0xLTEtMTAzNjI_ca3b5ddc-7af4-479b-b0f3-1ad5f493e649">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930" decimals="0" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtMy0xLTEtMTAzNjI_f614d092-2e82-4790-bad1-c3ab1dca61a7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtOS0xLTEtMTAzNjI_56829544-508a-4de5-b75f-769d3234266c">57,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtMTMtMS0xLTEwMzYy_96b203ee-9416-4350-bc66-1f4c44dba303">57,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMS0xLTEtMTAzNjI_6ec77e9e-1d97-4772-abfe-289b20019e25">5,130,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMy0xLTEtMTAzNjI_9745d5a1-d0be-4ab5-83d7-d65b2ada4605">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtOS0xLTEtMTAzNjI_2997f7ee-ef7e-4bb9-828c-9194062c6343">5,331,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMTMtMS0xLTEwMzYy_2dda0bd3-cd83-4f6c-9b3c-ee54de2a840c">5,331,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMS0xLTEtMTAzNjI_b48bd6ab-a58e-443b-b390-1651eaa155ca">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctOS0xLTEtMTAzNjI_e14a3939-256f-4271-a9ee-94b305db06da">78,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMTMtMS0xLTEwMzYy_82d8fe60-312e-4ce8-8214-15aae187c83f">78,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad60589c9a6a4dd7b40672b0faa48107_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMTEtMS0xLTEwMzYy_7191b8b4-8fc9-4570-8766-56b08069c1e6">1,716,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMTMtMS0xLTEwMzYy_225a39d9-76f7-4cb6-8c02-91aae0d36496">1,716,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i103946fb0b22442b9d8a5266ee347645_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMS0xLTEtMTAzNjI_255d53a3-bf54-4c22-8503-47f00193f2ee">19,818,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103946fb0b22442b9d8a5266ee347645_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMy0xLTEtMTAzNjI_916401ce-3a4c-4537-83e9-967d37d2f761">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b7745f01faa466f876bdd522070c58d_I20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktNS0xLTEtMTAzNjQ_66816edd-068f-421a-ab2c-4955958d23c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7745f01faa466f876bdd522070c58d_I20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktNy0xLTEtMTAzNjQ_ff1b5984-71c2-428d-a755-a9190ab5c18d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db0f3b8635a4838b6ac72d40a6ecc06_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktOS0xLTEtMTAzNjI_4215054d-ebab-4ec1-917e-754dfb774549">38,265,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f8c31eb4f14036be3bc5ad4af88834_I20200930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMTEtMS0xLTEwMzYy_0f5bdc91-900b-45a6-a208-2c92a8ad3caf">17,661,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMTMtMS0xLTEwMzYy_c014285e-7384-428d-ab8c-55e5b196e2e3">20,605,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11266e19063543088c03f4b86e4beca8_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMS0xLTEtMQ_bde7fc2b-6205-4e64-9858-4f121d72c9f7">23,808,546</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11266e19063543088c03f4b86e4beca8_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMy0xLTEtMQ_c321b884-6216-4767-a606-667d9f2bd794">2,381</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i177696ed3c044d74afa4d317d038fb4d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtNS0xLTEtMQ_84bfef17-89ca-4f5d-be4e-eb7d2ae02dad">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177696ed3c044d74afa4d317d038fb4d_I20201231" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtNy0xLTEtMQ_ba4b11be-4c1a-4bfd-a8e1-8e75666fd37b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdeccc9f1f44bff859e3f3fcc5cbdb0_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtOS0xLTEtMQ_c750160c-4084-45b8-9edf-d764dcd9060e">41,585,761</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70f542a0e98d4604a00099497a1f1804_I20201231" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMTEtMS0xLTE_2fbf2c63-465e-4424-b2cd-4c68c26e7ffa">19,428,954</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMTMtMS0xLTE_26fa1e42-21c7-40a4-a295-fdb52d110d8e">22,159,188</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity securities, net</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMS0xLTEtMQ_509a8288-0497-427a-b34d-61383addf2e3">19,627,215</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMy0xLTEtMQ_4c1311b1-5600-430b-addb-07551a369562">1,963</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4246855be8574284a65e3d4eba29df11_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctOS0xLTEtMQ_10cc8941-a4e1-4de1-a6f3-4e2d7352fb60">26,848,058</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMTMtMS0xLTE_db3aab85-e764-4e19-b33c-b94818c5d257">26,850,021</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised for cash, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMS0xLTEtMQ_cf3a1f5b-c199-4c1c-9da9-e1e5be2f6ce9">1,298,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331" decimals="0" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMy0xLTEtMQ_89ca500e-e07a-4c43-9208-20b64966242f">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4246855be8574284a65e3d4eba29df11_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtOS0xLTEtMQ_2a2bff5a-1851-473e-ba1e-e3b72586a00f">1,485,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMTMtMS0xLTE_298cca72-12d9-4356-a14e-3d3a0d27bb3b">1,485,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4246855be8574284a65e3d4eba29df11_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktOS0xLTEtMQ_f6c7a30a-753d-4641-8a7b-1038b2547df1">135,379</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMTMtMS0xLTE_be6769f4-b71a-4698-8de1-4433be3a6cd7">135,379</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b30b72e16c34ba3a2db567ae552cea6_D20210101-20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjAtMTEtMS0xLTE_78a271a6-21bf-4ce9-b233-8278ca54c056">1,851,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjAtMTMtMS0xLTE_9d2b5966-cd21-4eab-812e-46ee27398fd8">1,851,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88143d34f36d418e965adf2e6fd1ec52_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMS0xLTEtMQ_cb44389e-12ca-48af-b473-bde452ef4224">44,734,328</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88143d34f36d418e965adf2e6fd1ec52_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMy0xLTEtMQ_93a90ba0-975d-4edd-a88f-38e71ee27c41">4,473</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84baeb8b40334043b2e851612655fc30_I20210331" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtNS0xLTEtMQ_7d975453-03f4-42c0-8a04-4d7df0e2c2b3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84baeb8b40334043b2e851612655fc30_I20210331" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtNy0xLTEtMQ_752c0a15-2675-4093-8f8d-27e7cb837162">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58585740081444529b94b6645f75a15f_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtOS0xLTEtMQ_2c2b8903-fff0-4cc5-8e33-bf1c459fa81a">70,054,420</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bdd980a35274061bc26ccaccf9623a7_I20210331" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMTEtMS0xLTE_d8cf1429-c509-450e-a610-ff2f4d2468e9">21,280,850</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29d1e6d22804c40b7c53ce44db787ec_I20210331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMTMtMS0xLTE_29c1d59f-f93f-40ee-8fa8-4f40063a022c">48,778,043</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d02fc8d1b514c81839144c985474d09_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItMS0xLTEtMQ_5fee6dc6-d0fe-42b4-ac8b-18a27f57dc22">38,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d02fc8d1b514c81839144c985474d09_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItMy0xLTEtMQ_c37f226d-8ee6-4473-a747-9f3c2d78fbe9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c23cfd88914796ae8bcfbb6182d920_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItOS0xLTEtMQ_43c6d7e8-abc0-407c-be53-8a14ffc3f396">147,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb593881ffd4b39a7166b73ba48fad3_D20210401-20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItMTMtMS0xLTE_6e8e14c6-e106-459d-90af-ccc8009bbbed">147,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based services expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70f8c9fa71354fb58629cf1202290260_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjMtMS0xLTEtMQ_8103df7d-2683-44c0-9bb9-9794b3ba3e91">6,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia256a575bccf481fa61288d8f7b235d1_D20210401-20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjQtMTEtMS0xLTE_99a7cfbd-ec48-4965-a8ac-c92b59b36c38">3,074,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibeb593881ffd4b39a7166b73ba48fad3_D20210401-20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjQtMTMtMS0xLTE_2405d0fe-58b9-483e-a658-a78386d1bec0">3,074,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4486746847a436886263055e53f87f8_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMS0xLTEtMQ_c52cdb40-3b18-4be7-b91e-ec4a7ddc2649">44,778,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4486746847a436886263055e53f87f8_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMy0xLTEtMQ_20c09de8-318e-41ad-ad07-5efb257c3a81">4,477</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2408113d2df34fd08dad1aad2b45fc4d_I20210630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtNS0xLTEtMQ_f9f549ce-f541-418a-b72d-9f1a059a5ceb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2408113d2df34fd08dad1aad2b45fc4d_I20210630" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtNy0xLTEtMQ_3346e605-64b3-43e0-be21-9dff79b43074">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11851802384bfcb427ad4bdb517f9d_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtOS0xLTEtMQ_3a5c905e-5140-4325-bdfc-c4e3b002dd76">70,201,872</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80c8dcc9ab0b4b0ebdfe09ad48ecb9fb_I20210630" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMTEtMS0xLTE_f5976e9b-07ac-4a66-af49-ddfeb60ab606">24,355,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adff28f56e841a08e131253d1872d50_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMTMtMS0xLTE_d2a127f6-4ca8-46d4-9976-1a0544e3cf55">45,851,130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64588aad3ec4f21aae0e0cd7fb960cf_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzEtOS0xLTEtMTAzNjY_93329f61-68af-4cac-abb6-20e5476fa63d">130,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzEtMTMtMS0xLTEwMzY2_a0edc390-b18d-4474-9c8d-bf9b9a43f497">130,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.967%"><tr><td style="width:1.0%"></td><td style="width:32.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.760%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88c667283927432092625abe5f346269_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItMS0xLTEtMTAzNjg_c9d75576-d092-47ac-8d59-2bd0f1026a67">393,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c667283927432092625abe5f346269_D20210701-20210930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItMy0xLTEtMTAzNjg_4bac7ede-80db-4ab6-95a2-8d495cd3a65f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64588aad3ec4f21aae0e0cd7fb960cf_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItOS0xLTEtMTAzNjg_09e083ab-9c75-484d-b729-f35954830a37">406,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItMTMtMS0xLTEwMzY4_81b8269d-4c5c-4d94-a0ce-aba6c4307af3">406,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc81e334348d4c79b3f31451ed65c6b1_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzMtMTEtMS0xLTEwMzY4_e794c6ef-731e-4fbc-9c03-98d9b6390687">3,737,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzMtMTMtMS0xLTEwMzY4_a70d67da-2e54-4951-be85-91f431f11bbb">3,737,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMS0xLTEtMTAzNjg_4ba8be54-6dd1-4a7a-8dd3-9e604b8babe5">45,172,535</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMy0xLTEtMTAzNjg_4c880ea7-cfb4-4688-91a4-f7adc5ab3654">4,517</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d0a506d355e4b78bb7008211cbfe661_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtNS0xLTEtMTAzNjg_3e46cf43-6c15-48cd-a168-5eed1e561931">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0a506d355e4b78bb7008211cbfe661_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtNy0xLTEtMTAzNjg_53421554-54a6-4a94-9891-56d1ab1e8e79">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f38b06e4284e2dad48030ae167ccec_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtOS0xLTEtMTAzNjg_e8479d90-4dc2-42db-a5d0-0ca6e7c86e23">70,738,517</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f8bf301820e43f0bbc64c6954a84ac1_I20210930" decimals="0" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMTEtMS0xLTEwMzY4_58c8c443-d150-44ec-8f8d-d679779e3d2c">28,092,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMTMtMS0xLTEwMzY4_26d3b1c4-f7e1-4250-8628-49936412cbd2">42,650,715</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_34"></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNC9mcmFnOmExMGY2YmFmMjdhOTQwNzdhOTM5ZjMyYzdmZDljMzliL3RleHRyZWdpb246YTEwZjZiYWYyN2E5NDA3N2E5MzlmMzJjN2ZkOWMzOWJfMTgzOQ_aa804e75-58ff-4ef3-b981-87bf390e9767" continuedAt="ic58f2ef8add84c30a4c8639849f2639c" escape="true">ORGANIZATION AND OPERATIONS</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><span><br/></span></div><ix:continuation id="ic58f2ef8add84c30a4c8639849f2639c" continuedAt="id903776c57974b7482ca0625943b4ed0"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, the Company is developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The field concerned with gene expression regulation is called &#8216;epigenetics&#8217;. As cancers are often diseases driven by gene dysregulation, epigenetics is an area of interest for cancer treatment. The Company's lead epigenetic based technology was licensed from the University of Utah Research Foundation in 2011. The Company is located in Houston, Texas.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Covid-19 Pandemic</span></div></ix:continuation><div style="text-align:justify"><ix:continuation id="id903776c57974b7482ca0625943b4ed0" continuedAt="id24b34a8398c43f6b94dc9d177e33eac"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic is significantly affecting the United States, global economies, and businesses worldwide.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the potential magnitude and duration of the economic and social impact of the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may, in the future, reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. At this time we are experiencing minimal disruption to our clinical trials. However, our ongoing Phase 1/2 Ewing sarcoma clinical trial and Phase 1/2 AST clinical trial may encounter delays in enrolling new patients due to concerns or healthcare resource constraints because of the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id24b34a8398c43f6b94dc9d177e33eac">In addition, although at this time we have experienced no disruptions to manufacturing capabilities, certain aspects of our supply chain may be disrupted as certain of our third party suppliers and manufacturers have paused their operations in response to the COVID-19 pandemic or have otherwise encountered delays in providing supplies and services. The COVID-19 pandemic could also have a material and negative impact on our liquidity, capital resources (including our ability to secure additional financing if and when needed), our business and operations, and our workforce, as well as those of the third parties with which we do business or upon which we rely. While the situation is fluid and we do not yet know the full extent of potential delays or impacts on us or on healthcare systems or the global economy in general, we have worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic. However, we may experience disruptions in the future that have and could further adversely impact our business operations as well as our preclinical studies and clinical trials.</ix:continuation> </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_37"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDk_592f9fc8-0c3e-4419-b7c7-a37cd4494fb5" continuedAt="ib5ced8588e234ee48545df0419e9f8bd" escape="true">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib5ced8588e234ee48545df0419e9f8bd" continuedAt="ifbcb1fabb5f54fbaaa973b3c6d4fc739"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDg_23496ed9-fab1-4248-acec-c93b2348f045" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTg_f2e5797a-bcd8-429f-ba5a-c679beb3a5b3" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2020 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 18, 2021. In the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><ix:continuation id="ifbcb1fabb5f54fbaaa973b3c6d4fc739" continuedAt="i73abcb3200a741c08bde45238698ff7b"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2021 and the results of operations for the three and nine months ended September&#160;30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2020 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MjM_fb2b8f4b-83d3-43f3-bae3-fa2f57a5f981" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDI_d97981bf-2370-4b4a-9edb-2507fd28420e" continuedAt="ic8d8f62caec24a638b895c10020845d7" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. </span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8d8f62caec24a638b895c10020845d7">The Company maintains several bank accounts including an interest-bearing account for funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDM_cf771947-3c8e-4077-9736-5a2e0210644d" continuedAt="i7495670b475744fb9a736c42e6a7b6d3" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7495670b475744fb9a736c42e6a7b6d3">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</ix:continuation>  There were <ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_8abc45e5-a14f-4137-8966-ba1e89795191"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_b0dc9509-c374-46da-8253-9d660693d5fa"><ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_dddcb87b-9fbd-4e39-a647-56fd4311b778"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_fa035990-d4be-49c6-88cd-673e820e15f4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges related to long-lived assets for the three and nine months ended September&#160;30, 2021 and 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTA_89881b0c-4484-42ed-8c33-d40ef0669558" continuedAt="i0425ced9bca84276b5e90714171b5761" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0425ced9bca84276b5e90714171b5761">Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment charge is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_1f4fc628-b398-49fe-8cb9-a9db9d580933"><ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_3a9ea0c7-c750-4df3-af0b-73388f13494c"><ix:nonFraction unitRef="usd" contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_3ba37ba0-1a2d-40cb-90fe-1bcedf6f048e"><ix:nonFraction unitRef="usd" contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_91bf3612-eafe-4152-a21f-adef3b77889a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of goodwill during the three and nine months ended September&#160;30, 2021 or September&#160;30, 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTk_341edcf2-6c1a-432a-a62b-bdf24d673a26" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDQ_13ca785c-b5ac-4c36-85f3-8100dec53c31" continuedAt="ie314e05a3c00461c8de79e7d450855bd" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><ix:continuation id="i73abcb3200a741c08bde45238698ff7b" continuedAt="i184529588c6a4ca286bf1ff21fede3ac"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie314e05a3c00461c8de79e7d450855bd">the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.</ix:continuation></span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s preclinical and clinical trials are performed by third party contract research organizations (CROs) and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations (CMOs). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#8217;s research and development expenses in future periods. To date the Company has had no significant adjustments.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDU_7a990f07-77aa-4921-8e0b-da3bd5044808" continuedAt="ief1f2039ea3d4ecda05fad78764abccf" escape="true">Grants Receivable and Revenue Recognition </ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ief1f2039ea3d4ecda05fad78764abccf">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTU_d7bc9224-2d25-4bb2-8989-6522e954242e" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTE_bc1316ef-2631-4c44-a76d-d2c1316b69f5" continuedAt="ic82c5d919a124b7190a1521bf9b5aee8" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic82c5d919a124b7190a1521bf9b5aee8">The Company uses the Black-Scholes option valuation model to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDY_5b3eef41-0d6e-491e-81ba-e60efe78db0a" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) unvested restricted stock, (iv) convertible preferred stock and (v) rights entitling holders to receive warrants to purchase the Company's common shares, which have been excluded from the computation of diluted loss per share, was <ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfOTExMQ_5b81104a-ae3f-42cb-ab40-a0430c5c1f88">9,531,198</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTA5OTUxMTYyOTAxNDI_4197c2cd-8b4d-4908-aac9-9a2fdcfc17e0">10,075,278</ix:nonFraction> shares as of September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDc_94b95750-0f9e-4117-96ae-4d589366ff28" continuedAt="icaad22ee5f254642b19746c245c659d9" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><ix:continuation id="i184529588c6a4ca286bf1ff21fede3ac"><ix:continuation id="icaad22ee5f254642b19746c245c659d9"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of September&#160;30, 2021 and December&#160;31, 2020, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div></ix:continuation><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MjI_7d2861cc-9cf9-47f8-9a50-356ec97c7a78" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTc_a47acc42-bfd1-4f9f-976c-46cec413aa5f" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Application of New Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80My9mcmFnOjJhZmIxMzBmYjIyMjRjZjA4MTZjMmU0ZjA3OTU3ZGJiL3RleHRyZWdpb246MmFmYjEzMGZiMjIyNGNmMDgxNmMyZTRmMDc5NTdkYmJfMzI2_c653faff-113a-4e85-9f47-e167df42df9b" continuedAt="i5f7697defcd84e9280b14918ac983e18" escape="true">GRANTS RECEIVABLE</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f7697defcd84e9280b14918ac983e18">Grants receivable represents qualifying costs incurred where there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $<ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80My9mcmFnOjJhZmIxMzBmYjIyMjRjZjA4MTZjMmU0ZjA3OTU3ZGJiL3RleHRyZWdpb246MmFmYjEzMGZiMjIyNGNmMDgxNmMyZTRmMDc5NTdkYmJfMjcx_48774a0c-a095-4237-a5c7-238ba4c2faf3">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80My9mcmFnOjJhZmIxMzBmYjIyMjRjZjA4MTZjMmU0ZjA3OTU3ZGJiL3RleHRyZWdpb246MmFmYjEzMGZiMjIyNGNmMDgxNmMyZTRmMDc5NTdkYmJfMjg2_df4b4d18-9b6a-4b26-9053-c89a4807d240">3.9</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</ix:continuation></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_46"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfNjIx_06b7039f-6220-43e2-a469-371a5b6b30e9" continuedAt="i5b6a718667ac405b9c8f0fe97341137a" escape="true">PREPAID EXPENSES AND OTHER CURRENT ASSETS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i5b6a718667ac405b9c8f0fe97341137a" continuedAt="i8a2889c6bdb54b2c81a33f80267bd5bc"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfNjIy_f69aacf0-8d1d-4d89-a966-d69a7e28a791" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="flks:PrepaidClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMS0xLTEtMS0x_ffca9125-4849-4ba7-889e-9ea319723998">135,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:fixed-zero" name="flks:PrepaidClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMS0zLTEtMS0x_a4d04544-0793-46c0-a43d-f58906666fdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMi0xLTEtMS0x_729a893b-4974-4cc9-ae2c-5ddf16af61bd">963,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMi0zLTEtMS0x_bcd3d372-2a59-4418-af1a-ffa7b1038c59">684,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNC0xLTEtMS0x_2ec019aa-4194-40b8-8948-3ed98ece04b1">95,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNC0zLTEtMS0x_3e631ac3-4e75-4f76-8f83-a639439d0e27">137,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNS0xLTEtMS0x_14fd45ad-13ab-4448-9362-7a2ab1f03922">1,194,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNS0zLTEtMS0x_0209adbe-2d10-4df9-acb5-8479c13440ce">822,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a2889c6bdb54b2c81a33f80267bd5bc">Prepaid insurance is comprised of prepaid directors' and officers' insurance. In July 2020, the Company financed its directors' and officers' insurance premium with a short term note, the principal amount of which was approximately $<ix:nonFraction unitRef="usd" contextRef="i3365ee0645e1428a8bf15e40c57c905e_I20200731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfMzgx_038e19d7-b203-40b3-b858-7ea1c914c401"><ix:nonFraction unitRef="usd" contextRef="ifdc107ab4ba649ca943e231ca67e264f_I20190731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfMzgx_dd4a9e8d-e381-4feb-bd15-03cc53e801e3">0.9</ix:nonFraction></ix:nonFraction> million bearing interest at a rate of <ix:nonFraction unitRef="number" contextRef="i3365ee0645e1428a8bf15e40c57c905e_I20200731" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfNDE0_3b3bc4bb-b481-4c6e-acde-4edfd2e3631e">2.49</ix:nonFraction>%. In July 2021, the Company paid the directors' and officers' insurance policy in full.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_49"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjc4Mw_3c3d4310-9113-4421-ae41-5902b87cbf70" continuedAt="icabc856d105440d7b74057486f13c15c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icabc856d105440d7b74057486f13c15c"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with the University of Utah Research Foundation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 ("LSD1"). In exchange for the license, the Company issued <ix:nonFraction unitRef="number" contextRef="i75439519a47a4f6989cd2cd3b40b5195_I20111231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMzYx_d541bde7-5c2e-4be4-9d48-004a049162e2">2</ix:nonFraction>% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement subject to certain adjustments specified in the agreement, such as granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cancer Prevention and Research Institute of Texas</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i12375731a1584f5db3722367e5d44b8b_D20160601-20160630" decimals="-5" format="ixt:num-dot-decimal" name="flks:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfOTk5_ef862b42-e0c4-4e9a-9573-09964338d6f2">18.7</ix:nonFraction> million, further modified to $<ix:nonFraction unitRef="usd" contextRef="i88ae7eac7ac445aebc542f0429384d0a_D20160701-20160701" decimals="-5" format="ixt:num-dot-decimal" name="flks:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMTAyMw_9c481cf8-f751-4369-914e-0bc3fc5f4866">16.1</ix:nonFraction>&#160;million, to fund the development of an LSD1 inhibitor. This is a <ix:nonNumeric contextRef="i12375731a1584f5db3722367e5d44b8b_D20160601-20160630" format="ixt-sec:durwordsen" name="flks:RevenueFromGrantsAwardTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjc4NA_e3834d40-f4e6-406e-ab54-e05ba12d19db">3-year</ix:nonNumeric> grant award which originally expired on May 31, 2019. The grant now expires on May 31, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of a certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than <ix:nonFraction unitRef="number" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" name="flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjQxNg_176dfe4a-1174-4b13-943b-e916fb8e0d79">1</ix:nonFraction>% of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CPRIT grant is subject to funding conditions including a matching funds requirement where the Company will match <ix:nonFraction unitRef="number" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" name="flks:RevenueFromGrantsMatchingFundsRequirement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjU1MQ_0d3dec95-08ea-43b6-8994-f71e5b8def87">50</ix:nonFraction>% of funding from the CPRIT grant. As of September&#160;30, 2021, the Company has expended all allowable funds under the grant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021 and December&#160;31, 2020, the Company had grants receivable of $<ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjcxMg_48774a0c-a095-4237-a5c7-238ba4c2faf3">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjcyNw_df4b4d18-9b6a-4b26-9053-c89a4807d240">3.9</ix:nonFraction> million, respectively, related to the CPRIT contract.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_52"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RleHRyZWdpb246YjY0NGE4MGZiYzY0NGNlN2I2OTJhM2UwMDc0NGVjNjZfMTY4Ng_fe97ca04-cb54-4db2-b537-33bbda8685db" continuedAt="ib7a5716bcd2d4d6f80128495a4b53dc4" escape="true">FAIR VALUE OF FINANCIAL INSTRUMENTS </ix:nonNumeric></span></div><ix:continuation id="ib7a5716bcd2d4d6f80128495a4b53dc4" continuedAt="i9f3a9311a2214a56a3cc7bc9b0efa2e5"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><ix:continuation id="i9f3a9311a2214a56a3cc7bc9b0efa2e5"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RleHRyZWdpb246YjY0NGE4MGZiYzY0NGNlN2I2OTJhM2UwMDc0NGVjNjZfMTY4Nw_25cb47b2-1dfa-4dc4-9f96-3c0a235c86ba" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrants issued in connection with the Company's merger with Flex Pharma in 2019, which are measured at fair value on a recurring basis for the three and nine months ended September&#160;30, 2021:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f1fbc10f714bacb40851d5e79f0484_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RhYmxlOjM4ZDJjNDNiNmIwMjQ0ZTBhNzkxZmU5ZmUzYWI0YmRhL3RhYmxlcmFuZ2U6MzhkMmM0M2I2YjAyNDRlMGE3OTFmZTlmZTNhYjRiZGFfMS0xLTEtMS0x_5d016a74-6e39-4594-9e5d-9e3485722469">59,211</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i509e2e173464488a8d80584086100e5c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RhYmxlOjM4ZDJjNDNiNmIwMjQ0ZTBhNzkxZmU5ZmUzYWI0YmRhL3RhYmxlcmFuZ2U6MzhkMmM0M2I2YjAyNDRlMGE3OTFmZTlmZTNhYjRiZGFfMS0zLTEtMS0x_5644ba85-412f-4127-9037-b148e0afc12e">5,205</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice74598ecb934cd4a025ee4792e6670d_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RhYmxlOjM4ZDJjNDNiNmIwMjQ0ZTBhNzkxZmU5ZmUzYWI0YmRhL3RhYmxlcmFuZ2U6MzhkMmM0M2I2YjAyNDRlMGE3OTFmZTlmZTNhYjRiZGFfMS01LTEtMS0x_95f71860-4ac3-4705-bae4-df1704a77e22">54,006</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_55"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTYzMw_26e8cb4b-88a8-4f81-a5b0-4a86895bde52" continuedAt="ie5ea6c30f8dc40eab68fb3d17b8ce58c" escape="true">STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><ix:continuation id="ie5ea6c30f8dc40eab68fb3d17b8ce58c" continuedAt="i950f6480b9794591b44c8370506248c0"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock and Common Stock  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, the Company completed a public offering with total gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8980e464358d45fabde2cb82b652df91_D20200211-20200211" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTc1_7b15c4b2-8459-4b64-aa54-e3203005a130">11.0</ix:nonFraction> million, which includes the full exercise of the underwriter's over-allotment option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i8980e464358d45fabde2cb82b652df91_D20200211-20200211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjgx_70eec555-5ce0-4891-bf98-a9d83bfbfb04">1,252,173</ix:nonFraction> shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius (the &#8220;February 2020 Offering&#8221;). The February 2020 Offering was comprised of <ix:nonFraction unitRef="shares" contextRef="i0d4f1866e1f849c489daf2e3e0a10e39_D20200211-20200211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDgw_617fcc53-df2a-4648-b477-e0c58a331644">7,101,307</ix:nonFraction> Class A units, priced at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i03bc59929da24395880307913e87fb66_I20200211" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTM1_15ec5fbb-e522-4363-bf5a-f0f1de093983">1.15</ix:nonFraction> per unit, with each unit consisting of <ix:nonFraction unitRef="shares" contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTc3_1d081bc8-e5fb-42ab-8e5c-7b2ae862f6af">one</ix:nonFraction> share of common stock and a <ix:nonNumeric contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0Ng_ff28f6b0-efca-4a5e-a5ef-c629a1006a0f">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNjM2_d58ea350-61d1-4c03-974a-38156cabeaf0">one</ix:nonFraction> share of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNjg1_1c094e28-87f1-4efa-9133-1e7cf12627d5">1.15</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="i3725d493747d4bbe83005958d3ac6d23_D20200211-20200211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNzAz_3a0960e5-daba-4b4e-aa5a-31ef0df95d80">1,246,519</ix:nonFraction> Class B units, priced at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1f88e0cf88b84bf9854e0bedf0607dd1_I20200211" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNzU4_9b9e974d-ba96-469e-a793-8dec8b470810">1.15</ix:nonFraction> per unit, with each unit consisting of <ix:nonFraction unitRef="shares" contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfODAw_0af7b36e-e73e-4421-870c-8d4ced069e11">one</ix:nonFraction> share of Series A convertible preferred stock and a <ix:nonNumeric contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTYzOA_e9c6c7d8-dcca-47d5-b3c3-fa9c1b9e3dd3">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfODgz_439568a5-bc6b-428e-9b45-a3e6c8ead8e4">one</ix:nonFraction> share of common stock with and exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfOTM1_bbdd17e0-fcbf-403b-b9dd-f298e223c63f">1.15</ix:nonFraction> per share. A total of <ix:nonFraction unitRef="shares" contextRef="i507cbbf0634340df95b758b92062fb43_D20200211-20200211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfOTYw_07d91382-2f93-41f6-8308-c114760d7fd2">8,353,480</ix:nonFraction> shares of common stock, <ix:nonFraction unitRef="shares" contextRef="ieb060d868e36408ebdd36e2a2fe2658d_D20200211-20200211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfOTg3_c9be51ed-122e-4954-b815-ae4b70610778">1,246,519</ix:nonFraction> shares of Series A convertible preferred stock, and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i7fa8c9f6d7934dcaa6197a4ab35db643_I20200211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTA2OQ_e36816c4-fae8-4bf5-ab82-fc241986f785">9,599,999</ix:nonFraction> shares of common stock were issued in the offering, including the full exercise of the over-allotment option. The exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. All Series A preferred stock was converted to common stock prior to December 31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, in connection with the February 2020 Offering, the Company issued <ix:nonNumeric contextRef="i9309e3d556bc49209dff4d4ae28bffc9_I20200229" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0MQ_b1fbacb6-0d2f-41b0-9c42-5cdad4c0c2e3">five-year</ix:nonNumeric> warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i9309e3d556bc49209dff4d4ae28bffc9_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTQzNA_f3c75054-d3e9-4c7b-bf5c-09c6a3cc2191">one</ix:nonFraction> share of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i62ba6b78c05f44859360da199a2f4d38_I20200229" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTQ4Mw_da6dac0f-45f8-41ce-af41-80e67d2e5a6b">1.15</ix:nonFraction> per share (each a "warrant"). On December 11, 2020, the Company entered into warrant exercise inducement offer letters (&#8220;Inducement Letters&#8221;) with certain holders of <ix:nonFraction unitRef="shares" contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTY1Mg_677e39e6-94f3-4c81-883f-8b93d05fb518">3,964,065</ix:nonFraction> Warrants (collectively, the &#8220;Exercising Holders&#8221;) pursuant to which such holders agreed to exercise on December 11, 2020 for cash, their Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTgxMw_dce206d4-63c0-49ee-9683-4dadd7c2ef81">3,964,065</ix:nonFraction> shares of Common Stock in exchange for the Company&#8217;s agreement to (i) lower the exercise price of the Warrants held by the Exercising Holders to $<ix:nonFraction unitRef="usdPerShare" contextRef="idc44ad82e29143268254f26cd0b201a3_I20201211" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTk2MQ_b2281815-a45b-46d2-8515-65d337d8c6fd">0.90</ix:nonFraction> and (ii) issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="shares" contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjAzOA_b388a208-a061-4cdb-bade-c4d3305a4bb1">3,964,065</ix:nonFraction> shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjEyOA_026310f2-bdbb-4611-b351-3ad581390e89">1.182</ix:nonFraction> and expires on June 11, 2026.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2020, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="i8d324e00fd0449ada9306d7820e7650a_D20200803-20200803" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjIyMw_7141ddc1-6890-421a-959d-af4089c1f84c">5,130,390</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i637b5066c13e46c8ad5054fcf7d9db91_I20200803" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjI4MQ_4bf47f14-6a23-484f-b6d3-cc58fb50eb11">1.20</ix:nonFraction> per share. Total gross proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i97060a95644a4253a9d97d1b2c868b7e_D20200803-20200803" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjM1Mw_af2beade-f067-4e5b-97ae-b878ea73d08d">6.2</ix:nonFraction> million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2021, the Company entered into an At the Market Offering Agreement with Ladenburg Thalmann &amp; Co. Inc. Under this agreement the Company is able to issue and sell, from time to time, shares of its common stock. On February 5, 2021 and July 2, 2021, the Company filed prospectus supplements with the SEC to register the offering and sale of Common Stock having an aggregate offering price of up to $<ix:nonFraction unitRef="shares" contextRef="ie1455af2bd3e48fbab07d23af33ccf27_D20210205-20210205" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjg3MQ_244c6d58-a768-4554-8a85-eb07b9cb9f20">6.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="shares" contextRef="i8e0f9788dcba480c96b8fa31f68fb351_D20210702-20210702" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjg3OA_9a9ac783-e327-4e17-a409-4e5b44140cdf">25.0</ix:nonFraction>&#160;million, respectively. During the nine months ended September&#160;30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i22aba5a3e90e4e95a276ef89efe1ac98_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjk0Ng_18cbb509-267f-4516-a61f-f4e0cc2dd25f">3,214,234</ix:nonFraction> shares under the Sales Agreement for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i22aba5a3e90e4e95a276ef89efe1ac98_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzAwNA_e4297f86-7852-4f20-8195-91c747bf2d6f">6.7</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="id5ae6026c59f4ec38c6949b4bef8d233_D20210308-20210308" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzA3MA_f945e672-70bf-4d94-b1f5-08bf24dda9cc">16,806,722</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4075aa174dd346ae968ca14c8a84ba8a_I20210308" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzEyOA_9b053e6e-bdbf-40fa-9c48-08085b8f973a">1.3685</ix:nonFraction> per share. Total gross proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i38ec404e1c2a4fa19e8f881a89360a33_D20210308-20210308" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzIwMA_4d6e86cc-e814-46e8-bac4-d226bf89b107">23.0</ix:nonFraction>&#160;million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><ix:continuation id="i950f6480b9794591b44c8370506248c0"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants Exercised for Cash </span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i72d6648d8528478096111949d12cd28f_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="flks:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzM4NA_6c6ab96d-2ee2-445f-8401-583fb8710422">1,298,567</ix:nonFraction> common shares as a result of warrant exercises, and received cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzQ3OQ_b9982be7-2746-4ae5-a48b-443527386eab">1.5</ix:nonFraction> million. As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzUwMQ_d7055003-6f49-4b31-b03e-7e3994340a7a">7,747,587</ix:nonFraction> warrants remain outstanding. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Right to Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 3, 2019, Flex Pharma, Private Salarius and Merger Sub entered into the Merger Agreement. Pursuant to the Merger Agreement, Flex Pharma distributed <ix:nonFraction unitRef="shares" contextRef="i9f29b4bffdb04060b79c90b287ec75ee_I20190718" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzcxOA_ad95a074-39f3-4382-bfa0-0141c6c76f65">one</ix:nonFraction> right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive a warrant to purchase the Company's common shares on January 20, 2020. These warrants were issued on July 1, 2021 and are exercisable in the aggregate, into <ix:nonFraction unitRef="shares" contextRef="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDAzMQ_09ec4958-57d3-42a5-99b2-3aa71e36d847">142,711</ix:nonFraction> shares of the Company's common stock with a <ix:nonNumeric contextRef="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0MA_52c5e3d7-2c8c-403a-909d-fc8ddafc3fa5">5-year</ix:nonNumeric> term from January 20, 2020, at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDEzOA_bc1ef736-59bf-4c8e-94d0-10987a701308">15.17</ix:nonFraction> per share. The warrants are subject to a cashless exercise, at the option of the Company, at the closing of an issuance and sale of the Company&#8217;s common stock in certain qualified financing, upon the closing of which the holders of warrants shall be entitled to receive a number of shares of common stock equal to the greater of two formulae defined by the Merger Agreement, which are based on the volume weighted average price of the Company's common stock during the <ix:nonFraction unitRef="day" contextRef="i7b06abcc4a3c4d32837217db39cf0e29_D20190718-20190718" decimals="INF" name="flks:ClassOfWarrantOrRightThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDYxMA_797b58c0-a533-464e-8fcd-3480ea551ca1">10</ix:nonFraction> consecutive trading days ending on the trading day immediately preceding the date of exercise. As a result, the warrants have been classified as a liability.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for these warrants at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a Black-Scholes valuation model. Using this method, unobservable inputs included the Company&#8217;s equity value, expected timing of possible outcomes, risk free interest rates and stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price volatility. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTYzNg_67627345-5e6c-4cec-a205-68229c72f30d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variables used in the Black-Scholes model are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:43.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6b4f85b5e2f4b0da127ab2e310c28a8_I20210930" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMS0yLTEtMS0x_fbcafcdc-fec1-451f-8b10-f8e25b4060fc">0.53</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefe55d006aa740d7bdb83434769e6cec_I20201231" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMS00LTEtMS0x_85b14db7-171d-40a6-9e9b-54c3e24b89f8">0.27</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMi0yLTEtMS0x_55cd6b22-3316-4cc2-8db3-7814b91f234b">3.31</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMi00LTEtMS0x_02e5fc40-c90e-48ed-af4e-060d4ee5b5f7">4.06</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b1e7939df33476493958c5474f1ec12_I20210930" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMy0yLTEtMS0x_0313300d-72b8-479c-84ce-868e7bd5001e">130.23</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if20fa72ce8b44760a27f5514b956d6a1_I20201231" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMy00LTEtMS0x_8445459d-9912-4771-b1e8-3c16be4e7b8f">130.56</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3767d63d21841febd91f1664b87398c_I20210930" decimals="4" format="ixt:fixed-zero" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfNC0yLTEtMS0x_436bcb30-d03d-4d2b-9e09-f2d2d8ae085d">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie27743a41234488c94ecdbae56d5030e_I20201231" decimals="4" format="ixt:fixed-zero" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfNC00LTEtMS0x_3dde8c51-b1f9-4de5-a899-43af72229781">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wedbush Warrant</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, upon the closing of the merger, the Company elected to issue warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTI5OQ_9e2a5fca-b099-4649-9a1e-89c40433a98d">42,928</ix:nonFraction> common shares to Wedbush Securities Inc. ("Wedbush") to satisfy $<ix:nonFraction unitRef="usd" contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTM2Ng_8f6dc8b1-49eb-407f-8302-fcaa9294c93f">0.5</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTM4NA_be9fe3c9-5c4b-438d-8141-6070b49defe0">1.0</ix:nonFraction> million success fee payable to Wedbush at the closing of the merger. The remaining $<ix:nonFraction unitRef="usd" contextRef="i9de1973dc957478cb0bc2d769059d427_D20190719-20190719" decimals="-5" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTQ3MA_55643bbe-3731-48dd-9b1d-259a25543c17">0.5</ix:nonFraction> million success fee was paid in cash. These warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTU1Mg_4513aa02-2505-4e39-8b58-b5e7e7c8fcc3">18.90</ix:nonFraction> and a <ix:nonNumeric contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0Mg_5f611747-a9fd-46da-b8ee-b56b3323d9a5">5-year</ix:nonNumeric> term. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021, all warrants issued to Wedbush were outstanding.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_58"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU3OA_64c54756-0844-4020-a840-f79f64195a3f" continuedAt="ic4c3f8ae17a94dc181cb7db8216d3a82" escape="true">EQUITY-BASED COMPENSATION </ix:nonNumeric></span></div><ix:continuation id="ic4c3f8ae17a94dc181cb7db8216d3a82" continuedAt="i8842aef719904d6faeeb2e565ed94125"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of September&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="id806215bb22c4a6bbb84c72994b31e52_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfOTU1_ec16a5eb-11e3-4258-9a6b-50cf382baebe">1,026,690</ix:nonFraction> shares remaining available for the grant of stock awards under the 2015 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine-month periods ended September&#160;30, 2021 and 2020, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTEwMQ_d98d10e3-7a3b-485d-acff-ef3a355d5fa2">79,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9cd9bebb5d234611a3707cb6f311df80_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTEwOA_94cc8836-209e-4d2e-9385-c0a3cad64871">182,000</ix:nonFraction>, respectively, stock options to its employees and directors, pursuant to the plan described above. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI0NA_14cf129a-350a-4324-b668-9e3a5073d911">one</span> to <ix:nonNumeric contextRef="i618536f8debf473cb0710a7c02b3140f_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI1MA_88b443f6-5a85-4198-852e-e2e0ce9ae5e0">four years</ix:nonNumeric> and have a contractual term of <ix:nonNumeric contextRef="i28b2f8b8184949889f3aa6bcf52f8836_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI4NA_a60ae93f-f4ca-4abf-a189-a813266bd880">ten years</ix:nonNumeric>. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><ix:continuation id="i8842aef719904d6faeeb2e565ed94125"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU3Nw_9234e57c-cec3-4ff2-ac6b-2b0b9bebd986" continuedAt="if8500f0f2e2c465c8f82e5a8b2b1deab" escape="true">The fair value of the option grants awarded during each of the nine month periods ended September&#160;30, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTk5Ng_c5063401-9aa0-4d5e-8512-e24cec6c887c">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTA5OTUxMTYyODAzOTA_6d01847a-2de5-4742-ac93-15447bc86cca">0.7</ix:nonFraction> million, respectively, which has been estimated with the following assumptions on the grant date.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><ix:continuation id="if8500f0f2e2c465c8f82e5a8b2b1deab"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.467%"><tr><td style="width:1.0%"></td><td style="width:36.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3/10/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/16/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/2/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMS0xLTEtMS0x_75027b64-0719-404e-bf2b-eccad6d901b0">1.00</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMS0yLTEtMS0x_7a78aaca-2688-4769-bd93-8525ac926261">1.09</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMS00LTEtMS0xMDM3Ng_3ce45de8-d614-4b84-9ee1-a50b086f4869">0.93</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMi0xLTEtMS0x_028af1a1-6f90-40d1-be22-dac7c6913c62">133.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMi0yLTEtMS0x_1823a53f-9f1b-4273-9efd-dc6960ee6c6d">131.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMi00LTEtMS0xMDM3Ng_81e4e6b5-2062-4755-bcda-1ce539c1faae">130.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMy0xLTEtMS0x_11bb73aa-1e22-4528-8688-d46a66c9cebb">6.00</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMy0yLTEtMS0x_d36aeb56-52b5-4f4f-bcd2-420a1ec88540">6.00</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMy00LTEtMS0xMDM3Ng_a3e1e42a-a827-4b18-911f-31617c2242c2">6.00</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfNC0xLTEtMS0x_e70278c5-5313-42cf-967f-750c8778e996">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfNC0yLTEtMS0x_e44c9e6b-b7fe-4f2e-93da-4d4c4cf4eaa5">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfNC00LTEtMS0xMDM3Ng_c5fd352f-c6e3-49ba-9c5a-99dc9d253d68">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU3Mw_cf41fbe9-6751-4ee4-9848-6c7a4722a6cb" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for employees and non-employees for the nine months ended September&#160;30, 2021 and 2020: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:44.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS0xLTEtMS0x_f10fcaa4-3b4f-4c08-bd1d-4c99a902dc6e">166,233</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS0zLTEtMS0x_a1a6f26e-3b0a-4bd3-8e8f-38ac35356966">34.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id634fbf36df7473db3bb7e070c784cad_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS01LTEtMS0x_fecb6402-ebd8-42c0-8259-13c0a5601c86">6.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS03LTEtMS0x_1d40cea8-8643-455d-bf22-113fe042d3b4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMi0xLTEtMS0x_2c0d32e9-2c61-4fcc-bbef-422266449ad3">743,118</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMi0zLTEtMS0x_abf9ec10-70a6-460e-b14b-75c24a950c09">0.61</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMy0xLTEtMS0x_042fe7cd-0590-4d50-b109-b13464411a00">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNC0xLTEtMS0x_d252ebba-6602-4532-8dab-386b0f5ac3a5">36,613</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNC0zLTEtMS0x_97411e2a-6b02-4624-a53c-42ccae31abd3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNS0xLTEtMS0x_c740fcde-132d-4386-9e56-7d306537e832">30,766</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi0xLTEtMS0x_20ab71f2-ed1a-484b-9919-0599a57e74dd">841,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi0zLTEtMS0x_db4d3313-caa5-42c4-8e3d-11e871f6708a">4.55</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi01LTEtMS0x_5ddcd007-1cb8-48e1-9255-ef6978f32e82">9.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi03LTEtMS0x_6787c5c2-aa73-4748-abd2-9281b2390d05"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy0xLTEtMS0x_40fd0772-c130-4f2a-b9b4-a9c07515e0fc">69,813</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy0zLTEtMS0x_37767c6b-b1bd-4b27-a06b-97be51deb31a">37.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy01LTEtMS0x_8c79efa5-a2ed-4144-8e53-04520bf90b43">5.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy03LTEtMS0x_057ceaf9-11d3-4862-a1b0-85cd7d07e303">&#8212;</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS0xLTEtMS0x_bbb394fa-0ce8-44ca-a284-cb0ac3851709">1,563,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS0zLTEtMS0x_d0723bd7-6304-4b32-88df-58746714a7d4">2.78</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab6f2c50c3e144b5b8f013949d188cfd_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS01LTEtMS0x_bc896e04-b0f4-4435-8b1e-c097e63311f6">9.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS03LTEtMS0x_758c24fd-abe7-4a0f-b626-353564993821">175,770</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTAtMS0xLTEtMQ_d98d10e3-7a3b-485d-acff-ef3a355d5fa2">79,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if61674fa0744426bad5a356d5af164c9_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTAtMy0xLTEtMS90ZXh0cmVnaW9uOjIxZTYwZThhNjU1OTQzZDVhYTVkNDMxNTA2ZGE4YmE4XzQ_4be82777-7ac2-4e15-a612-1d5438e2acde">1.04</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i01803b42cf2b4af6b7b175622f3970f8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTAtMy0xLTEtMS90ZXh0cmVnaW9uOjIxZTYwZThhNjU1OTQzZDVhYTVkNDMxNTA2ZGE4YmE4Xzc_6edd18d8-c287-4a2d-a118-febea3f6404c">1.49</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTEtMS0xLTEtMQ_0192362f-001c-44d7-a08d-2f47f7695ee0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTItMS0xLTEtMQ_af4ed0fc-e60a-44db-a631-e93ad836f460">45,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTMtMS0xLTEtMQ_a394f7f3-8710-451b-9c50-5e52a565860e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtMS0xLTEtMQ_61283609-437f-4244-b481-d10a33023d36">1,597,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtMy0xLTEtMQ_765ce476-ea24-4989-bbc8-4907f68cda5c">2.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtNS0xLTEtMQ_0229cdbf-a2ec-48ae-ba65-594eec662364">8.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtNy0xLTEtMQ_ab6c4222-b6ed-4c34-ace1-3693810d5808">271,540</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtMS0xLTEtMQ_2eaee187-61a2-4ccf-9202-41f891ec1182">323,730</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtMy0xLTEtMQ_0b62bb25-9389-4edb-b205-61214137bc30">9.27</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtNS0xLTEtMQ_3445c3f6-54cc-4048-8a8a-d2cd1a0a8fff">7.74</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtNy0xLTEtMQ_ba3c3431-97e8-445c-84ce-58a9075b122e">34,440</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjI1MQ_d92381f7-a518-4e47-83ba-7f8f65f94f2b">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjI2Nw_7fd911e3-8a0b-45b4-af28-f9ef52f30e83">0.4</ix:nonFraction> million respectively of total unrecognized compensation cost related to unvested stock options. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of <ix:nonNumeric contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU2Mw_84733612-ff57-4376-94d3-c4abeb65539a">2.45</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_61"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis should be read in conjunction with the unaudited financial information and the notes thereto included herein, as well as our audited financial statements and notes thereto contained in our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Annual Report</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under "Part I - Item 1A - Risk Factors" discussed in our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual Report</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> on Form 10-K for the year ended December 31, 2020, in other subsequent filings with the SEC, and elsewhere in this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and we undertake no obligation to update or revise these statements in light of future developments.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, we are developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The field concerned with gene expression regulation is called &#8216;epigenetics&#8217;. As cancers are often diseases driven by gene dysregulation, epigenetics is an area of interest for cancer treatment. Our lead epigenetic based technology, seclidemstat ("SP-2577"), may treat cancers by restoring correct gene expression. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2011, Salarius licensed SP-2577 and related compounds from the University of Utah Research Foundation.  SP-2577 is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (&#8220;LSD1&#8221;). LSD1&#8217;s enzymatic activity can cause genes to turn on or off and thereby affect the cell&#8217;s gene expression and overall activity. In addition, LSD1 can act via its scaffolding properties (protein-protein interactions), independently of its enzymatic function, to alter gene expression and modulate cell fate. In healthy cells, LSD1 is necessary for stem cell maintenance and normal cell development processes. However, in several cancers LSD1 is highly expressed and acts to incorrectly silence or activate genes leading to disease progression. High levels of LSD1 expression are often associated with aggressive cancer phenotypes and poor patient prognosis. Hence, development of targeted LSD1 inhibitors is of interest for the treatment of various cancers. SP-2577 uses a novel, reversible mechanism to effectively inhibit LSD1&#8217;s enzymatic and scaffolding properties and thereby treat and prevent cancer progression. To effectively develop SP-2577, we are pursuing a speed-to-market and market expansion strategy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As part of our speed-to-market strategy, we are initially focused on developing SP-2577 for the treatment of sarcomas with high unmet needs. We are investigating SP-2577 for the treatment of several advanced sarcoma subtypes, including Ewing sarcoma, myxoid liposarcoma, and other sarcomas that share similar biology, i.e. FET-rearranged sarcomas. The described sarcomas are all driven by a chromosomal translocation involving a FET-gene family member (EWS, FUS, or TAF15). The translocation results in an FET-rearranged fusion oncoprotein. SP-2577&#8217;s target, LSD1, has been shown to associate with FET-rearranged fusion oncoproteins to help promote tumor growth. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We believe SP-2577 disrupts LSD1 from associating with FET-rearranged fusion oncoproteins and therefore leads to inhibition of the fusion oncoprotein&#8217;s cancer promoting activity. As a result, SP-2577 has the potential to treat FET-rearranged sarcomas by reversing cancer promoting gene expression and thereby possibly preventing tumor growth and causing cancer cell death. Preclinical studies of SP-2577 in several FET-rearranged sarcoma cell lines including Ewing sarcoma, myxoid liposarcoma, clear cell sarcoma, and desmoplastic small round cell tumors demonstrated that SP-2577 was effective in inhibiting cell proliferation and viability.  Additionally, in certain Ewing sarcoma animal models, SP-2577 showed a significant tumor reduction as well as a significant survival benefit compared to untreated animals. Our ongoing Phase 1/2 clinical trial was designed as a single agent dose escalation followed by a dose expansion study in Ewing sarcoma. As a result, given the described preclinical data in FET-rearranged sarcomas and clinical data in FET-rearranged sarcoma patients from our Advanced Solid Tumor (AST) trial, in 2021 we expanded the trial to study SP-2577 in non-Ewing FET-rearranged sarcomas. The amended ongoing dose expansion portion of the trial is studying SP-2577 in combination with a common chemotherapeutic regimen, topotecan and cyclophosphamide ("TC") in Ewing sarcoma patients and single agent SP-2577 in myxoid liposarcoma and other FET-rearranged sarcoma patients. The dose expansion portion can enroll up to 30 relapsed or refractory Ewing sarcoma patients and up to 30 relapsed or refractory FET-rearranged patients (of which up to 15 will be myxoid liposarcoma). In Ewing sarcoma patients, the trial will assess the safety and tolerability of SP-2577 and TC and study preliminary efficacy of the regimen. In myxoid liposarcoma and other FET-rearranged sarcoma patients, the trial is studying single-agent SP-2577 safety, tolerability, and preliminary efficacy. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As LSD1 can interact with over 60 regulatory proteins other than FET-fusion oncoproteins, we believe that LSD1 may also play a critical role in progression of various other cancer types. Preliminary efficacy data from our Phase 1/2 AST trial supports this notion and work is ongoing to identify large market solid tumor indications with the highest potential for SP-2577 success. Continued progress in this area will support the market expansion portion of our strategy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to solid tumors, SP-2577 has shown promising preclinical activity in hematologic cancers. We recently announced the initiation of an Investigator Initiated Trial studying SP-2577 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Myelodysplastic syndromes can progress into Acute Myeloid Leukemia (AML) and data from our ongoing trial will inform development of SP-2577 in hematologic cancers (also referred to as &#8220;liquid tumors" or "blood cancer&#8221;), including AML.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The American Cancer Society estimates there were almost 20,000 new cases of AML in the US alone in 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recent data from &#8220;LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade&#8221; by W. Sheng, et al. and &#8220;Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade&#8221; by Y. Qin, et al. suggests that LSD1 plays a role in tumor immune activity and can sensitize tumors to checkpoint inhibitors. These works have sparked interest in combining LSD1 inhibitors with checkpoint inhibitors. We are conducting preclinical work with SP-2577 in this area.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception. We had an accumulated deficit of $28.1 million as of September&#160;30, 2021. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared using Generally Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should we be unable to continue as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, our product candidate, add personnel necessary to continue to operate as a public company, and work to develop an advanced clinical pipeline of product candidates. We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs and efforts to achieve regulatory approval.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, the Cancer Prevention and Research Institution of Texas ("CPRIT") fund matching requirements had been fully met and we have expended all current available funds under the grant. Our September&#160;30, 2021 balance sheet reflects a receivable due from CPRIT of approximately $2.1 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our $31.9 million in cash and cash equivalents on hand as of September&#160;30, 2021, and the collection of the CPRIT receivable are sufficient to fund our anticipated operating and capital requirements through the completion of our current clinical trials in 2022 and beyond, however, we will continue to require substantial additional capital to continue our clinical development activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations as a whole. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development, regulatory and commercialization efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop and commercialize our product candidate and to fund our operations.</span></div><div style="margin-top:6.6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend, when required, to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments. We may also consider new collaborations or selectively partnering our technology. However, we cannot provide any assurance that we will be successful in accomplishing any of our plans to obtain additional capital or be able to do so on favorable terms or on terms acceptable to us.</span></div><div style="margin-top:6.6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6.6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Developments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 2, 2021, the Company filed a prospectus supplement with the SEC to register the offering and sale of our common stock pursuant to the terms of that certain At the Market Offering Agreement (the &#8220;Sales Agreement&#8221;) between the Company and Ladenburg Thalmann &amp; Co. Inc. (&#8220;Ladenburg&#8221;), dated as of on February 5, 2021, having an aggregate offering price of up to $25.0 million (the &#8220;Additional Shares&#8221;). We had previously filed a prospectus supplement with the SEC registering the offering and sale of our common stock under the Sales Agreement having an aggregate offering price of up to $6.3 million (together with the Additional Shares, the &#8220;ATM Shares&#8221;). Under the Sales Agreement the Company is able to issue and sell, from time to time, shares of its common stock with Ladenburg acting as an agent for such sales. Sales of the ATM Shares may be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the NASDAQ Capital Market. During the three month period ending September 30, 2021 the Company sold 393,741 ATM shares for aggregate net proceeds of $0.4 million. In aggregate, during the nine months ended September 30, 2021, we issued 3,214,234 shares under the Sales Agreement for net proceeds of $6.7 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6.6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Special Note About Coronavirus (COVID-19)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic is significantly affecting the United States, global economies, and businesses worldwide.  While the potential magnitude and duration of the economic and social impact of the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may, in the future, reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. At this time we are experiencing minimal disruption to our clinical trials. However, our ongoing Phase 1/2 Ewing sarcoma clinical trial and Phase 1/2 AST clinical trial may encounter delays in enrolling new patients due to concerns or healthcare resource constraints because of the COVID-19 pandemic.  In addition, although at this time we have experienced no disruptions to manufacturing capabilities, certain aspects of our supply chain may be disrupted as certain of our third party suppliers and manufacturers have paused their operations in response to the COVID-19 pandemic or have otherwise encountered delays in providing supplies and services. The COVID-19 pandemic could also have a material and negative impact on our liquidity, capital resources (including our ability to secure additional financing if and when needed), our business and operations, and our workforce, as well as those of the third parties with which we do business or upon which we rely. While the situation is fluid and we do not yet know the full extent of potential delays or impacts on us or on healthcare systems or the global economy in general, we have worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic. However, we may experience disruptions in the future that have and could further adversely impact our business operations as well as our preclinical studies and clinical trials. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the condensed consolidated results of our operations for the nine and three months ended September&#160;30, 2021 compared to September&#160;30, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:36.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840,216&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,754,379&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378,239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,852,887)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,890,375)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,015,930)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,803,682)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,655,404)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,893,021)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730,730)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,333,062)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">265,538&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government grants and other income </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income(expense), net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,230)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,663,365)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,584,706)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,737,100)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,716,632)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue, which was derived solely from the CPRIT grant, was $0 for the three month period ended September 30, 2021 resulting from the completion of CPRIT available funding under the grant during the second quarter of 2021. We have reached the maximum amount of the eligible spending that can be reimbursed from CPRIT. </span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased during both the current period and nine months ended September 30, 2021 compared to the same periods in 2020 resulting from significantly higher personnel costs, clinical trial costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and higher laboratory costs resulting from increased non clinical efforts, all of which more than offset lower manufacturing and process development costs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses increased during the current three month period compared to the same period a year ago resulting from higher personnel costs and increased professional fees. For the nine months ended September 30, 2021 general and administrative costs were lower than the same period a year ago resulting from lower overall personnel costs (severance costs in 2020 that did not repeat in the current period), and lower professional fees.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Government Grant Other Income </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 12, 2021, the Small Business Administration (SBA) authorized full forgiveness of $0.2 million for the Company's Paycheck Protection Program (PPP) Loan. The Company had previously recognized this as government grants and other income during the nine months ended September 30, 2020.</span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_70"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and we anticipate that we will continue to incur losses for the foreseeable future. To date, we have secured capital from the sale of equity and grant revenue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize our product candidate. At the same time, we expect our expenses to increase in connection with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ongoing research and development and manufacturing activities, particularly as we advance our product candidates to later stages of development.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until we can generate a sufficient amount of revenue from our products, if ever, we expect to finance future cash needs through public or private equity or debt offerings or other collaborations. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidate.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, we may be unable to complete a collaboration, or if we do, we may be forced to relinquish valuable future product rights.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that, based on our current operating plan, our current unrestricted cash and cash and cash equivalent balances will be sufficient to fund our operations through the completion of our current clinical trials in 2022 and beyond.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had $33.6 million of working capital and our cash and cash equivalents totaled $31.9 million, which were held in bank deposit accounts and a money market account. Our cash and cash equivalents balance increased during the nine months ended September 30, 2021, primarily due to sales of our common stock in our public offering which closed on March 8, 2021 and receipt of $2.7 million as a payment of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our CPRIT remaining receivable.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by in:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,479,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,937,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,264,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,756,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,785,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,818,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in operating activities was $7.5 million in the current period, a decrease of approximately $1.5 million from the same period a year ago. The Company collected approximately $3.6 million in grants receivable from CPRIT during the nine months ended September 30, 2021 compared to $0.8 million for the same period a year ago.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities for the nine months ended September&#160;30, 2021 was $28.3 million, compared to $14.8 million for the same period of the year 2020. The increase resulted from the Company's completion of common stock sales in February and September 2021 and a public offering in March 2021 with total net proceeds of approximately $27.0 million, and the receipt of approximately $1.5 million from the exercise of warrants during the nine months ended September&#160;30, 2021.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Critical Accounting Policies and Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the condensed consolidated balance sheet and the reported amounts of expenses during the reporting period. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our condensed consolidated financial statements prospectively from the date of the change in estimate.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes to our critical accounting policies from those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K filed with SEC on March 18, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Readers should refer to our Annual Report on Form10-K filed with SEC on March 18, 2021, Note 2, Basis of Presentation and Significant Accounting Policies to the accompanying financial statements for descriptions of these policies and estimates.</span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_73"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quantitative and Qualitative Disclosures about Market Risk</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_76"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 4. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controls and Procedures</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules 13a-15(e) and 15d-15(e)</span><span style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">under the Exchange Act, that are designed to ensure that information required to be disclosed in our periodic and current reports that we file under the Exchange Act with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer and principal accounting officer), as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer), of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.  Based on the foregoing, our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, there was no significant change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_82"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not a party to any material legal proceedings on the date of this report. We may from time to time become involved in legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material.</span></div><div><span><br/></span></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_85"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a discussion of certain factors that could materially affect our business, financial condition, and operating results, you should carefully review and consider the information under &#8220;Part I, Item 1A- Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, as well as the risk factors set forth below.  The risk factors below are in addition to and supplement (and with respect to certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">matters, update) the risk factors discussed in our Annual Report on Form 10-K and in our Current Report on Form 8-K filed on July 29, 2020.  Other than as set forth below, there have been no material changes to the risk factors included in our Annual Report on Form 10-K filed with the SEC on March 18, 2021 and in our Current Report on Form 8-K filed on July 29, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Our Industry</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 pandemic could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, the COVID-19 pandemic has negatively impacted the global economy and the magnitude, severity, and duration of this impact is unclear and difficult to assess. In addition, certain areas, including Texas where we are headquartered, have recently experienced a resurgence of COVID-19 cases. We have worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic. At this time we have experiencing minimal disruption to our clinical trials during the nine months ended September 30, 2021. While both our Ewing sarcoma clinical study and our Advanced Solid Tumor clinical study are active., either or both may encounter delays in enrolling new patients due to concerns or healthcare resource constraints because of the COVID-19 pandemic. We plan to release clinical data from both studies, as previously disclosed, during 2021 and 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, the situation with respect to the COVID-19 pandemic and its impact changes daily and is difficult to predict. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, although at this time we have experienced no disruptions to manufacturing capabilities, certain aspects of our supply chain may be disrupted as certain of our third party suppliers and manufacturers have paused their operations in response to the COVID-19 pandemic or have otherwise encountered delays in providing supplies and services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">To combat the spread of COVID-19, the United States and other locations in which we operate have imposed measures such as quarantines and &#8220;shelter-in-place&#8221; orders that are restricting business operations and travel and requiring individuals to work from home (&#8220;WFH&#8221;), which has impacted all aspects of our business as well as those of the third-parties we rely upon for certain supplies and services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The continuation of WFH and other restrictions for an extended period of time may negatively impact our productivity, research and development, operations, preclinical studies and clinical trials, business and financial results. Among other things, the COVID-19 pandemic may result in: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a global economic recession or depression that could significantly and negatively impact our business or those of third parties upon which we rely for services and supplies;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">constraints on our ability to conduct our operations and our preclinical studies and clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in our ability to extend the term of the CPRIT grant;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced productivity in our business operations, research and development, marketing, and other activities; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disruptions to our third-party manufacturers and suppliers;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">increased costs resulting from WFH or from our efforts to mitigate the impact of COVID-19; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced access to financing to fund our operations due to a deterioration of credit and financial markets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:99%">We continue to monitor the situation and the continued disruption of the COVID-19 pandemic and its effects on the worldwide economy could negatively and materially impact our operating and financial operating results. The resumption of normal business operations may be delayed and a resurgence of COVID-19 could occur resulting in continued disruption to us or to the third parties with which we do business. As a result, the effects of the COVID-19 pandemic could have a material adverse impact on our business, results of operations, and financial condition for the remainder of 2021 and beyond.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:99%">  </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Salarius&#8217; Financial Condition and Capital Requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We will continue to require substantial additional capital to fund our clinical activities and operations and the impact of the COVID-19 pandemic on the financial markets will likely negatively impact our ability to raise additional financing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical development-stage biopharmaceutical company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception. Our net losses were $7.4 million for the year ended December 31, 2020, and we have incurred a net loss of $3.7 million and $8.7 million for the three and nine months ended September&#160;30, 2021, respectively. We have prepared our financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should we be unable to continue in existence.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to require substantial additional capital to continue our clinical development and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The development of our product candidate and funding our operations have been funded through sales of equity and funds received from CPRIT. The amount and timing of our future funding requirements will depend on many factors, including but not limited to the pace and results of our clinical development efforts, as well as our ability to access the funding remaining available under the CPRIT grant. Further, the global economic downturn may impair our ability to obtain additional financing through other means, such as debt financing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance we will be able to secure additional financing on favorable terms to us, or at all.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further any debt financing may contain restrictive covenants which limit our operating flexibility and any equity financing will likely result in additional and possibly significant dilution to existing stockholders. Failure to raise sufficient capital, as and when needed or on commercially reasonable terms, would have a significant and negative impact on our financial condition and our ability to develop our product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%">We rely on funding from CPRIT and failure to receive additional funds may harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the course of the development of our product candidate, we have been funded through the sale of equity and the funding we received from the CPRIT grant. The CPRIT agreement was awarded in June 2016 and originally provided for a three-year grant award of up to $18.7 million, further modified to $16.1 million, to fund the development of the LSD-1 inhibitor. We have received $14 million since inception of the grant. The term of the CPRIT agreement was extended through May 31, 2022. We currently have a $2.1 million receivable due from CPRIT on our September 30, 2021 balance sheet. If CPRIT terminates our agreement prior to the expiration due to an event of default or if we terminate the agreement, CPRIT may require us to repay some or all of the disbursed grant. Although we may apply for government contracts and grants in the future, we may not be successful in obtaining additional grants for any product candidates or programs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to maintain listing of our securities on the Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for our stockholders to sell their securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nasdaq requires listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any reason, Nasdaq should delist our securities from trading on its exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the following may occur, each of which could materially adversely affect our stockholders.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, if at any time the bid price of our common stock closes at below $1.00 per share for more than 30 consecutive trading days, we may be subject to delisting from the Nasdaq Capital Market. If we receive a delisting notice, we would have 180 calendar days to regain compliance (subject to any additional 180-day compliance period which may be available to us), which would mean having a bid price above the minimum of $1.00 for at least 10 consecutive days in the 180-day period. During this 180-day period, we would anticipate reviewing our options to regain compliance with the minimum bid requirements, including conducting a reverse stock split. To the extent that we are unable to resolve any listing deficiency, there is a risk that our common stock may be delisted from Nasdaq, which would adversely impact liquidity of our common stock and potentially result in even lower bid prices for our common stock. On November 1, 2021, the closing price of our common stock was $0.85 per share.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.342%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1615219/000161521921000070/flks-20210701.htm">Form of Flex Warrant (incorporated by reference to the Company&#8217;s Current Report on Form 8-K that was filed with SEC on July 1, 2021).</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrx20210930ex-311.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrx20210930ex-312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrx20210930ex-321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Salarius Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in XBRL (eXtensible Business Reporting Language):(i) Unaudited Condensed Consolidated Balance Sheets, (ii) Unaudited Condensed Consolidated Statements of Operations (iii) Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit), (iv) Unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Unaudited Consolidated Financial Statements.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.362%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">*   The material contained in Exhibit 32.1 is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filing, except to the extent that the registrant specifically incorporates it by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i3735967cc9cb41008b6e1b6e77b8d64e_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3735967cc9cb41008b6e1b6e77b8d64e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:4.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David J. Arthur</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Arthur</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer (Principal Executive Officer)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark J. Rosenblum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rosenblum</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chief Financial Officer and Executive Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>slrx20210930ex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0a5971ff63b240c3b94f0c4c0fee830e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Arthur, President and Chief Executive Officer, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:47.25pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief&#160;Executive&#160;Officer (Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>slrx20210930ex-312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic146fd99917a4fd19209c6c390f65f4e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark J. Rosenblum, Executive Vice President and Interim Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter  that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:47.25pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Interim Chief Financial Officer<br>(Principal&#160;Financial and Accounting&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>slrx20210930ex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1213113e7bbc4e36b0de417634dc6557_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font><br></font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Salarius Pharmaceuticals, Inc. (the &#34;Company&#34;) for the fiscal period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:47.25pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief&#160;Executive&#160;Officer (Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Interim Chief Financial Officer<br>(Principal&#160;Financial Officer and Principal Accounting&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>flks-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:933be885-fec0-4346-88e3-96fdb95628e8,g:3a038917-b4df-486f-8fdf-f41d10c2cf87-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:flks="http://www.flex-pharma.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.flex-pharma.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://www.flex-pharma.com/role/COVERPAGE">
        <link:definition>0001001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDOPERATIONS" roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2102102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2404401 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GRANTSRECEIVABLE" roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLE">
        <link:definition>2105103 - Disclosure - GRANTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GRANTSRECEIVABLEDetails" roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails">
        <link:definition>2406402 - Disclosure - GRANTS RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETS" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS">
        <link:definition>2107104 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables">
        <link:definition>2308301 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2409403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails">
        <link:definition>2410404 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2111105 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2412405 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTS" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS">
        <link:definition>2113106 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTSTables" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables">
        <link:definition>2314302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTSDetails" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails">
        <link:definition>2415406 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2116107 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2317303 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>2418407 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails">
        <link:definition>2419408 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATION" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION">
        <link:definition>2120108 - Disclosure - EQUITY-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONTables" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables">
        <link:definition>2321304 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2422409 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails">
        <link:definition>2423410 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails">
        <link:definition>2424411 - Disclosure - EQUITY-BASED COMPENSATION - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="flks_UniversityOfUtahResearchFoundationMember" abstract="true" name="UniversityOfUtahResearchFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_RevenueFromGrantsAwardTerm" abstract="false" name="RevenueFromGrantsAwardTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="flks_EquityIncentivePlan2015Member" abstract="true" name="EquityIncentivePlan2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="flks_RevenueFromGrantsMatchingFundsRequirement" abstract="false" name="RevenueFromGrantsMatchingFundsRequirement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" abstract="false" name="RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="flks_PrepaidExpenseFinancedByNotePayable" abstract="false" name="PrepaidExpenseFinancedByNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_PrepaidClinicalTrialExpense" abstract="false" name="PrepaidClinicalTrialExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_WarrantsOutstandingMeasurementInput" abstract="false" name="WarrantsOutstandingMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="flks_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" abstract="false" name="ClassOfWarrantOrRightThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="flks_SatisfySuccessFeeDueToRelatedPartyMember" abstract="true" name="SatisfySuccessFeeDueToRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="flks_StockIssuanceCostsAccruedAndAmortized" abstract="false" name="StockIssuanceCostsAccruedAndAmortized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_WedbushSecuritiesIncMember" abstract="true" name="WedbushSecuritiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>flks-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:933be885-fec0-4346-88e3-96fdb95628e8,g:3a038917-b4df-486f-8fdf-f41d10c2cf87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_92de36e7-eaa5-4157-af6f-f3f0f4b1c7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_61be5654-d2e7-4a3d-83fa-f66d46132549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_92de36e7-eaa5-4157-af6f-f3f0f4b1c7f6" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_61be5654-d2e7-4a3d-83fa-f66d46132549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1d604acf-d206-432a-9d48-83c81e636165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_92de36e7-eaa5-4157-af6f-f3f0f4b1c7f6" xlink:to="loc_us-gaap_AccountsPayableCurrent_1d604acf-d206-432a-9d48-83c81e636165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_f4773238-2a74-4ca8-b740-93bb2583c4fd" xlink:href="flks-20210930.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_92de36e7-eaa5-4157-af6f-f3f0f4b1c7f6" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_f4773238-2a74-4ca8-b740-93bb2583c4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_d4b3f327-1582-498a-8be2-070858e9df92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_92de36e7-eaa5-4157-af6f-f3f0f4b1c7f6" xlink:to="loc_us-gaap_NotesPayableCurrent_d4b3f327-1582-498a-8be2-070858e9df92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_750fd202-3479-4b2b-b0ad-b579ec8db8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9a88378d-24c5-4008-b400-ab196e91a5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_750fd202-3479-4b2b-b0ad-b579ec8db8ba" xlink:to="loc_us-gaap_AssetsCurrent_9a88378d-24c5-4008-b400-ab196e91a5cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0663db97-15d7-41e9-8386-9299b9a4942a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_750fd202-3479-4b2b-b0ad-b579ec8db8ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0663db97-15d7-41e9-8386-9299b9a4942a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4483a8dc-23aa-40bd-b333-5b829261b78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_750fd202-3479-4b2b-b0ad-b579ec8db8ba" xlink:to="loc_us-gaap_Goodwill_4483a8dc-23aa-40bd-b333-5b829261b78b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fc2d42bf-ceb9-4470-9643-c60fd4e1dcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_750fd202-3479-4b2b-b0ad-b579ec8db8ba" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fc2d42bf-ceb9-4470-9643-c60fd4e1dcca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_06fec015-91c0-42f4-b2f3-b3e7a80228d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3f611dda-7bde-413e-b850-f1ccd2741054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_06fec015-91c0-42f4-b2f3-b3e7a80228d6" xlink:to="loc_us-gaap_PreferredStockValue_3f611dda-7bde-413e-b850-f1ccd2741054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c870d750-4449-40f3-a6e0-67cea2087cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_06fec015-91c0-42f4-b2f3-b3e7a80228d6" xlink:to="loc_us-gaap_CommonStockValue_c870d750-4449-40f3-a6e0-67cea2087cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3c408c2c-15a8-4b65-9cf4-40e5ebb82d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_06fec015-91c0-42f4-b2f3-b3e7a80228d6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3c408c2c-15a8-4b65-9cf4-40e5ebb82d59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9383c8bd-9ab6-42dc-a64b-21ffacbce339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_06fec015-91c0-42f4-b2f3-b3e7a80228d6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9383c8bd-9ab6-42dc-a64b-21ffacbce339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30a0eb56-8fc5-4dcb-8c58-8bb13e844601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2af638a2-e6ed-4e93-9e9a-ec4f63dee515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30a0eb56-8fc5-4dcb-8c58-8bb13e844601" xlink:to="loc_us-gaap_StockholdersEquity_2af638a2-e6ed-4e93-9e9a-ec4f63dee515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9f018557-8d79-45d9-a367-a90de295d453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30a0eb56-8fc5-4dcb-8c58-8bb13e844601" xlink:to="loc_us-gaap_Liabilities_9f018557-8d79-45d9-a367-a90de295d453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_addbe825-18f3-457f-a9fb-42231bf67a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30a0eb56-8fc5-4dcb-8c58-8bb13e844601" xlink:to="loc_us-gaap_CommitmentsAndContingencies_addbe825-18f3-457f-a9fb-42231bf67a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3509f88c-37ea-4b4e-b539-1f61481f6379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_71aedf16-2be3-4074-8f50-3b40cbf89cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3509f88c-37ea-4b4e-b539-1f61481f6379" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_71aedf16-2be3-4074-8f50-3b40cbf89cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123148f8-8bf8-41cd-8716-499d86e83575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3509f88c-37ea-4b4e-b539-1f61481f6379" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123148f8-8bf8-41cd-8716-499d86e83575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d55a996e-2f4f-417a-a127-72e23ce7a072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3509f88c-37ea-4b4e-b539-1f61481f6379" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d55a996e-2f4f-417a-a127-72e23ce7a072" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_73cfb76c-a9ed-4831-8f46-b4765e712f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_afef8330-f98d-4173-8b2a-3dd086fe5cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_73cfb76c-a9ed-4831-8f46-b4765e712f67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_afef8330-f98d-4173-8b2a-3dd086fe5cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bec5d160-240f-4d8b-a758-4b33dcd22a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_73cfb76c-a9ed-4831-8f46-b4765e712f67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bec5d160-240f-4d8b-a758-4b33dcd22a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eafae7ba-c167-491d-a007-08eb005e1494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_576787af-ac85-485b-8c3c-37d783d126a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eafae7ba-c167-491d-a007-08eb005e1494" xlink:to="loc_us-gaap_OperatingExpenses_576787af-ac85-485b-8c3c-37d783d126a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbcd76fe-f14a-4dda-b7e9-6411c7824e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eafae7ba-c167-491d-a007-08eb005e1494" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbcd76fe-f14a-4dda-b7e9-6411c7824e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_a0af94a1-0aa9-47a6-adb6-0c042705dc20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_51d253d5-6966-4700-acc6-8069c3867e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_a0af94a1-0aa9-47a6-adb6-0c042705dc20" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_51d253d5-6966-4700-acc6-8069c3867e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3d0297a9-ce7a-4431-9fa5-13e1f82aeedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_a0af94a1-0aa9-47a6-adb6-0c042705dc20" xlink:to="loc_us-gaap_OperatingIncomeLoss_3d0297a9-ce7a-4431-9fa5-13e1f82aeedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e70d89df-ca4d-460f-800e-712609c9dabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_a0af94a1-0aa9-47a6-adb6-0c042705dc20" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e70d89df-ca4d-460f-800e-712609c9dabd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_41636a4f-0b24-4bce-8ed8-92c68dd132a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_a0af94a1-0aa9-47a6-adb6-0c042705dc20" xlink:to="loc_us-gaap_OtherNonoperatingIncome_41636a4f-0b24-4bce-8ed8-92c68dd132a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_018318a4-6e61-46c1-9ca1-d36ab440edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_9068f1ad-5c96-4ea8-aba2-1c4ad8555f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_018318a4-6e61-46c1-9ca1-d36ab440edbd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_9068f1ad-5c96-4ea8-aba2-1c4ad8555f90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fe94498-3168-4a49-99fd-2d46e87b0ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7340dcf8-119a-4c4b-ae7f-55465c900123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fe94498-3168-4a49-99fd-2d46e87b0ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7340dcf8-119a-4c4b-ae7f-55465c900123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5383721-08db-4de2-8ff7-99b1869598c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fe94498-3168-4a49-99fd-2d46e87b0ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5383721-08db-4de2-8ff7-99b1869598c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b112b816-0b4e-44a5-b643-fb1c224b2490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_db080cdd-6d36-4dc7-8720-72c24b6037b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b112b816-0b4e-44a5-b643-fb1c224b2490" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_db080cdd-6d36-4dc7-8720-72c24b6037b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_262c0e93-c4d3-4fec-9db6-4b931f175478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b112b816-0b4e-44a5-b643-fb1c224b2490" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_262c0e93-c4d3-4fec-9db6-4b931f175478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_0c995c68-42d1-45f1-a87e-d8f0fb651200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b112b816-0b4e-44a5-b643-fb1c224b2490" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_0c995c68-42d1-45f1-a87e-d8f0fb651200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7cef9e87-c711-4477-8691-72551d46d066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7cef9e87-c711-4477-8691-72551d46d066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_93aab226-0ff0-43ab-8bfc-4198d7323b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_93aab226-0ff0-43ab-8bfc-4198d7323b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9652e4b2-bd8d-4b2a-9955-711711f346b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9652e4b2-bd8d-4b2a-9955-711711f346b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8accfc86-71a9-489b-bbbb-37bf39a766de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8accfc86-71a9-489b-bbbb-37bf39a766de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6dabf1a5-db08-449a-99e2-e264078e917e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_NetIncomeLoss_6dabf1a5-db08-449a-99e2-e264078e917e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_46c96be7-3027-443a-ba4e-2906b9b87cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_46c96be7-3027-443a-ba4e-2906b9b87cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_28f5555d-160a-4bcb-b541-9bb59a61ff18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_28f5555d-160a-4bcb-b541-9bb59a61ff18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dbf86f18-a39f-4ee6-ad98-bdb1dbf3bf69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_ShareBasedCompensation_dbf86f18-a39f-4ee6-ad98-bdb1dbf3bf69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a2ca4f93-19c0-4fc6-a006-63c7c7d42455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a2ca4f93-19c0-4fc6-a006-63c7c7d42455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5f8b25c8-5f4c-45bb-880c-a4921df0ddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0e4283d-3162-4545-9f29-298ccbc1206f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5f8b25c8-5f4c-45bb-880c-a4921df0ddbf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ec25453-5344-4f44-9fd8-5e94629a7569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ec32f123-37e1-41d7-a5d5-16c3910ee2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ec25453-5344-4f44-9fd8-5e94629a7569" xlink:to="loc_us-gaap_OtherAssetsCurrent_ec32f123-37e1-41d7-a5d5-16c3910ee2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_d9b9577c-fabf-4f99-abd7-12ae0900758b" xlink:href="flks-20210930.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ec25453-5344-4f44-9fd8-5e94629a7569" xlink:to="loc_flks_PrepaidClinicalTrialExpense_d9b9577c-fabf-4f99-abd7-12ae0900758b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_63630234-b61a-4b5a-a440-b46bf5f2ced3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ec25453-5344-4f44-9fd8-5e94629a7569" xlink:to="loc_us-gaap_PrepaidInsurance_63630234-b61a-4b5a-a440-b46bf5f2ced3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>flks-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:933be885-fec0-4346-88e3-96fdb95628e8,g:3a038917-b4df-486f-8fdf-f41d10c2cf87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended" id="ic782a2b14f0c4039a58f9f28247a7235_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9a058c6d-069c-413d-af2f-e185bf538d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9a058c6d-069c-413d-af2f-e185bf538d6d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_528e80e6-9009-41ae-b476-64b36975467e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_SharesOutstanding_528e80e6-9009-41ae-b476-64b36975467e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1186a892-eccc-47b4-92e0-11b7702aef49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockholdersEquity_1186a892-eccc-47b4-92e0-11b7702aef49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6b60dea-313c-4960-8464-5b1a772570d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6b60dea-313c-4960-8464-5b1a772570d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0e05d11-3743-4e53-aefe-a00c8dca521e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0e05d11-3743-4e53-aefe-a00c8dca521e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_7b18bd5a-b94a-415f-91e6-8e9c7c8934b4" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_7b18bd5a-b94a-415f-91e6-8e9c7c8934b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodValueWarrantsExercised_47087432-b2ad-4739-bea8-d01357908a7c" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_flks_StockIssuedDuringPeriodValueWarrantsExercised_47087432-b2ad-4739-bea8-d01357908a7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e676e37b-3936-4861-bbfc-4f126ecb2350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e676e37b-3936-4861-bbfc-4f126ecb2350" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_b0111df5-508f-4edc-8fd1-6fc2a00b85e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_b0111df5-508f-4edc-8fd1-6fc2a00b85e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8866ce6-3227-4450-94b9-829eb9ffc6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8866ce6-3227-4450-94b9-829eb9ffc6ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3fe048df-5abe-4fd4-a14f-7762102f4beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3fe048df-5abe-4fd4-a14f-7762102f4beb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1152812e-4f52-43f6-8716-126bb47af18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_NetIncomeLoss_1152812e-4f52-43f6-8716-126bb47af18c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9ea34aec-cf8b-4263-9939-515b8e284310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c13bc255-4ff8-4c76-ac1a-3da6bcba25fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9a058c6d-069c-413d-af2f-e185bf538d6d" xlink:to="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6cd85a4-7969-4954-b618-b97a84b8e5a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:to="loc_us-gaap_EquityComponentDomain_a6cd85a4-7969-4954-b618-b97a84b8e5a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:to="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_639b6ec4-1885-45a0-bd10-df29eac16d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_CommonStockMember_639b6ec4-1885-45a0-bd10-df29eac16d07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_2eeb671a-6267-4044-b12e-f7e7f0deb5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_PreferredStockMember_2eeb671a-6267-4044-b12e-f7e7f0deb5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53eafe2c-b7ed-4d92-8d24-a75ae7966227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53eafe2c-b7ed-4d92-8d24-a75ae7966227" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f362ca1b-36e9-473f-ba5a-83caa7636f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_RetainedEarningsMember_f362ca1b-36e9-473f-ba5a-83caa7636f57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:to="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_a1617744-1e9d-45ef-b412-86c88190c637_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:to="loc_us-gaap_GranteeStatusDomain_a1617744-1e9d-45ef-b412-86c88190c637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_4444a612-e946-4306-9429-2b947cd9ba09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:to="loc_us-gaap_GranteeStatusDomain_4444a612-e946-4306-9429-2b947cd9ba09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_a88c39bd-cd3f-49b9-a943-601b0aa49edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_4444a612-e946-4306-9429-2b947cd9ba09" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_a88c39bd-cd3f-49b9-a943-601b0aa49edb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="extended" id="i964ccd7d75344f15a061792ddf66d57e_PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_db96ddee-69f4-4822-93c4-d014baa7b4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_db96ddee-69f4-4822-93c4-d014baa7b4b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcde4d7-4dca-4fe4-9495-98c5af43f9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcde4d7-4dca-4fe4-9495-98c5af43f9e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_de9ba146-9996-498e-8dd5-1704f1db1a6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_de9ba146-9996-498e-8dd5-1704f1db1a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_eadb9ed1-0771-443f-be47-a03a6779b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_eadb9ed1-0771-443f-be47-a03a6779b73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_cb826401-a548-4e79-9740-ec3ffecd56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_eadb9ed1-0771-443f-be47-a03a6779b73f" xlink:to="loc_us-gaap_NotesPayableToBanksMember_cb826401-a548-4e79-9740-ec3ffecd56ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="iaaade065a4fc41c686f2961884ffaaa1_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7fb27296-65e2-4139-9f64-4e8262b135ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7fb27296-65e2-4139-9f64-4e8262b135ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward_559d5d36-3e64-4c36-9dc0-7fb47dd5d4a5" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsMaximumAward_559d5d36-3e64-4c36-9dc0-7fb47dd5d4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm_f475243e-1969-4123-bb27-2efe8997aea8" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsAwardTerm_f475243e-1969-4123-bb27-2efe8997aea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_49ff1dd2-9ea4-4555-bfc1-f3416548d5bd" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_49ff1dd2-9ea4-4555-bfc1-f3416548d5bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMatchingFundsRequirement_067bf8b5-1545-485a-aaf3-58c8847863d4" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsMatchingFundsRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsMatchingFundsRequirement_067bf8b5-1545-485a-aaf3-58c8847863d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_0174550d-9532-46a9-ac36-ae623b140231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_us-gaap_ReceivablesNetCurrent_0174550d-9532-46a9-ac36-ae623b140231" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:to="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c8feb9ab-f401-4eef-99c4-b2902532fb54_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:to="loc_srt_OwnershipDomain_c8feb9ab-f401-4eef-99c4-b2902532fb54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6262aa20-dec3-489b-ba9d-c762ebac671b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:to="loc_srt_OwnershipDomain_6262aa20-dec3-489b-ba9d-c762ebac671b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember_c84284d2-c702-4b29-89e8-10706e9791c5" xlink:href="flks-20210930.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6262aa20-dec3-489b-ba9d-c762ebac671b" xlink:to="loc_flks_UniversityOfUtahResearchFoundationMember_c84284d2-c702-4b29-89e8-10706e9791c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="extended" id="i29f0ef3eafaa4f408063f635b981bc2d_FAIRVALUEOFFINANCIALINSTRUMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4b9b5f6-e597-4716-8c78-1e4db8d552f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4b9b5f6-e597-4716-8c78-1e4db8d552f0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b64baa5-93c9-40f5-b5aa-af33c1dbb977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b64baa5-93c9-40f5-b5aa-af33c1dbb977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ea495b38-66ee-4f16-a089-f6a9ddeb914e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ea495b38-66ee-4f16-a089-f6a9ddeb914e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ebc80f26-1eb3-4e15-ba2b-f4ca2fcde79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4b9b5f6-e597-4716-8c78-1e4db8d552f0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75fb43c1-7b15-4dd6-a928-336bdd5c3093_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75fb43c1-7b15-4dd6-a928-336bdd5c3093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd0d8ba8-7e86-46a3-a39e-afd34663ddab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd0d8ba8-7e86-46a3-a39e-afd34663ddab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1da21861-ccf4-43b4-94fb-7ef12c8c9cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd0d8ba8-7e86-46a3-a39e-afd34663ddab" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1da21861-ccf4-43b4-94fb-7ef12c8c9cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6d5dc13-289e-4c05-aab7-072ae2e833a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6d5dc13-289e-4c05-aab7-072ae2e833a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_97c53221-efe1-428a-bf2c-032ed3292b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6d5dc13-289e-4c05-aab7-072ae2e833a6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_97c53221-efe1-428a-bf2c-032ed3292b20" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended" id="ia1750f5c4d0647bc8c7d52779af26025_STOCKHOLDERSEQUITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04dcecca-9347-4bdb-9148-598503ea6700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04dcecca-9347-4bdb-9148-598503ea6700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb75a9d-f0a1-4826-9d05-2c191d1b67e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb75a9d-f0a1-4826-9d05-2c191d1b67e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a7a45adf-483e-4ea8-bf79-58ac362f3982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a7a45adf-483e-4ea8-bf79-58ac362f3982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6527c8c3-a343-4e1c-8cd0-7489ebe2d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6527c8c3-a343-4e1c-8cd0-7489ebe2d7db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2e28fb88-52cd-45a4-b5c1-fedd389e56ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2e28fb88-52cd-45a4-b5c1-fedd389e56ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d904a68c-2ad5-41d6-bd13-f3f49742dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d904a68c-2ad5-41d6-bd13-f3f49742dc09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2cb3afe5-a141-4fc2-803c-ba952150a1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2cb3afe5-a141-4fc2-803c-ba952150a1c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b88b5ef-6fcc-40b0-a958-c0d57c645ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b88b5ef-6fcc-40b0-a958-c0d57c645ac5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_fbdd3996-b911-4fd0-8b13-96535fd48280" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_fbdd3996-b911-4fd0-8b13-96535fd48280" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a4f62fc4-6394-47a7-880c-ec68548f911e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a4f62fc4-6394-47a7-880c-ec68548f911e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d93149db-1f35-48a7-8ba7-48f88692bd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d93149db-1f35-48a7-8ba7-48f88692bd60" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_604a81f8-a7f7-47a3-926e-9285461cd9c6" xlink:href="flks-20210930.xsd#flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_604a81f8-a7f7-47a3-926e-9285461cd9c6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_700912d2-8f92-4966-8680-803e9fc91c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_700912d2-8f92-4966-8680-803e9fc91c22" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6eb13638-e6b1-45c9-ba29-980401c69516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6eb13638-e6b1-45c9-ba29-980401c69516" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_4ca1a945-3ece-45ab-924c-ba91d83b652f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_4ca1a945-3ece-45ab-924c-ba91d83b652f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e6317a3-691c-4c15-886c-3f946b26b036_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:to="loc_us-gaap_ClassOfStockDomain_9e6317a3-691c-4c15-886c-3f946b26b036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:to="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_308d15c5-7b56-400c-9e01-931d402c9d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:to="loc_us-gaap_CommonClassAMember_308d15c5-7b56-400c-9e01-931d402c9d44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_84c4ed95-2b12-4a9e-a253-a297a4b388b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:to="loc_us-gaap_CommonClassBMember_84c4ed95-2b12-4a9e-a253-a297a4b388b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_40294747-058b-43dc-9e96-dbd4168b9de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_40294747-058b-43dc-9e96-dbd4168b9de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57724aa6-fd6a-4e63-9485-591064fb7279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:to="loc_us-gaap_EquityComponentDomain_57724aa6-fd6a-4e63-9485-591064fb7279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:to="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6fc2a825-f3cd-4372-a78b-1c411462cbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:to="loc_us-gaap_CommonStockMember_6fc2a825-f3cd-4372-a78b-1c411462cbb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_387094bf-864a-4b78-a7b4-2230f516ccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:to="loc_us-gaap_PreferredStockMember_387094bf-864a-4b78-a7b4-2230f516ccb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:to="loc_srt_RangeMember_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_823a4e08-f1ac-4c66-8013-b27cafef741e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:to="loc_srt_RangeMember_823a4e08-f1ac-4c66-8013-b27cafef741e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_52070854-2bc6-422b-9d1e-a46c63c7da2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_823a4e08-f1ac-4c66-8013-b27cafef741e" xlink:to="loc_srt_MinimumMember_52070854-2bc6-422b-9d1e-a46c63c7da2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd099d6f-8213-4ee7-9cd5-90c0bce685c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd099d6f-8213-4ee7-9cd5-90c0bce685c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8af43b9b-3975-480d-8cd8-4b30777be088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8af43b9b-3975-480d-8cd8-4b30777be088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AtTheMarketOfferingAgreementMember_1093b6e1-db4b-4459-abf4-9afa01ca4cbd" xlink:href="flks-20210930.xsd#flks_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:to="loc_flks_AtTheMarketOfferingAgreementMember_1093b6e1-db4b-4459-abf4-9afa01ca4cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2c317c98-63e8-4faf-b570-bba07a92ed9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:to="loc_us-gaap_RelatedPartyDomain_2c317c98-63e8-4faf-b570-bba07a92ed9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0281c12b-1981-4e18-a5be-4826b0cdc5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:to="loc_us-gaap_RelatedPartyDomain_0281c12b-1981-4e18-a5be-4826b0cdc5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WedbushSecuritiesIncMember_ee9e8f02-a707-4e31-9f16-8e27df56825a" xlink:href="flks-20210930.xsd#flks_WedbushSecuritiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0281c12b-1981-4e18-a5be-4826b0cdc5b7" xlink:to="loc_flks_WedbushSecuritiesIncMember_ee9e8f02-a707-4e31-9f16-8e27df56825a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a3079464-8b8e-4cc2-a094-77506aa19123_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a3079464-8b8e-4cc2-a094-77506aa19123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_172b7374-eba4-478a-87b8-4dc9b0c7595e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_172b7374-eba4-478a-87b8-4dc9b0c7595e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_052119d4-ea16-4f8e-8c1e-dd5922e836a2" xlink:href="flks-20210930.xsd#flks_SatisfySuccessFeeDueToRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_172b7374-eba4-478a-87b8-4dc9b0c7595e" xlink:to="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_052119d4-ea16-4f8e-8c1e-dd5922e836a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="extended" id="i731a21be8f4c4b88af291a84cadca6b2_STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsOutstandingMeasurementInput_a16f504d-5a40-4926-bde4-1b7f2acc3c5b" xlink:href="flks-20210930.xsd#flks_WarrantsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:to="loc_flks_WarrantsOutstandingMeasurementInput_a16f504d-5a40-4926-bde4-1b7f2acc3c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b74be8a1-9f80-440a-9ed9-994cda65aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b74be8a1-9f80-440a-9ed9-994cda65aaab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7f19183e-efab-429d-90cd-1a4614545511_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7f19183e-efab-429d-90cd-1a4614545511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_e430471a-1d1b-4444-bd3b-ad9368bca1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_e430471a-1d1b-4444-bd3b-ad9368bca1bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_c12fff6e-5c53-4477-bd0b-3130c9babde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_c12fff6e-5c53-4477-bd0b-3130c9babde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a842968-11cf-4981-8dde-a5b55b67c516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a842968-11cf-4981-8dde-a5b55b67c516" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i107f9e52902b40849d8f862f0dc6e51a_EQUITYBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3a57a6e-4f5e-494e-b253-462d362b92e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3a57a6e-4f5e-494e-b253-462d362b92e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd97dc9e-52da-4fcd-ac19-ec297cc64afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd97dc9e-52da-4fcd-ac19-ec297cc64afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f9b1334-44aa-4f4e-8b69-8901aec846bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f9b1334-44aa-4f4e-8b69-8901aec846bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c807f09d-4e55-4c08-9bd2-4891f0cb734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c807f09d-4e55-4c08-9bd2-4891f0cb734a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a4fe5899-3950-44b2-beec-f5e32bb75d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a4fe5899-3950-44b2-beec-f5e32bb75d88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b3dd412d-993d-4453-9064-54641d7025c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b3dd412d-993d-4453-9064-54641d7025c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc7bd581-1963-44bc-a616-6ebbfc0ac172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc7bd581-1963-44bc-a616-6ebbfc0ac172" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_729eccba-87c1-437b-be75-62025fcf4282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:to="loc_us-gaap_PlanNameDomain_729eccba-87c1-437b-be75-62025fcf4282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e90f75fc-ddde-485d-9336-fcc02da3f322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:to="loc_us-gaap_PlanNameDomain_e90f75fc-ddde-485d-9336-fcc02da3f322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member_2a30bf94-99a9-420f-ae5f-3760537cefa0" xlink:href="flks-20210930.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e90f75fc-ddde-485d-9336-fcc02da3f322" xlink:to="loc_flks_EquityIncentivePlan2015Member_2a30bf94-99a9-420f-ae5f-3760537cefa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2de05838-b8d6-42cb-bfed-9c93e40deb97_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:to="loc_srt_RangeMember_2de05838-b8d6-42cb-bfed-9c93e40deb97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:to="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b9a90983-6b43-4358-9de3-35d03f8080e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:to="loc_srt_MinimumMember_b9a90983-6b43-4358-9de3-35d03f8080e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ba0b0c6-6e57-4a54-811a-fd9dea7a90e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:to="loc_srt_MaximumMember_1ba0b0c6-6e57-4a54-811a-fd9dea7a90e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a844c4da-334e-4480-a788-45339eccf143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a844c4da-334e-4480-a788-45339eccf143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e0b514-a957-406e-ac23-1eb09ec0db93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e0b514-a957-406e-ac23-1eb09ec0db93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_408ef24f-b8f3-4e2f-b4e6-c8b55b1b21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e0b514-a957-406e-ac23-1eb09ec0db93" xlink:to="loc_us-gaap_EmployeeStockOptionMember_408ef24f-b8f3-4e2f-b4e6-c8b55b1b21e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="extended" id="iedec17763a1841e8addc9746c8610530_EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd319f7-ccd8-49c5-a441-a70c8f4eef06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd319f7-ccd8-49c5-a441-a70c8f4eef06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fc3384a1-d38e-4eae-be82-b24fd0727f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fc3384a1-d38e-4eae-be82-b24fd0727f9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c994637-5e64-4c0a-b130-469603d6723b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c994637-5e64-4c0a-b130-469603d6723b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6df206db-fc18-4bdf-a7e5-71a5f6ac7b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6df206db-fc18-4bdf-a7e5-71a5f6ac7b63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_88dc2617-c4ad-4583-be37-935599feccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_88dc2617-c4ad-4583-be37-935599feccb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_033661dd-cfbe-4ce8-a809-10b8aadf2f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c7c2a456-658c-41c7-8126-e2d9cd048815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c7c2a456-658c-41c7-8126-e2d9cd048815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_157f77a3-4e56-4c29-b5b8-0e3fc33646ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_157f77a3-4e56-4c29-b5b8-0e3fc33646ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ae8e4bab-c02d-4870-9a63-8ccc722b1fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ae8e4bab-c02d-4870-9a63-8ccc722b1fc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c4fa8f5-7191-48d6-a295-a99da4775524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c4fa8f5-7191-48d6-a295-a99da4775524" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4013a163-7224-443e-82b7-1152335427c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8450c4eb-c4df-413f-ae82-37145a3c264b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8450c4eb-c4df-413f-ae82-37145a3c264b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f8930dd-4092-4c6e-8865-c88f21945c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f8930dd-4092-4c6e-8865-c88f21945c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b27fc06f-acfd-45d9-88e9-9d105b90d53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b27fc06f-acfd-45d9-88e9-9d105b90d53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56619eda-e9e3-492a-b4c1-e8011fb7cd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56619eda-e9e3-492a-b4c1-e8011fb7cd14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42e63f04-e8f2-4eb4-a54a-2ce243d28d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42e63f04-e8f2-4eb4-a54a-2ce243d28d3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:to="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4839e3be-3698-4b3e-8c5b-1b0ced68fa25_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:to="loc_srt_RangeMember_4839e3be-3698-4b3e-8c5b-1b0ced68fa25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:to="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0044c17d-d98e-4bbf-9de2-77a4201c1a66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:to="loc_srt_MinimumMember_0044c17d-d98e-4bbf-9de2-77a4201c1a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_240fe77e-e4cd-4710-8628-957a26a09446" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:to="loc_srt_MaximumMember_240fe77e-e4cd-4710-8628-957a26a09446" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>flks-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:933be885-fec0-4346-88e3-96fdb95628e8,g:3a038917-b4df-486f-8fdf-f41d10c2cf87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_bc6ceda1-b72c-4d25-8187-e3105c3f7808_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised for cash</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9fde1348-ef28-42de-a439-10b42678db75_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_120e3902-b45a-43b2-9736-5b8a2eda6317_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsMaximumAward" xlink:to="lab_flks_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_3433cdd6-865e-4df3-ac3c-34e21ed2528f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5949b1f9-71d9-409c-9f74-6bbd67cc8655_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3038e6bc-ca9b-4672-b4e3-97c156844129_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8bfc7009-5742-4917-bd2c-fc71dea541f6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a6ed3355-e49a-425d-878c-fefa0af90148_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44e881aa-e8ce-4c41-9037-cdfae8a2dcfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_91d53917-09db-493f-b47f-cfed4659122f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c3a1afde-bcee-4d2a-9747-46f2c24aefab_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2040c892-325a-4c8e-93f6-56f964d96bfb_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for services</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_525a5a2c-1288-4205-8b79-0bbf57444a0a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_e2c56086-6edb-4e95-a9aa-c1344035c21b_terseLabel_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days</link:label>
    <link:label id="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:href="flks-20210930.xsd#flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:to="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c49ea492-ee69-4985-9203-24ce8f14ca74_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_416ddbcc-adae-4a01-b703-130ea956967b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_64426a0b-df46-4281-a991-09b01df76d77_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1aabc416-8be6-4fc3-a572-dda7c1357981_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_291d2953-1e6c-47c9-ad17-b0e46edd0257_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_75a0d967-4fcd-494d-a01c-c35498dd5e3b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, product and service</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_90fc93ff-a3ec-41c5-9f96-3ee5fb712129_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_51acafca-b768-4c63-8b82-f2c2c83d6610_terseLabel_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued issuance costs for public offering</link:label>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_label_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Accrued and Amortized</link:label>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_documentation_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Accrued and Amortized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuanceCostsAccruedAndAmortized" xlink:href="flks-20210930.xsd#flks_StockIssuanceCostsAccruedAndAmortized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuanceCostsAccruedAndAmortized" xlink:to="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_20c023ee-a5ad-4c2f-a690-e01a01da2fa7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_edd4fbaf-5e53-477c-9fb9-8b00632cc305_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_014e9fa8-9bf6-4fdb-9ce4-88056e389e04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_b48d7413-c22e-47e2-a99d-37822a08b6e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e345dd2d-1ffb-4dd7-b967-5c6cac3451f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ebbb0494-0c10-40d2-83d2-53ca809d8344_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c6ae607d-8b89-4d93-b3fb-7e653c9d4830_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_11b071b6-6f26-48b9-9223-4cf68378bee5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b210c370-8d21-4cd1-9539-7fd8cf92f25f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_82230a11-56bc-4c15-a43d-cde6cfc5ef1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_08539437-35e2-47e6-81b5-e581f9ac8ff5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_340ad1ca-d692-4c49-ba98-55fb64f49434_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_57eda58d-8807-49c1-9f83-9e2ab7b61966_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7a21f300-1cf2-44f1-9045-fbd1da2a0612_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5521ae19-e972-4763-9ad6-81cd7d757d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant of stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2e4b129-9e68-4fcc-9e94-4ae7906028eb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_5f61fd60-949e-4941-b449-187bb7e77cb0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1fe6429c-6722-4298-ad9a-2bc7ce89ab46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted-average exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25395a5d-6183-4459-8ae7-5c837e7c8d84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7dc91c-df8e-4ea9-b8d9-82ba6c6cc7c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fa32e0ce-0ea0-4517-bbbe-0aa10675f056_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1e4168e2-ebbb-44f5-aa25-d51f062ed6de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_25c76736-82dd-465c-8e83-7d62cb8cc227_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a6f4ebf0-7604-4b59-a78b-36b6e6f7e742_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_db9eafca-081d-4462-9417-56f0076b8102_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_AtTheMarketOfferingAgreementMember_e12190fe-71f0-47a8-8874-d7acab675f36_terseLabel_en-US" xlink:label="lab_flks_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_flks_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_flks_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering Agreement [Member]</link:label>
    <link:label id="lab_flks_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_flks_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AtTheMarketOfferingAgreementMember" xlink:href="flks-20210930.xsd#flks_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_AtTheMarketOfferingAgreementMember" xlink:to="lab_flks_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_732ca689-2496-44f3-92d9-b8c8cfb29074_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_32fe342b-268a-4f0e-b49b-9b8093eb7e6c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6dbaa332-798a-41ef-a121-631fd6787a2e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_565c19be-c673-44f6-8584-8e9612670bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_a8d9f64a-5e2e-4c61-a82a-2f81855d4333_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government grants and other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cec5a53e-aff0-471e-9886-b196fdbc10d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9940e963-8043-447a-b653-9a4085f3b550_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised_e7ce2ef8-05e5-4c2f-90dd-5f2ddcc7be7a_terseLabel_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised for cash, net (in shares)</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_flks_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ac7d3e00-48e9-4caf-882c-901f9729dde0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_34c13c21-44f9-400a-a2fd-5e74bfa39ae2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d0241306-1a3e-489a-9717-572a334e9be9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_093ec8ca-b96b-4940-8f29-f84fc2c18c9c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_e5704e17-6eb9-4118-8381-e2e5050b2933_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_19630032-e5ab-47e6-97e6-aec305d7b078_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_db1d5bba-0b14-48cd-a7c5-fa1025b51193_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_be099392-3ccf-4c40-a002-63e4a1c95a33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation and services expense (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_ef32fb2d-1a5c-470b-842e-5e0db7b3c0c8_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_label_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Award Term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Award Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsAwardTerm" xlink:to="lab_flks_RevenueFromGrantsAwardTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35fc09d1-9583-43af-9c4a-d84ad644528f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_cad94ab9-9cb6-499f-bec4-01fb249f53b7_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bba0ca69-4484-4ca0-ac6a-ca4cb05a57de_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5095b421-370e-4130-9165-5c337f7b2cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1c6781b8-16c4-4b3e-b48d-72c269820b4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4c4f8147-66e7-4646-afb5-e1813a880ffe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149a800d-bf1e-418a-a8f4-46595713b4bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_WedbushSecuritiesIncMember_d898ebb7-65a8-45a1-8000-236a3aa6c164_terseLabel_en-US" xlink:label="lab_flks_WedbushSecuritiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wedbush</link:label>
    <link:label id="lab_flks_WedbushSecuritiesIncMember_label_en-US" xlink:label="lab_flks_WedbushSecuritiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wedbush Securities Inc. [Member]</link:label>
    <link:label id="lab_flks_WedbushSecuritiesIncMember_documentation_en-US" xlink:label="lab_flks_WedbushSecuritiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wedbush Securities Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WedbushSecuritiesIncMember" xlink:href="flks-20210930.xsd#flks_WedbushSecuritiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_WedbushSecuritiesIncMember" xlink:to="lab_flks_WedbushSecuritiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_7d5dcb7c-5fb3-4855-a1fd-f55e8be4e9c7_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf14f3d-1eba-4a1e-b425-ae133412d0e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_332c90f1-8a3a-4512-a4b2-b2cf80bee161_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2d4c2498-bc9e-49cc-818a-69ceccfbb8cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation and services expense</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_ccbd89ea-beb7-4d16-9aa6-a405ac76591e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5484b27-e694-4c20-9085-c9f5be630279_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c107462-5803-494c-9a74-16f6e47a367c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8a338206-637f-4a33-bae6-64eea19dd78d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ec4e8895-6e9c-4503-851a-d2990b937a1e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5cb56383-6c36-4d4d-a9bc-7f5b73fcb416_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b16ca802-706a-4429-b0a9-c0f8584d7cf8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f8620a9a-47e2-4e20-99e8-1bb1c3990b0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_d0ea78e7-c239-4b9a-86c8-657560f37330_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_e94b7cab-8bfa-4273-9cce-17f2428f2f02_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ee8e8c3-c1a0-47c8-a624-6cbaf3a9fc2d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bd79f154-f0cd-46b4-ac55-1d39ac402ca4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_PrepaidExpenseFinancedByNotePayable_00b34287-f7d7-43ea-b379-747d4076c90e_terseLabel_en-US" xlink:label="lab_flks_PrepaidExpenseFinancedByNotePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense financed by note payable</link:label>
    <link:label id="lab_flks_PrepaidExpenseFinancedByNotePayable_label_en-US" xlink:label="lab_flks_PrepaidExpenseFinancedByNotePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense Financed by Note Payable</link:label>
    <link:label id="lab_flks_PrepaidExpenseFinancedByNotePayable_documentation_en-US" xlink:label="lab_flks_PrepaidExpenseFinancedByNotePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense Financed by Note Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidExpenseFinancedByNotePayable" xlink:href="flks-20210930.xsd#flks_PrepaidExpenseFinancedByNotePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_PrepaidExpenseFinancedByNotePayable" xlink:to="lab_flks_PrepaidExpenseFinancedByNotePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_68f5f044-8ab5-48c3-8795-49803eed41d3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of equity securities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity" xlink:to="lab_us-gaap_ProceedsFromOtherEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d9dd756a-87d3-473a-a1b7-240301a10999_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4e289c5-8563-4eb2-8553-6aa8a83231c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3f9189ab-d551-4c8e-a7df-e6c40a366dc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ac775c67-35c7-4e64-b063-e528d3515a30_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1f740164-fdbb-46d6-9a11-86069f14140b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_afa7d41c-1624-4687-8d08-e2c9c5cc1c0c_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6f9e4ac5-c686-48f5-81f6-e29f7b1969df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d8de3ccc-85c4-42fd-8a26-759ba56a78e3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2dc70ad0-b630-4742-b0cc-d9fc707dbf07_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0a9a71f4-0dc7-4866-a76d-d245b64451c7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_25af6d09-f251-4c12-848a-cc10375a6700_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e66da98a-17bd-4a7b-9579-d7045221efac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, basic ( in dollar per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_af50ee1a-e456-4b25-b3ee-eb7853f8d281_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_e8e3e75e-f120-4c84-8691-446c16534c9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on note payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3ff43420-91a9-4ce2-8835-613f4df30cdd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b25a7ef-992c-4c3b-aa2f-89b009310769_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d93a296b-d2c6-4952-b7d5-10eca4515a25_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September 30, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_abe7448c-ba78-4183-bbdf-ef6702bf615a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_aa1ed498-f3c9-45c9-af15-30c62fb2b789_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09bd6d10-dab8-4cd9-9058-d1de184032b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36101c87-3a9a-4f19-86cf-e66c249b8810_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7b6dc533-20df-4fb8-b2d5-048f89de7487_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_adaa0969-7ddf-4a21-9f35-a631f8072426_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e91e625b-6873-4cfa-9b82-6e6d2391446d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5dc4a8cd-2780-4f48-ab8c-9e00152d9ca6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6c82e2d1-6c97-4468-9585-52797d452040_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eeee1f6c-a6ae-4b6a-986c-d233a2448cc7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_12ad9fcd-5b28-4b70-a2b5-53972da80584_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, diluted ( in dollar per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_297b2eee-dfbc-4d85-8e60-88855dee3181_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_4386cdc8-2d80-4471-9360-adc82a7b7c59_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable from CPRIT</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_dde8e421-88b4-421e-972a-a49b4fa099d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e7d20508-c5df-4127-8af1-234a76cd0b54_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c770c4a-75c4-4048-ad55-591652651968_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_457c8393-fb4d-43be-857d-20041dd93a80_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa514fad-aff7-4ae0-8ba4-67133996063e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_63e5d5cc-383c-4d1b-b609-6cb7497d55da_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6efcac43-f092-4770-b4a2-6e5cec094ee4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7c71bdb9-4ce1-44f2-aa8e-d3cf93ed5136_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_03f94991-7bc1-43e4-b075-1349ac5d636b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b06b43be-3f91-4619-9151-a4a50baae820_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2a067cbd-2646-44ab-bd5f-a9f10bc0dfe3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c2864e50-83b5-4d6a-bf5c-e74d1119173e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and impairment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a18558d9-36f2-48fe-b64b-a0e7e4f69df8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_29150609-920d-4802-a8c3-d65fd4878a94_terseLabel_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_label_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_documentation_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member" xlink:href="flks-20210930.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_EquityIncentivePlan2015Member" xlink:to="lab_flks_EquityIncentivePlan2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd2404d1-ceb3-4ee1-8edf-464c2236ce35_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_06798b57-8661-4042-bcab-37bf80b9e6bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_33fb1147-ad7b-4bcd-af6e-4b5c99062edd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_c23cfecc-424e-4e56-904d-b9806afb6235_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f3c26451-445d-4aea-babc-27c98f315429_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_a73e2343-08a7-4ff5-9dad-b2b8106562fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_69c3bcbc-846f-4a2f-b3a3-c1fe830d7311_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c9f2b00f-6f88-4b72-b028-5b464b6b1003_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a4c3d1ba-6471-4782-82c9-6cf1a5347a24_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_e954d6da-fd0d-42ef-92d9-ecfec1e387f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cdd02088-8d57-414d-949a-cb32d2ec63b3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember_b44bc9ea-3d3f-4556-97f3-15f0fe7bbc81_verboseLabel_en-US" xlink:label="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfy Success Fee</link:label>
    <link:label id="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember_label_en-US" xlink:label="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfy Success Fee Due to Related Party [Member]</link:label>
    <link:label id="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember_documentation_en-US" xlink:label="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfy Success Fee Due to Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:href="flks-20210930.xsd#flks_SatisfySuccessFeeDueToRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:to="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7f61fc6f-ff83-4b7c-88a2-b8bd42bb7916_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_ee3162f1-4d66-455d-9c81-4cf0e1af7718_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_94c5cf81-dce1-4485-9d9b-6c96481055c7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7babaee2-ff21-42d6-907a-e1eda22010fd_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9455bb9c-8fdf-4a60-a202-45102373b885_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0629b513-4cbb-4684-a02d-03191d5dbc6a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1e7ad3ab-8728-4e4e-bbdb-03ef89f2ad6e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_94ed089f-b9cf-4a93-b48c-3a8c9a74efc9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6502fdfd-bd4c-40a4-acc9-ad038b6ee20f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5ecd70fc-d939-4465-95ae-a62c0e1b575a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_5a8e0af3-62c6-4764-a302-aca2fa754c87_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_344eb242-8b85-4ff1-8db3-cb5acdc0b6b8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_109b3cbc-2cd4-4899-b3f2-fe994796269d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8adc452b-bd41-4b5d-b64a-4d94e0c31e94_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8ce77c66-9498-4a03-b933-b590f300a4e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_f8142010-ef6d-4d83-b71a-66a58427d886_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to related party</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0df7f4ad-3bc9-42cd-931c-bf271025cb7c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0bf9c7a7-3973-4474-850f-7ddfd8586fc3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fd9a028e-09aa-43f9-9e48-0db116affe10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_ab35cde2-c0c0-4f2a-b0fe-19280223afaf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4366adfe-35f5-48fb-9d57-64bcfa14ebf6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b38a4344-cae2-4e78-8802-70086b97c4ab_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4b9353e5-8a4b-4294-a4b7-921da4dd2f14_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b4084e3a-37e8-4d2e-9a45-023c9f75c9a5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised_7e136f0c-8d9a-4853-9f68-00f42ee28cab_terseLabel_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised for cash, net</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_flks_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f3808c26-3d64-46e6-8b36-782d0922b7d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0abf5bf7-ce77-4d88-a212-6ce90f26eaed_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_WarrantsOutstandingMeasurementInput_2176c6dc-4da0-44ac-9f92-b45ac4341ae8_terseLabel_en-US" xlink:label="lab_flks_WarrantsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants measurement input</link:label>
    <link:label id="lab_flks_WarrantsOutstandingMeasurementInput_label_en-US" xlink:label="lab_flks_WarrantsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Measurement Input</link:label>
    <link:label id="lab_flks_WarrantsOutstandingMeasurementInput_documentation_en-US" xlink:label="lab_flks_WarrantsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsOutstandingMeasurementInput" xlink:href="flks-20210930.xsd#flks_WarrantsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_WarrantsOutstandingMeasurementInput" xlink:to="lab_flks_WarrantsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_be7e6e7a-a8bf-4bbc-9feb-52b934254d83_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_743e5576-10a8-419e-a09e-e748ef64e6cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_dcaced7a-0a4c-4e8a-b1fa-11692fb296bf_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_88cc35ae-271d-48bf-b344-7a3c2041a7c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 100,000,000 shares authorized; 45,172,535 and 23,810,541 shares issued at September&#160;30, 2021 and December&#160;31, 2020, and 45,172,535 and 23,808,546 shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_36847658-96fa-4455-bca8-38151327f5a0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_ddb2ca6d-48f9-4dc3-90be-956a584a6d6a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2d85330c-ec94-4e54-b640-ae2cd2ecb6c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4b0305bf-cbdc-4f5b-bfbb-3c4ab51b020f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b890de4b-7e81-40d1-914e-7c20966badb1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d9f66f12-8665-4bf1-8462-6033548a39af_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8cac8ebd-369e-45e4-8afb-2581c1cf5c90_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owner</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_91099288-faee-4a43-b4f8-e92190440810_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_8f2d9b2d-94db-4401-886d-b53e1234a0c8_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_eeb6362d-3dec-4927-b1ac-bc76b00538ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_39cb2119-847a-4b46-bee8-6471fac38a29_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e80c5c85-6854-40a7-9c50-a121d9d0e28e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_2fc3b697-f50c-4135-9707-8f60bad9ef7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6031626-139a-4958-93c2-40e8d1440fc8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a872e48-6465-4f7f-b311-1ba242c57398_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1d205927-827b-4b94-b464-02ea0f8e075f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8f95b1ba-d420-44cf-9c36-bf2cbde5678c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_86df94bc-a431-4dc9-a474-e80e07840962_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c1f6eb57-ea54-40c5-baad-00027830863e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_d2912eaf-6e7c-47a0-80d1-0271b4962681_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9349635b-82e9-4168-b003-9bda93972915_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_08e55f72-b075-4dc2-81e7-fda09296c423_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_446be998-ce27-48cc-90b7-013ec626da7c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_e6782da4-d48c-4b19-90fd-e4a368c1cd74_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_afe7d3ad-4f60-4083-ac90-a9d1d0955ebc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_128f9286-4a53-44d3-96c2-155a4decc274_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_00dde8b8-c80a-4203-8c35-79a57bf5a63a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3a775eac-a471-468a-9161-fcf9ea9330c9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9d5fd605-62e3-4609-8803-da5464d3c025_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc43eba0-1702-4962-b361-9bc8d2d298b4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f038dfde-f888-496a-b389-360a50338f48_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0a5477e8-fa83-4f31-a238-7defc6f2cf9c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_3298068f-8ff4-4a8a-85ce-791298c15aba_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant value</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_843375dd-61a1-45b2-a45a-bed00f03c0af_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_42126606-52ae-4f84-a62d-f2e087afd0bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f01861be-759d-4fe5-b0e7-c654ff34c409_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_cd8f759b-08cd-45a5-876b-17cec26e3deb_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0a7f87a2-318a-43da-9ef1-91b52f2636a9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_417787c1-dbbd-4074-a8c3-1abd43fb21b2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7c53d755-b1b4-4c2b-be9f-7cc4f29fc06a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1b84a221-8679-452c-a6e3-d6d0dd501d8c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of rights per share (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsMatchingFundsRequirement_fda80606-48ca-41b0-a3e3-21dca9de26d3_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching funds requirement</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMatchingFundsRequirement_label_en-US" xlink:label="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Matching Funds Requirement</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMatchingFundsRequirement_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Matching Funds Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsMatchingFundsRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:to="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a08b2d0a-974a-4199-a7cb-a6799a849002_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_acb00187-3391-478a-a24c-6d476b13b478_terseLabel_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical trial expenses</link:label>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_label_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Expense</link:label>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_documentation_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense" xlink:href="flks-20210930.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_PrepaidClinicalTrialExpense" xlink:to="lab_flks_PrepaidClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_d8ca48e9-1a50-4e2c-aebf-808b5abada1e_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRANTS RECEIVABLE</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_848537ee-0933-4d3e-9cbc-665c38e0b8bc_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_e7e5e5fc-54d1-4b03-8892-f4c767064b26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b30800b3-0e23-49f6-99ee-585446789796_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b14348db-d7bd-4da0-9cf8-e23fcfc7e0fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_afc9c3f7-42ac-4135-a997-137187e1c8a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares converted to common shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1e89776b-ffee-4b2b-960e-61306789e988_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_8e5030fa-aaa8-48bb-8be9-f241f612df0f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_a91c9a72-0d33-4e8b-b4b5-9096c5922173_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_7c7727c0-2db6-46d1-8e36-fbbb483d106c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_146446e4-7496-4350-9e0b-674f40cb601c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3eee5a81-038c-4a1e-a773-2e819ecd511d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f69ee1d3-3aff-4a38-a816-ce4a868fb71d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1280b0f4-6770-4b74-980a-1bdba330e1f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f5fed825-b1ef-45ff-af2e-02440a20016b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before other income (expense)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b51f86b2-61ba-4202-bf74-685df2deb650_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_bfba78cc-8289-47e9-9c83-aa794c812393_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fcf6e531-a814-493d-b244-53b81d11d32d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1a0c13cb-6987-47df-b1cf-2c0039aae7fa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0486c85d-0b42-4725-be0b-4684d4331b71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_b9391d3a-ddac-4b88-a85d-2aff01e770f4_terseLabel_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="flks-20210930.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5a1eee02-0616-4654-962e-2cc37c2d6b80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_11984497-56ea-4166-883a-b91ae2f9731e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4bda3d6b-5324-430c-b7c2-6059f5e62920_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_44faa562-a93d-441c-8701-6f704f74957a_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2a82dad2-52d2-457d-a250-25378ddf6267_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5a3d6537-8992-4282-8012-872870282842_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_89f2af11-6fa5-45ba-92d0-c8cc5e960273_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c32d7a9a-ff53-47bc-9645-a4a9374e3939_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_35b4d14c-9458-48be-9101-b12bd0d2c73a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_bd89fe35-59ec-4b73-93fb-75b9ddd241bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6e043a06-eebe-4e20-95cd-ce9ae7e65a5b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Application of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_71736e25-c575-4a11-8237-3530bdd67052_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_44de0dd2-5e44-48c4-ab8d-44303f7f3df1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb592af3-2bb2-4aa3-83ac-dcd9bafa218b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_be7fe741-76c4-4ab4-bcac-559236cb3b76_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_f4406213-fbca-4905-8c0c-ef4af3605bf3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ee902c26-0c9e-41d3-be9a-3a07aff377fe_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_48df2b15-ac78-46e3-aa0d-cdb02f6452b6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a68a189f-bad2-4a3f-bec7-a02feee47465_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_4af6f5b9-a66b-4fd3-b73d-7080ff0f774c_terseLabel_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation</link:label>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_label_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation [Member]</link:label>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_documentation_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember" xlink:href="flks-20210930.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_UniversityOfUtahResearchFoundationMember" xlink:to="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_a383154b-60ad-4739-8936-a2a62f502e01_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4a3bbaf1-6e70-45c8-bc32-2c8b5e75fa85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted-average exercise price (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_28e65a0d-0c47-431c-80b1-970f0de2b43f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e348691e-93e5-4f5f-b1b5-d925386bd6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f2916ac3-5a8b-4fd0-87df-3b5c92351e47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0d1237a7-92cf-47ee-b794-c64b531fa3bb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3aeeaa78-1a67-496d-abad-0b583e8cb24a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3537d46e-a1f0-4dd1-afb8-966078ed2d6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_684041a6-5ea3-4d57-ba70-1a9e8ed9ee9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_a6dbce7e-3215-4f6c-97df-179cc4bd3941_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_914e2435-8bc5-41bf-ae9a-c5c040b221bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variables Used in Black-Scholes Model</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a9e650dd-9a79-4335-a55a-fd647b8bab61_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares converted to common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_651c86e1-d2f2-4149-8ed5-b62a83b5f1ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a68494f7-55a7-4b04-a19b-f1365c162f18_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_32bae712-2d7f-4a9d-bc92-b96adff91290_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d887b657-ff90-4020-9968-c43794ef831c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2ab163e3-3445-4484-a57b-cd3d3bfedf5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_2cb3773b-1f36-44fd-bf35-e71d99499607_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_bbf7b684-38fa-4aed-99fb-45984b22714d_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continued payments, percent of net sales</link:label>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_label_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</link:label>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:to="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>flks-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:933be885-fec0-4346-88e3-96fdb95628e8,g:3a038917-b4df-486f-8fdf-f41d10c2cf87-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="simple" xlink:href="flks-20210930.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a7c91351-5db1-4aee-8232-0779bce5052f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_DocumentType_a7c91351-5db1-4aee-8232-0779bce5052f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_773bed79-7580-4643-bcdc-e6370f8b5357" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_DocumentQuarterlyReport_773bed79-7580-4643-bcdc-e6370f8b5357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_87aebba1-95cf-4d55-bc44-8b8913eee3e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_DocumentPeriodEndDate_87aebba1-95cf-4d55-bc44-8b8913eee3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_379acd1c-83a9-4d4e-bdb4-58be2ce26fd6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_DocumentTransitionReport_379acd1c-83a9-4d4e-bdb4-58be2ce26fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bec1b671-96de-4aa2-8464-f0d88e3f0907" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityFileNumber_bec1b671-96de-4aa2-8464-f0d88e3f0907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_81ac1d20-42a4-4619-9ea3-cb8f8449a557" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityRegistrantName_81ac1d20-42a4-4619-9ea3-cb8f8449a557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cf7b4625-420b-47ed-96eb-de7c29a1cb2b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cf7b4625-420b-47ed-96eb-de7c29a1cb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a6c8a21f-e185-407e-abcf-86ea2afc44ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityTaxIdentificationNumber_a6c8a21f-e185-407e-abcf-86ea2afc44ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba89060f-811b-4bc8-81c9-b39fca931b24" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityAddressAddressLine1_ba89060f-811b-4bc8-81c9-b39fca931b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e60a8f2e-2f87-406f-b801-953cc815f89e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityAddressAddressLine2_e60a8f2e-2f87-406f-b801-953cc815f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a8bcf9e3-f841-4cb5-bbce-ef1dcf6f49c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityAddressCityOrTown_a8bcf9e3-f841-4cb5-bbce-ef1dcf6f49c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_370a26d9-7c08-4735-a5b9-6340c4dae107" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityAddressStateOrProvince_370a26d9-7c08-4735-a5b9-6340c4dae107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ad28e02f-4c82-46eb-809c-1d38bcef5e86" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityAddressPostalZipCode_ad28e02f-4c82-46eb-809c-1d38bcef5e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ef967bb2-edd2-49ed-9d86-76045c3dac8a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_CityAreaCode_ef967bb2-edd2-49ed-9d86-76045c3dac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_07ba07c9-cd1b-4c72-b8db-13817a8c8ff6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_LocalPhoneNumber_07ba07c9-cd1b-4c72-b8db-13817a8c8ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8846883e-c4af-435f-aa6c-6e1941b9acd2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_Security12bTitle_8846883e-c4af-435f-aa6c-6e1941b9acd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_05d6dfe9-65d6-401e-ac26-fc53f482ba9e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_TradingSymbol_05d6dfe9-65d6-401e-ac26-fc53f482ba9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ed68ec6d-d615-4754-91ba-ce8c217ce85c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_SecurityExchangeName_ed68ec6d-d615-4754-91ba-ce8c217ce85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_439536fa-fbd7-431b-b487-c430bdcaf410" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityCurrentReportingStatus_439536fa-fbd7-431b-b487-c430bdcaf410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1f627d0f-9e41-4728-b31e-a7d62889d12e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityInteractiveDataCurrent_1f627d0f-9e41-4728-b31e-a7d62889d12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_60b1aef0-4969-4865-b780-c30b4b48a1c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityFilerCategory_60b1aef0-4969-4865-b780-c30b4b48a1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ade9d0cc-6db5-4f3b-98ed-33cfc1766f94" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntitySmallBusiness_ade9d0cc-6db5-4f3b-98ed-33cfc1766f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_50e804b5-e840-4c14-9473-d3f41386ebc6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityEmergingGrowthCompany_50e804b5-e840-4c14-9473-d3f41386ebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d5d262a1-0d39-4212-a3a6-495c9d3ea4ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityShellCompany_d5d262a1-0d39-4212-a3a6-495c9d3ea4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0c010899-4e86-4eac-b30b-274e4b764cbf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0c010899-4e86-4eac-b30b-274e4b764cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b15d7427-4ae5-4f41-9583-0be9edf2a68d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_EntityCentralIndexKey_b15d7427-4ae5-4f41-9583-0be9edf2a68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1eb75789-3e59-4f6e-afcc-794da76ec6ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_CurrentFiscalYearEndDate_1eb75789-3e59-4f6e-afcc-794da76ec6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c879cdfe-58c1-4028-a423-299fe0dd2ef5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_DocumentFiscalYearFocus_c879cdfe-58c1-4028-a423-299fe0dd2ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f305a6eb-42a9-4b4b-a7d2-5d522234c568" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f305a6eb-42a9-4b4b-a7d2-5d522234c568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9444f763-d5e8-4641-af23-4d81dc12bb70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7397c2eb-9fd1-4ee7-89ac-80792bc664c8" xlink:to="loc_dei_AmendmentFlag_9444f763-d5e8-4641-af23-4d81dc12bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_33b1934e-16ed-4a54-993f-5e926907eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33b1934e-16ed-4a54-993f-5e926907eeb0" xlink:to="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3449304d-1a0d-4015-bd73-73062f1b5df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3449304d-1a0d-4015-bd73-73062f1b5df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37a11fb3-e261-490d-ba7f-7ba0971b6d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3449304d-1a0d-4015-bd73-73062f1b5df3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37a11fb3-e261-490d-ba7f-7ba0971b6d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_687669fe-7786-4f29-aaae-f6b45461f88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3449304d-1a0d-4015-bd73-73062f1b5df3" xlink:to="loc_us-gaap_ReceivablesNetCurrent_687669fe-7786-4f29-aaae-f6b45461f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69e9e6cb-c19c-4e4e-9479-5b6e90650e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3449304d-1a0d-4015-bd73-73062f1b5df3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_69e9e6cb-c19c-4e4e-9479-5b6e90650e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c26f8ab-4c28-4c3f-95c8-c3e010cac639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3449304d-1a0d-4015-bd73-73062f1b5df3" xlink:to="loc_us-gaap_AssetsCurrent_1c26f8ab-4c28-4c3f-95c8-c3e010cac639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45ca29f1-58a8-41d9-90dd-5dc9a4d2fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_45ca29f1-58a8-41d9-90dd-5dc9a4d2fcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ea772611-ca68-4afd-8678-23c7bf7f20d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ea772611-ca68-4afd-8678-23c7bf7f20d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7339bf27-0012-4bd4-8c3e-00ca900aadf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:to="loc_us-gaap_Goodwill_7339bf27-0012-4bd4-8c3e-00ca900aadf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_30e35037-ca17-4a04-83f2-c84efd37b363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_baf1087d-e8a1-437c-84af-d0b123ecfb13" xlink:to="loc_us-gaap_Assets_30e35037-ca17-4a04-83f2-c84efd37b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_33b1934e-16ed-4a54-993f-5e926907eeb0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c9c4996b-2046-4e4b-8456-fc5331c71191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c9c4996b-2046-4e4b-8456-fc5331c71191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_99468d01-8cda-4819-9ee3-ad6f19f1f089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9c4996b-2046-4e4b-8456-fc5331c71191" xlink:to="loc_us-gaap_AccountsPayableCurrent_99468d01-8cda-4819-9ee3-ad6f19f1f089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_7f0998e2-6c51-4a1e-ab1e-5ad1c10f3af2" xlink:href="flks-20210930.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9c4996b-2046-4e4b-8456-fc5331c71191" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_7f0998e2-6c51-4a1e-ab1e-5ad1c10f3af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_5c3ac83e-667f-483a-843c-cbf53187d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9c4996b-2046-4e4b-8456-fc5331c71191" xlink:to="loc_us-gaap_NotesPayableCurrent_5c3ac83e-667f-483a-843c-cbf53187d93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_5d376750-7b99-462c-9f31-326df815d044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9c4996b-2046-4e4b-8456-fc5331c71191" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_5d376750-7b99-462c-9f31-326df815d044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aba7d55a-fa91-4d89-9831-3224ad993edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:to="loc_us-gaap_Liabilities_aba7d55a-fa91-4d89-9831-3224ad993edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a7cbd9c4-7702-4ae8-a309-9dcd803cd553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a7cbd9c4-7702-4ae8-a309-9dcd803cd553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6600a092-f9ed-49ae-92ab-7bd3c747711b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:to="loc_us-gaap_PreferredStockValue_6600a092-f9ed-49ae-92ab-7bd3c747711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7d51f127-ff3c-4f47-94e5-949280f4fc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:to="loc_us-gaap_CommonStockValue_7d51f127-ff3c-4f47-94e5-949280f4fc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c24ca620-6862-469c-afdb-d6ca43e8c669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c24ca620-6862-469c-afdb-d6ca43e8c669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4de4a7cc-60ae-4512-a22b-264a769422b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4de4a7cc-60ae-4512-a22b-264a769422b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb7a7698-b413-4a6e-8f46-3826046fb17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d3ef2e17-778e-48ac-a313-4fb6fa9384a9" xlink:to="loc_us-gaap_StockholdersEquity_eb7a7698-b413-4a6e-8f46-3826046fb17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_00715d1e-ad4a-45bc-acb5-8f7f84c9ad88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f35e3bb8-5fc9-4489-8237-c4776c1f36bf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_00715d1e-ad4a-45bc-acb5-8f7f84c9ad88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_61249c4b-b0ff-4059-a902-2d89200bef68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_61249c4b-b0ff-4059-a902-2d89200bef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_46cf36ef-27eb-4b1c-ada6-4fa420980b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_46cf36ef-27eb-4b1c-ada6-4fa420980b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_61b9c6c3-c758-4d86-8337-0e2f14a7b440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_PreferredStockSharesIssued_61b9c6c3-c758-4d86-8337-0e2f14a7b440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2900275f-45f0-48a0-b3bc-04afdbc5eed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2900275f-45f0-48a0-b3bc-04afdbc5eed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f81e8bd0-4ba0-412f-a175-4530320108fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f81e8bd0-4ba0-412f-a175-4530320108fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f6229e5b-d7d5-4307-9845-d3215ae2ed50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f6229e5b-d7d5-4307-9845-d3215ae2ed50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fe6a88dc-dcb1-4734-9bdf-5ed735f7edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_CommonStockSharesIssued_fe6a88dc-dcb1-4734-9bdf-5ed735f7edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9fd72d7b-1823-4f0b-b5d7-0892c3ecf2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c70d4a65-806b-4b70-8270-10b65b01cc35" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9fd72d7b-1823-4f0b-b5d7-0892c3ecf2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_c2b24f7b-aea0-4ec3-8f48-a51609991cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_c2b24f7b-aea0-4ec3-8f48-a51609991cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cbc58f55-76e3-4cc4-aff7-cc3e6cca2f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cbc58f55-76e3-4cc4-aff7-cc3e6cca2f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f1ec0bf-01bc-4db4-95a7-1a5545023d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f1ec0bf-01bc-4db4-95a7-1a5545023d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47fafec2-cb65-4fec-baed-180cb8f186f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f1ec0bf-01bc-4db4-95a7-1a5545023d7a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47fafec2-cb65-4fec-baed-180cb8f186f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_debc1c58-b56b-4ada-b92b-f2f6ce0f5064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f1ec0bf-01bc-4db4-95a7-1a5545023d7a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_debc1c58-b56b-4ada-b92b-f2f6ce0f5064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b30e86f6-8fcf-4206-97f6-003859ada05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f1ec0bf-01bc-4db4-95a7-1a5545023d7a" xlink:to="loc_us-gaap_OperatingExpenses_b30e86f6-8fcf-4206-97f6-003859ada05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a2bc7f3-ef72-46ac-a3b2-822cf113d96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a2bc7f3-ef72-46ac-a3b2-822cf113d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d3b39d2b-cab4-43e1-8265-148bd4d66d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d3b39d2b-cab4-43e1-8265-148bd4d66d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_08e639af-e84f-4d80-ae0f-ff39d6213075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_OtherNonoperatingIncome_08e639af-e84f-4d80-ae0f-ff39d6213075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0b00c959-2881-42d6-a492-37dfca8303cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0b00c959-2881-42d6-a492-37dfca8303cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_f929a03e-df31-409d-99ab-88e8e74e2712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_f929a03e-df31-409d-99ab-88e8e74e2712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_daabedf4-3a5b-49ba-a376-523be4303fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_NetIncomeLoss_daabedf4-3a5b-49ba-a376-523be4303fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_24567e49-678e-40ca-a3b6-e9ecdedf0932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_EarningsPerShareBasic_24567e49-678e-40ca-a3b6-e9ecdedf0932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ae44ccd0-71a5-4bc5-9939-024e4997c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ae44ccd0-71a5-4bc5-9939-024e4997c73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_23496be5-0686-41b3-96e9-451a948b1995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_23496be5-0686-41b3-96e9-451a948b1995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bb680f9-7a60-40db-b87f-51f309afe999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74f849dd-324d-4630-8cf9-4b2d56f1a6e6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bb680f9-7a60-40db-b87f-51f309afe999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31f01171-8155-4c87-8251-2a40c2c79a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31f01171-8155-4c87-8251-2a40c2c79a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df8ccfeb-1504-4c27-85f3-e8863e214f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31f01171-8155-4c87-8251-2a40c2c79a26" xlink:to="loc_us-gaap_NetIncomeLoss_df8ccfeb-1504-4c27-85f3-e8863e214f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31f01171-8155-4c87-8251-2a40c2c79a26" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0984b3e3-d1c5-49e5-9c2e-b1459cf1b8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0984b3e3-d1c5-49e5-9c2e-b1459cf1b8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f9eb1045-e205-46ed-94ce-3cfc4aa3b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:to="loc_us-gaap_ShareBasedCompensation_f9eb1045-e205-46ed-94ce-3cfc4aa3b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ed64214a-e1d0-4754-b25d-15b2539a7405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ed64214a-e1d0-4754-b25d-15b2539a7405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_c7a133e8-a1ec-42fc-a02b-c067350d4973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_c7a133e8-a1ec-42fc-a02b-c067350d4973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36b40d12-d1ef-4d1e-bf0d-11529fe93175" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_46f93e06-3386-4e0b-b778-e4fbbfc92a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_46f93e06-3386-4e0b-b778-e4fbbfc92a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_72024938-88bf-4470-8c17-71d22415a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_72024938-88bf-4470-8c17-71d22415a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_03414e4e-954a-468a-bc39-b732905dd717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_03414e4e-954a-468a-bc39-b732905dd717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9639905a-e5e0-4969-9a18-8b9c7a63ffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9639905a-e5e0-4969-9a18-8b9c7a63ffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_db3473d3-6197-4168-b759-ffd705dd0e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45a3c459-adc5-4662-b612-d53c13c38738" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_db3473d3-6197-4168-b759-ffd705dd0e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b8dacaa-53e9-4689-a420-787ff5fc513d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_31f01171-8155-4c87-8251-2a40c2c79a26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b8dacaa-53e9-4689-a420-787ff5fc513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a16592d9-3bad-4b38-9c6d-05332759e5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a16592d9-3bad-4b38-9c6d-05332759e5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_fac1d15a-b920-4d0a-b006-12fb2cffe3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a16592d9-3bad-4b38-9c6d-05332759e5a3" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_fac1d15a-b920-4d0a-b006-12fb2cffe3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_240f0beb-c161-4f9a-9d41-8b24df905d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a16592d9-3bad-4b38-9c6d-05332759e5a3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_240f0beb-c161-4f9a-9d41-8b24df905d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_04696fcd-e0aa-4c31-915a-5cdb790544b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a16592d9-3bad-4b38-9c6d-05332759e5a3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_04696fcd-e0aa-4c31-915a-5cdb790544b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9904b85d-f149-4d79-989e-5003109e9766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a16592d9-3bad-4b38-9c6d-05332759e5a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9904b85d-f149-4d79-989e-5003109e9766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_83c6f1cd-10cc-4d4e-8f59-86eb3a68ff55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_83c6f1cd-10cc-4d4e-8f59-86eb3a68ff55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2457829-5162-4046-a0bb-a68a7a4f8cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2457829-5162-4046-a0bb-a68a7a4f8cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1448ceb-3bbe-4987-a326-a775a81ee8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1448ceb-3bbe-4987-a326-a775a81ee8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f259c1be-58a7-4b26-910a-a47c640470a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_914986ca-f450-4bff-86d2-3a93a26bb115" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f259c1be-58a7-4b26-910a-a47c640470a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e9190143-812b-4a72-acf7-ce97cebea038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f259c1be-58a7-4b26-910a-a47c640470a6" xlink:to="loc_us-gaap_InterestPaidNet_e9190143-812b-4a72-acf7-ce97cebea038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2060fca9-da21-422d-bbf9-d877f7b93e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f259c1be-58a7-4b26-910a-a47c640470a6" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2060fca9-da21-422d-bbf9-d877f7b93e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuanceCostsAccruedAndAmortized_f0a62c78-8a97-44be-be05-d5fdc6f4344a" xlink:href="flks-20210930.xsd#flks_StockIssuanceCostsAccruedAndAmortized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2060fca9-da21-422d-bbf9-d877f7b93e82" xlink:to="loc_flks_StockIssuanceCostsAccruedAndAmortized_f0a62c78-8a97-44be-be05-d5fdc6f4344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidExpenseFinancedByNotePayable_bf3a66e2-b744-48ca-a084-7bc96879cf23" xlink:href="flks-20210930.xsd#flks_PrepaidExpenseFinancedByNotePayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2060fca9-da21-422d-bbf9-d877f7b93e82" xlink:to="loc_flks_PrepaidExpenseFinancedByNotePayable_bf3a66e2-b744-48ca-a084-7bc96879cf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="flks-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9b0587cc-16f4-4849-bb7f-42ad3d0755ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9b0587cc-16f4-4849-bb7f-42ad3d0755ce" xlink:to="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6cd85a4-7969-4954-b618-b97a84b8e5a4" xlink:to="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_639b6ec4-1885-45a0-bd10-df29eac16d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_CommonStockMember_639b6ec4-1885-45a0-bd10-df29eac16d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_2eeb671a-6267-4044-b12e-f7e7f0deb5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_PreferredStockMember_2eeb671a-6267-4044-b12e-f7e7f0deb5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53eafe2c-b7ed-4d92-8d24-a75ae7966227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53eafe2c-b7ed-4d92-8d24-a75ae7966227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f362ca1b-36e9-473f-ba5a-83caa7636f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ac1f72c5-e0a8-4473-94f6-a7bb375e8484" xlink:to="loc_us-gaap_RetainedEarningsMember_f362ca1b-36e9-473f-ba5a-83caa7636f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:to="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_4444a612-e946-4306-9429-2b947cd9ba09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_a1617744-1e9d-45ef-b412-86c88190c637" xlink:to="loc_us-gaap_GranteeStatusDomain_4444a612-e946-4306-9429-2b947cd9ba09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_a88c39bd-cd3f-49b9-a943-601b0aa49edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_4444a612-e946-4306-9429-2b947cd9ba09" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_a88c39bd-cd3f-49b9-a943-601b0aa49edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9a058c6d-069c-413d-af2f-e185bf538d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37b19880-cfcd-466d-9999-81335a39a307" xlink:to="loc_us-gaap_StatementLineItems_9a058c6d-069c-413d-af2f-e185bf538d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9a058c6d-069c-413d-af2f-e185bf538d6d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_528e80e6-9009-41ae-b476-64b36975467e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_SharesOutstanding_528e80e6-9009-41ae-b476-64b36975467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1186a892-eccc-47b4-92e0-11b7702aef49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockholdersEquity_1186a892-eccc-47b4-92e0-11b7702aef49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6b60dea-313c-4960-8464-5b1a772570d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6b60dea-313c-4960-8464-5b1a772570d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0e05d11-3743-4e53-aefe-a00c8dca521e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0e05d11-3743-4e53-aefe-a00c8dca521e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_7b18bd5a-b94a-415f-91e6-8e9c7c8934b4" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_7b18bd5a-b94a-415f-91e6-8e9c7c8934b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodValueWarrantsExercised_47087432-b2ad-4739-bea8-d01357908a7c" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_flks_StockIssuedDuringPeriodValueWarrantsExercised_47087432-b2ad-4739-bea8-d01357908a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e676e37b-3936-4861-bbfc-4f126ecb2350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e676e37b-3936-4861-bbfc-4f126ecb2350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_b0111df5-508f-4edc-8fd1-6fc2a00b85e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_b0111df5-508f-4edc-8fd1-6fc2a00b85e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8866ce6-3227-4450-94b9-829eb9ffc6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8866ce6-3227-4450-94b9-829eb9ffc6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3fe048df-5abe-4fd4-a14f-7762102f4beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3fe048df-5abe-4fd4-a14f-7762102f4beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1152812e-4f52-43f6-8716-126bb47af18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_NetIncomeLoss_1152812e-4f52-43f6-8716-126bb47af18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9ea34aec-cf8b-4263-9939-515b8e284310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_SharesOutstanding_9ea34aec-cf8b-4263-9939-515b8e284310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c13bc255-4ff8-4c76-ac1a-3da6bcba25fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a2aae1d-cef6-43e2-ae34-d30b694758b6" xlink:to="loc_us-gaap_StockholdersEquity_c13bc255-4ff8-4c76-ac1a-3da6bcba25fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="simple" xlink:href="flks-20210930.xsd#ORGANIZATIONANDOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15b17a3e-4508-4c49-9fb5-41f32fa2db7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b3298f27-94db-4f87-b3cb-507f09f1cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15b17a3e-4508-4c49-9fb5-41f32fa2db7d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b3298f27-94db-4f87-b3cb-507f09f1cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="flks-20210930.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f4fa6a1-5165-4c05-bbad-938ba3f5f8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3a4ba498-065c-4179-be14-b689cbfd60b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f4fa6a1-5165-4c05-bbad-938ba3f5f8f9" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3a4ba498-065c-4179-be14-b689cbfd60b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="flks-20210930.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9252a34c-a1b1-46b1-8c60-ed68a8697dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9252a34c-a1b1-46b1-8c60-ed68a8697dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6db1377e-ef28-4a8a-8721-81f31e107f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6db1377e-ef28-4a8a-8721-81f31e107f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_895026b8-a29d-46c2-bf3a-021a607be22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_UseOfEstimates_895026b8-a29d-46c2-bf3a-021a607be22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_85eb28f4-7d33-4c8a-a6f2-b04214427b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_85eb28f4-7d33-4c8a-a6f2-b04214427b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_79d0afbb-2479-4925-a770-c35606bff4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_79d0afbb-2479-4925-a770-c35606bff4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f1305db7-6d4d-4b72-b021-649037abdaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f1305db7-6d4d-4b72-b021-649037abdaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7698fb92-8aed-4eb8-91fa-7853898bd15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7698fb92-8aed-4eb8-91fa-7853898bd15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_9a4c2a6b-8550-4c1f-80bc-ae1764d752d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_9a4c2a6b-8550-4c1f-80bc-ae1764d752d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_404aaf7a-80ee-4a88-b3c9-786ae4b9753b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_404aaf7a-80ee-4a88-b3c9-786ae4b9753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_cf4e070a-bdda-4db7-8092-bff111629926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_cf4e070a-bdda-4db7-8092-bff111629926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c6873626-6dc6-46d7-bbd7-c1134a687357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c6873626-6dc6-46d7-bbd7-c1134a687357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8a308c65-61b6-4c4b-9136-aa4d0251325f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8a308c65-61b6-4c4b-9136-aa4d0251325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_80cea91a-d8f4-44ba-bf55-6cf7504e2d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_80cea91a-d8f4-44ba-bf55-6cf7504e2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_cdd4066e-0f83-4ca2-87cc-d75b7bd93480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_cdd4066e-0f83-4ca2-87cc-d75b7bd93480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d571efaa-4ef3-466e-981d-c79c54de1ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e18957c-5f7c-4222-a0e3-235e89cdc412" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d571efaa-4ef3-466e-981d-c79c54de1ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39cb703d-d5c9-43d7-9b32-7bb466020c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1f3d3f47-ec28-42c8-b2f1-226624bcdffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39cb703d-d5c9-43d7-9b32-7bb466020c93" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1f3d3f47-ec28-42c8-b2f1-226624bcdffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_34f53374-38e2-4303-bb05-475b2338b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39cb703d-d5c9-43d7-9b32-7bb466020c93" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_34f53374-38e2-4303-bb05-475b2338b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ab6fd154-e8fb-4419-9f7a-9430df1a42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39cb703d-d5c9-43d7-9b32-7bb466020c93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ab6fd154-e8fb-4419-9f7a-9430df1a42cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="simple" xlink:href="flks-20210930.xsd#GRANTSRECEIVABLE"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2b1f0f90-ad84-4804-870c-55c8de320e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_82a215e1-cb30-4999-b442-0287d8a16aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2b1f0f90-ad84-4804-870c-55c8de320e5a" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_82a215e1-cb30-4999-b442-0287d8a16aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#GRANTSRECEIVABLEDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_76df6918-661e-4575-bb57-7e29e9a5994d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1a9de043-ee6f-4d13-888f-4cdc3984b54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_76df6918-661e-4575-bb57-7e29e9a5994d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_1a9de043-ee6f-4d13-888f-4cdc3984b54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="simple" xlink:href="flks-20210930.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2d095a7e-0ed0-43b5-a37c-6f90b6d9c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_117f8da3-1747-4164-b643-2343399d00d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2d095a7e-0ed0-43b5-a37c-6f90b6d9c2fa" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_117f8da3-1747-4164-b643-2343399d00d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="simple" xlink:href="flks-20210930.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7752420a-bc5f-47a5-8bc4-c7d1a9c685e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_c408e20b-7bb9-4709-bde1-58aaf0feb4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_7752420a-bc5f-47a5-8bc4-c7d1a9c685e8" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_c408e20b-7bb9-4709-bde1-58aaf0feb4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36ccf7ca-f4dd-4468-b132-9f891055ec73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_f7c9d755-1c93-4671-bacb-42a55a5d0dfb" xlink:href="flks-20210930.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36ccf7ca-f4dd-4468-b132-9f891055ec73" xlink:to="loc_flks_PrepaidClinicalTrialExpense_f7c9d755-1c93-4671-bacb-42a55a5d0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_6fa6defe-a510-45ee-9900-91a787714178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36ccf7ca-f4dd-4468-b132-9f891055ec73" xlink:to="loc_us-gaap_PrepaidInsurance_6fa6defe-a510-45ee-9900-91a787714178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ae5b9226-b27a-4948-83e8-f665492e88b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36ccf7ca-f4dd-4468-b132-9f891055ec73" xlink:to="loc_us-gaap_OtherAssetsCurrent_ae5b9226-b27a-4948-83e8-f665492e88b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73e3ec28-b73b-4ce8-9847-a1a2d5294284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36ccf7ca-f4dd-4468-b132-9f891055ec73" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73e3ec28-b73b-4ce8-9847-a1a2d5294284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf55434e-6762-4aae-b21f-2876ed55256e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cf55434e-6762-4aae-b21f-2876ed55256e" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_eadb9ed1-0771-443f-be47-a03a6779b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_de9ba146-9996-498e-8dd5-1704f1db1a6f" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_eadb9ed1-0771-443f-be47-a03a6779b73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_cb826401-a548-4e79-9740-ec3ffecd56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_eadb9ed1-0771-443f-be47-a03a6779b73f" xlink:to="loc_us-gaap_NotesPayableToBanksMember_cb826401-a548-4e79-9740-ec3ffecd56ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_18e43d71-cd91-46bc-8219-a3b52cf12cc3" xlink:to="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_db96ddee-69f4-4822-93c4-d014baa7b4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_db96ddee-69f4-4822-93c4-d014baa7b4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcde4d7-4dca-4fe4-9495-98c5af43f9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5bfe9a12-ee76-4e25-9b55-6cf69022109f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3fcde4d7-4dca-4fe4-9495-98c5af43f9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="flks-20210930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d72ce079-0d4e-44ff-bfca-ebd07f6791d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_974c1757-5fcb-4e44-a510-08e1fb480430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d72ce079-0d4e-44ff-bfca-ebd07f6791d1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_974c1757-5fcb-4e44-a510-08e1fb480430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa0f1c-f3e3-4879-bf39-5a245646b34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8aa0f1c-f3e3-4879-bf39-5a245646b34f" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:to="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6262aa20-dec3-489b-ba9d-c762ebac671b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c8feb9ab-f401-4eef-99c4-b2902532fb54" xlink:to="loc_srt_OwnershipDomain_6262aa20-dec3-489b-ba9d-c762ebac671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember_c84284d2-c702-4b29-89e8-10706e9791c5" xlink:href="flks-20210930.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6262aa20-dec3-489b-ba9d-c762ebac671b" xlink:to="loc_flks_UniversityOfUtahResearchFoundationMember_c84284d2-c702-4b29-89e8-10706e9791c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c7e8e0e7-f18a-4fed-8f3e-4a1787298e9f" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7fb27296-65e2-4139-9f64-4e8262b135ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7fb27296-65e2-4139-9f64-4e8262b135ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward_559d5d36-3e64-4c36-9dc0-7fb47dd5d4a5" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsMaximumAward_559d5d36-3e64-4c36-9dc0-7fb47dd5d4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm_f475243e-1969-4123-bb27-2efe8997aea8" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsAwardTerm_f475243e-1969-4123-bb27-2efe8997aea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_49ff1dd2-9ea4-4555-bfc1-f3416548d5bd" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_49ff1dd2-9ea4-4555-bfc1-f3416548d5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMatchingFundsRequirement_067bf8b5-1545-485a-aaf3-58c8847863d4" xlink:href="flks-20210930.xsd#flks_RevenueFromGrantsMatchingFundsRequirement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_flks_RevenueFromGrantsMatchingFundsRequirement_067bf8b5-1545-485a-aaf3-58c8847863d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_0174550d-9532-46a9-ac36-ae623b140231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_783e9f6c-3bce-44e8-aae3-53fdd714f607" xlink:to="loc_us-gaap_ReceivablesNetCurrent_0174550d-9532-46a9-ac36-ae623b140231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="flks-20210930.xsd#FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0bfe2378-17c3-4985-8745-537ad40a5224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9f0e0aaf-7df0-4cd8-9ff9-03aba323b276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bfe2378-17c3-4985-8745-537ad40a5224" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9f0e0aaf-7df0-4cd8-9ff9-03aba323b276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="flks-20210930.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_62a28c9f-ca8b-4f90-889c-bd6fd0e4b8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7d1a053c-a1ee-4c8b-b67b-6e4d61ac4abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_62a28c9f-ca8b-4f90-889c-bd6fd0e4b8f6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7d1a053c-a1ee-4c8b-b67b-6e4d61ac4abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_92208ffe-715d-4257-9b16-00f8681bf3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92208ffe-715d-4257-9b16-00f8681bf3bb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd0d8ba8-7e86-46a3-a39e-afd34663ddab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75fb43c1-7b15-4dd6-a928-336bdd5c3093" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd0d8ba8-7e86-46a3-a39e-afd34663ddab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1da21861-ccf4-43b4-94fb-7ef12c8c9cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd0d8ba8-7e86-46a3-a39e-afd34663ddab" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1da21861-ccf4-43b4-94fb-7ef12c8c9cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6d5dc13-289e-4c05-aab7-072ae2e833a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_63f45fb9-c8ad-4d01-bfd3-2777a9218ea3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6d5dc13-289e-4c05-aab7-072ae2e833a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_97c53221-efe1-428a-bf2c-032ed3292b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6d5dc13-289e-4c05-aab7-072ae2e833a6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_97c53221-efe1-428a-bf2c-032ed3292b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4b9b5f6-e597-4716-8c78-1e4db8d552f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_79cff37d-d28b-464e-965b-35718ae38589" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4b9b5f6-e597-4716-8c78-1e4db8d552f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b4b9b5f6-e597-4716-8c78-1e4db8d552f0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b64baa5-93c9-40f5-b5aa-af33c1dbb977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4b64baa5-93c9-40f5-b5aa-af33c1dbb977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ea495b38-66ee-4f16-a089-f6a9ddeb914e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ea495b38-66ee-4f16-a089-f6a9ddeb914e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ebc80f26-1eb3-4e15-ba2b-f4ca2fcde79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6235ac9c-e202-4af4-97c0-d88e6f7dfb17" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ebc80f26-1eb3-4e15-ba2b-f4ca2fcde79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20210930.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_78cbe9c2-5c34-44fb-8dac-ef8cb7c588d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_106bda53-ba01-4a06-8731-c1c9d0bb65f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78cbe9c2-5c34-44fb-8dac-ef8cb7c588d6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_106bda53-ba01-4a06-8731-c1c9d0bb65f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="flks-20210930.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c1395aa2-34c8-4af2-8467-e9734fef5fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f8b1faaa-ec53-4c19-a278-9bfacfc5f0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1395aa2-34c8-4af2-8467-e9734fef5fe0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f8b1faaa-ec53-4c19-a278-9bfacfc5f0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f9f9ab6b-5e48-4bbe-9892-578739a9bbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f9f9ab6b-5e48-4bbe-9892-578739a9bbda" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e6317a3-691c-4c15-886c-3f946b26b036" xlink:to="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_308d15c5-7b56-400c-9e01-931d402c9d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:to="loc_us-gaap_CommonClassAMember_308d15c5-7b56-400c-9e01-931d402c9d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_84c4ed95-2b12-4a9e-a253-a297a4b388b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:to="loc_us-gaap_CommonClassBMember_84c4ed95-2b12-4a9e-a253-a297a4b388b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_40294747-058b-43dc-9e96-dbd4168b9de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4c09bf41-f07a-4157-b8c7-aa52666b3c90" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_40294747-058b-43dc-9e96-dbd4168b9de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_57724aa6-fd6a-4e63-9485-591064fb7279" xlink:to="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6fc2a825-f3cd-4372-a78b-1c411462cbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:to="loc_us-gaap_CommonStockMember_6fc2a825-f3cd-4372-a78b-1c411462cbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_387094bf-864a-4b78-a7b4-2230f516ccb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_315baba0-497e-42bd-8702-6b775f7cb995" xlink:to="loc_us-gaap_PreferredStockMember_387094bf-864a-4b78-a7b4-2230f516ccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_823a4e08-f1ac-4c66-8013-b27cafef741e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f1ac73e-3f3e-45f8-84a2-288c6fa4d9ce" xlink:to="loc_srt_RangeMember_823a4e08-f1ac-4c66-8013-b27cafef741e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_52070854-2bc6-422b-9d1e-a46c63c7da2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_823a4e08-f1ac-4c66-8013-b27cafef741e" xlink:to="loc_srt_MinimumMember_52070854-2bc6-422b-9d1e-a46c63c7da2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd099d6f-8213-4ee7-9cd5-90c0bce685c0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_8af43b9b-3975-480d-8cd8-4b30777be088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_8af43b9b-3975-480d-8cd8-4b30777be088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AtTheMarketOfferingAgreementMember_1093b6e1-db4b-4459-abf4-9afa01ca4cbd" xlink:href="flks-20210930.xsd#flks_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbae8185-6437-49d1-8cd8-120bca86dc8d" xlink:to="loc_flks_AtTheMarketOfferingAgreementMember_1093b6e1-db4b-4459-abf4-9afa01ca4cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0281c12b-1981-4e18-a5be-4826b0cdc5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c317c98-63e8-4faf-b570-bba07a92ed9d" xlink:to="loc_us-gaap_RelatedPartyDomain_0281c12b-1981-4e18-a5be-4826b0cdc5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WedbushSecuritiesIncMember_ee9e8f02-a707-4e31-9f16-8e27df56825a" xlink:href="flks-20210930.xsd#flks_WedbushSecuritiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0281c12b-1981-4e18-a5be-4826b0cdc5b7" xlink:to="loc_flks_WedbushSecuritiesIncMember_ee9e8f02-a707-4e31-9f16-8e27df56825a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_172b7374-eba4-478a-87b8-4dc9b0c7595e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a3079464-8b8e-4cc2-a094-77506aa19123" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_172b7374-eba4-478a-87b8-4dc9b0c7595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_052119d4-ea16-4f8e-8c1e-dd5922e836a2" xlink:href="flks-20210930.xsd#flks_SatisfySuccessFeeDueToRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_172b7374-eba4-478a-87b8-4dc9b0c7595e" xlink:to="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_052119d4-ea16-4f8e-8c1e-dd5922e836a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c847dec6-5a65-4dfa-a5f4-75c79d094940" xlink:to="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04dcecca-9347-4bdb-9148-598503ea6700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04dcecca-9347-4bdb-9148-598503ea6700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb75a9d-f0a1-4826-9d05-2c191d1b67e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb75a9d-f0a1-4826-9d05-2c191d1b67e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a7a45adf-483e-4ea8-bf79-58ac362f3982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a7a45adf-483e-4ea8-bf79-58ac362f3982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6527c8c3-a343-4e1c-8cd0-7489ebe2d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6527c8c3-a343-4e1c-8cd0-7489ebe2d7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2e28fb88-52cd-45a4-b5c1-fedd389e56ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2e28fb88-52cd-45a4-b5c1-fedd389e56ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d904a68c-2ad5-41d6-bd13-f3f49742dc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d904a68c-2ad5-41d6-bd13-f3f49742dc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2cb3afe5-a141-4fc2-803c-ba952150a1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2cb3afe5-a141-4fc2-803c-ba952150a1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b88b5ef-6fcc-40b0-a958-c0d57c645ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b88b5ef-6fcc-40b0-a958-c0d57c645ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_fbdd3996-b911-4fd0-8b13-96535fd48280" xlink:href="flks-20210930.xsd#flks_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_flks_StockIssuedDuringPeriodSharesWarrantsExercised_fbdd3996-b911-4fd0-8b13-96535fd48280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a4f62fc4-6394-47a7-880c-ec68548f911e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a4f62fc4-6394-47a7-880c-ec68548f911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d93149db-1f35-48a7-8ba7-48f88692bd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d93149db-1f35-48a7-8ba7-48f88692bd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_604a81f8-a7f7-47a3-926e-9285461cd9c6" xlink:href="flks-20210930.xsd#flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_604a81f8-a7f7-47a3-926e-9285461cd9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_700912d2-8f92-4966-8680-803e9fc91c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_700912d2-8f92-4966-8680-803e9fc91c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6eb13638-e6b1-45c9-ba29-980401c69516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_6eb13638-e6b1-45c9-ba29-980401c69516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_4ca1a945-3ece-45ab-924c-ba91d83b652f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f17a4332-2820-4851-8764-94f627bbcf89" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_4ca1a945-3ece-45ab-924c-ba91d83b652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_26fcfd76-7b71-4396-872f-2cde1499ea07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_26fcfd76-7b71-4396-872f-2cde1499ea07" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7f19183e-efab-429d-90cd-1a4614545511" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_e430471a-1d1b-4444-bd3b-ad9368bca1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_e430471a-1d1b-4444-bd3b-ad9368bca1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_c12fff6e-5c53-4477-bd0b-3130c9babde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_c12fff6e-5c53-4477-bd0b-3130c9babde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a842968-11cf-4981-8dde-a5b55b67c516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b8bb190c-f42d-4b1a-8a8e-fa1f74cef50d" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a842968-11cf-4981-8dde-a5b55b67c516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_8ab373bf-9077-461f-b00f-aa96e7ae9add" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsOutstandingMeasurementInput_a16f504d-5a40-4926-bde4-1b7f2acc3c5b" xlink:href="flks-20210930.xsd#flks_WarrantsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:to="loc_flks_WarrantsOutstandingMeasurementInput_a16f504d-5a40-4926-bde4-1b7f2acc3c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b74be8a1-9f80-440a-9ed9-994cda65aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_814cd5e8-e50d-4004-8bd2-b703140dfc21" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b74be8a1-9f80-440a-9ed9-994cda65aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5901c074-4f37-45ea-92bb-d9c807b72f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9d0c59ef-5b83-448c-9bba-5c572671489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5901c074-4f37-45ea-92bb-d9c807b72f91" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9d0c59ef-5b83-448c-9bba-5c572671489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb28de7d-924e-4da7-b04a-a7e62064f567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_051b7d15-59a5-48a5-acfc-693ee4d0b332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb28de7d-924e-4da7-b04a-a7e62064f567" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_051b7d15-59a5-48a5-acfc-693ee4d0b332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f51a3d0e-ec3e-4f86-b271-c21cee16c797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb28de7d-924e-4da7-b04a-a7e62064f567" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f51a3d0e-ec3e-4f86-b271-c21cee16c797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a866fa61-76a1-4b9f-9a32-03bb0b4baeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a866fa61-76a1-4b9f-9a32-03bb0b4baeaf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e90f75fc-ddde-485d-9336-fcc02da3f322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_729eccba-87c1-437b-be75-62025fcf4282" xlink:to="loc_us-gaap_PlanNameDomain_e90f75fc-ddde-485d-9336-fcc02da3f322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member_2a30bf94-99a9-420f-ae5f-3760537cefa0" xlink:href="flks-20210930.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e90f75fc-ddde-485d-9336-fcc02da3f322" xlink:to="loc_flks_EquityIncentivePlan2015Member_2a30bf94-99a9-420f-ae5f-3760537cefa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2de05838-b8d6-42cb-bfed-9c93e40deb97" xlink:to="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b9a90983-6b43-4358-9de3-35d03f8080e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:to="loc_srt_MinimumMember_b9a90983-6b43-4358-9de3-35d03f8080e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ba0b0c6-6e57-4a54-811a-fd9dea7a90e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9bd6b43-dc97-4f9e-bdae-a35f5110011d" xlink:to="loc_srt_MaximumMember_1ba0b0c6-6e57-4a54-811a-fd9dea7a90e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e0b514-a957-406e-ac23-1eb09ec0db93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a844c4da-334e-4480-a788-45339eccf143" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e0b514-a957-406e-ac23-1eb09ec0db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_408ef24f-b8f3-4e2f-b4e6-c8b55b1b21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e0b514-a957-406e-ac23-1eb09ec0db93" xlink:to="loc_us-gaap_EmployeeStockOptionMember_408ef24f-b8f3-4e2f-b4e6-c8b55b1b21e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1e0ead4-9c89-4f26-ba8f-d74c289b2282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3a57a6e-4f5e-494e-b253-462d362b92e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3a57a6e-4f5e-494e-b253-462d362b92e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd97dc9e-52da-4fcd-ac19-ec297cc64afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dd97dc9e-52da-4fcd-ac19-ec297cc64afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f9b1334-44aa-4f4e-8b69-8901aec846bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3f9b1334-44aa-4f4e-8b69-8901aec846bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c807f09d-4e55-4c08-9bd2-4891f0cb734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c807f09d-4e55-4c08-9bd2-4891f0cb734a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a4fe5899-3950-44b2-beec-f5e32bb75d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a4fe5899-3950-44b2-beec-f5e32bb75d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b3dd412d-993d-4453-9064-54641d7025c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b3dd412d-993d-4453-9064-54641d7025c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc7bd581-1963-44bc-a616-6ebbfc0ac172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93abad93-cc16-47a3-aa04-db461a40415f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc7bd581-1963-44bc-a616-6ebbfc0ac172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7835147-be90-4272-852a-c006127373b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_91ab9362-f92c-47c1-8744-dab1b5d615c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7835147-be90-4272-852a-c006127373b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_91ab9362-f92c-47c1-8744-dab1b5d615c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80a22dd2-2c64-4a15-903d-39125ea96eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7835147-be90-4272-852a-c006127373b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80a22dd2-2c64-4a15-903d-39125ea96eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13f33ce3-0468-42c2-b164-b2075177be8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7835147-be90-4272-852a-c006127373b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13f33ce3-0468-42c2-b164-b2075177be8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7eb1a41d-0569-409d-814c-292c3dba8bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7835147-be90-4272-852a-c006127373b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7eb1a41d-0569-409d-814c-292c3dba8bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="flks-20210930.xsd#EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ac6e47d-dcdf-4a68-804f-ab416353510d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ac6e47d-dcdf-4a68-804f-ab416353510d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:to="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4839e3be-3698-4b3e-8c5b-1b0ced68fa25" xlink:to="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0044c17d-d98e-4bbf-9de2-77a4201c1a66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:to="loc_srt_MinimumMember_0044c17d-d98e-4bbf-9de2-77a4201c1a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_240fe77e-e4cd-4710-8628-957a26a09446" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d222739d-cd37-4315-bc53-de23c7c9eef3" xlink:to="loc_srt_MaximumMember_240fe77e-e4cd-4710-8628-957a26a09446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46149f40-1e6e-4d61-acaf-f4de3f0a12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd319f7-ccd8-49c5-a441-a70c8f4eef06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fd319f7-ccd8-49c5-a441-a70c8f4eef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fc3384a1-d38e-4eae-be82-b24fd0727f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fc3384a1-d38e-4eae-be82-b24fd0727f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c994637-5e64-4c0a-b130-469603d6723b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c994637-5e64-4c0a-b130-469603d6723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6df206db-fc18-4bdf-a7e5-71a5f6ac7b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6df206db-fc18-4bdf-a7e5-71a5f6ac7b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_88dc2617-c4ad-4583-be37-935599feccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_88dc2617-c4ad-4583-be37-935599feccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_033661dd-cfbe-4ce8-a809-10b8aadf2f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9be8c3c1-6376-4a11-8711-91ca13728042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_033661dd-cfbe-4ce8-a809-10b8aadf2f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c7c2a456-658c-41c7-8126-e2d9cd048815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c7c2a456-658c-41c7-8126-e2d9cd048815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_157f77a3-4e56-4c29-b5b8-0e3fc33646ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_157f77a3-4e56-4c29-b5b8-0e3fc33646ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ae8e4bab-c02d-4870-9a63-8ccc722b1fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ae8e4bab-c02d-4870-9a63-8ccc722b1fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c4fa8f5-7191-48d6-a295-a99da4775524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c4fa8f5-7191-48d6-a295-a99da4775524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4013a163-7224-443e-82b7-1152335427c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f01b9dbe-dd40-4b3e-87f5-551cd5ff96fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4013a163-7224-443e-82b7-1152335427c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8450c4eb-c4df-413f-ae82-37145a3c264b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8450c4eb-c4df-413f-ae82-37145a3c264b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c96f9fa1-e1f7-420f-9e20-119100c54ed8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f8930dd-4092-4c6e-8865-c88f21945c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f8930dd-4092-4c6e-8865-c88f21945c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b27fc06f-acfd-45d9-88e9-9d105b90d53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b27fc06f-acfd-45d9-88e9-9d105b90d53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56619eda-e9e3-492a-b4c1-e8011fb7cd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56619eda-e9e3-492a-b4c1-e8011fb7cd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42e63f04-e8f2-4eb4-a54a-2ce243d28d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c55c1751-b0a2-40c3-97b6-620e164e110e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42e63f04-e8f2-4eb4-a54a-2ce243d28d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>flks-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:flks="http://www.flex-pharma.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="flks-20210930.xsd" xlink:type="simple"/>
    <context id="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb85bd86da7243f5aa57922b11eff1e9_I20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc576fa0a40d46a09cde34e4add1d831_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d20dc51e5fe4ea99139098eb7f83411_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i91ac971072f1418a89a4376f024276cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0024786ef67540f7ac2c0db72574744a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d2ac1c7ee44444cb491532bc41f23f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i18254c89c4564a21a71a20589bc53179_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieb03da10c8aa48f08dc0254a264659dd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifdadb645f0404a4d95746cc2ba5ff395_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id72958b2722c44979991d7838b0e41c5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i879f0c3963444b66916504729b1e3d17_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibf5af0205ac648a5a2afbfdf5f6e3274_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4d5e105e076d46699489e811c97d2199_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6ef3be74ccc4ed780f60aaea7b84cd6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id883671275ee47f29805bc8d421e6c30_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i89b959c132384760adfcad6637c903e0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i77cb73c0bc694074878b0432e6f254cf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibf6b4d878dea4f218fc2f35d89ffb0c3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia4078d2163404318a25c07dba8baec76_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i38e80edb414d4a79ae54153572f0e6eb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i56344979fde94e63aa913f4a5e8723d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3a378992dd7b49d9a157ab15eab9f3ed_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i494e149e02d3480995871fe3ca7e8497_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i008da512d397437a9cba8e4395f8379c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad60589c9a6a4dd7b40672b0faa48107_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i103946fb0b22442b9d8a5266ee347645_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7b7745f01faa466f876bdd522070c58d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0db0f3b8635a4838b6ac72d40a6ecc06_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i45f8c31eb4f14036be3bc5ad4af88834_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i11266e19063543088c03f4b86e4beca8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i177696ed3c044d74afa4d317d038fb4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecdeccc9f1f44bff859e3f3fcc5cbdb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70f542a0e98d4604a00099497a1f1804_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib552ff1dbb674586b246269a7598461d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4246855be8574284a65e3d4eba29df11_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0b30b72e16c34ba3a2db567ae552cea6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i88143d34f36d418e965adf2e6fd1ec52_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i84baeb8b40334043b2e851612655fc30_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i58585740081444529b94b6645f75a15f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7bdd980a35274061bc26ccaccf9623a7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic29d1e6d22804c40b7c53ce44db787ec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7d02fc8d1b514c81839144c985474d09_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id8c23cfd88914796ae8bcfbb6182d920_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibeb593881ffd4b39a7166b73ba48fad3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70f8c9fa71354fb58629cf1202290260_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia256a575bccf481fa61288d8f7b235d1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib4486746847a436886263055e53f87f8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2408113d2df34fd08dad1aad2b45fc4d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaf11851802384bfcb427ad4bdb517f9d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i80c8dcc9ab0b4b0ebdfe09ad48ecb9fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4adff28f56e841a08e131253d1872d50_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic64588aad3ec4f21aae0e0cd7fb960cf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88c667283927432092625abe5f346269_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc81e334348d4c79b3f31451ed65c6b1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d0a506d355e4b78bb7008211cbfe661_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i60f38b06e4284e2dad48030ae167ccec_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5f8bf301820e43f0bbc64c6954a84ac1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3365ee0645e1428a8bf15e40c57c905e_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ifdc107ab4ba649ca943e231ca67e264f_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i75439519a47a4f6989cd2cd3b40b5195_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">flks:UniversityOfUtahResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i12375731a1584f5db3722367e5d44b8b_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i88ae7eac7ac445aebc542f0429384d0a_D20160701-20160701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-01</endDate>
        </period>
    </context>
    <context id="i56f1fbc10f714bacb40851d5e79f0484_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i509e2e173464488a8d80584086100e5c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ice74598ecb934cd4a025ee4792e6670d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8980e464358d45fabde2cb82b652df91_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i0d4f1866e1f849c489daf2e3e0a10e39_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i03bc59929da24395880307913e87fb66_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i6026e2ea63474bb6b5241d862bf6c303_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i3725d493747d4bbe83005958d3ac6d23_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i1f88e0cf88b84bf9854e0bedf0607dd1_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i507cbbf0634340df95b758b92062fb43_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="ieb060d868e36408ebdd36e2a2fe2658d_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i7fa8c9f6d7934dcaa6197a4ab35db643_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i9309e3d556bc49209dff4d4ae28bffc9_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i62ba6b78c05f44859360da199a2f4d38_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i154dce57782f49a0b2407f5f8b6c7819_I20201211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="idc44ad82e29143268254f26cd0b201a3_I20201211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="i8d324e00fd0449ada9306d7820e7650a_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i637b5066c13e46c8ad5054fcf7d9db91_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i97060a95644a4253a9d97d1b2c868b7e_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="ie1455af2bd3e48fbab07d23af33ccf27_D20210205-20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="i8e0f9788dcba480c96b8fa31f68fb351_D20210702-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i22aba5a3e90e4e95a276ef89efe1ac98_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">flks:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5ae6026c59f4ec38c6949b4bef8d233_D20210308-20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-08</startDate>
            <endDate>2021-03-08</endDate>
        </period>
    </context>
    <context id="i4075aa174dd346ae968ca14c8a84ba8a_I20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="i38ec404e1c2a4fa19e8f881a89360a33_D20210308-20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-03-08</startDate>
            <endDate>2021-03-08</endDate>
        </period>
    </context>
    <context id="i72d6648d8528478096111949d12cd28f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f29b4bffdb04060b79c90b287ec75ee_I20190718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-18</instant>
        </period>
    </context>
    <context id="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="i7b06abcc4a3c4d32837217db39cf0e29_D20190718-20190718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-07-18</startDate>
            <endDate>2019-07-18</endDate>
        </period>
    </context>
    <context id="ic6b4f85b5e2f4b0da127ab2e310c28a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iefe55d006aa740d7bdb83434769e6cec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b1e7939df33476493958c5474f1ec12_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if20fa72ce8b44760a27f5514b956d6a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3767d63d21841febd91f1664b87398c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie27743a41234488c94ecdbae56d5030e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i9de1973dc957478cb0bc2d769059d427_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="id806215bb22c4a6bbb84c72994b31e52_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9cd9bebb5d234611a3707cb6f311df80_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e25a08a7b8243698baceb726d714709_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i618536f8debf473cb0710a7c02b3140f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28b2f8b8184949889f3aa6bcf52f8836_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-03-10</startDate>
            <endDate>2021-03-10</endDate>
        </period>
    </context>
    <context id="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2021-09-02</startDate>
            <endDate>2021-09-02</endDate>
        </period>
    </context>
    <context id="id634fbf36df7473db3bb7e070c784cad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab6f2c50c3e144b5b8f013949d188cfd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if61674fa0744426bad5a356d5af164c9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01803b42cf2b4af6b7b175622f3970f8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>flks:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF80LTEtMS0xLTE_4025973f-e0da-4325-a644-3a27c4ec2da0">0001615219</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF81LTEtMS0xLTE_c0a6294f-a111-4cfa-9222-04e9befd5f99">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF84LTEtMS0xLTE_16f24709-68dc-4801-b7bc-0716cc878d56">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF85LTEtMS0xLTE_9a429455-fa23-46e9-ac67-bd8b3fc0b1c1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80L2ZyYWc6M2YwMjkwNGRkMjRmNGRhMmE4ZWYzYTNjNzMxZDYyYWMvdGFibGU6Mjc4ZWE1MzVlYzdhNGQyNDljZTRlMWM4N2JlODU4NTAvdGFibGVyYW5nZToyNzhlYTUzNWVjN2E0ZDI0OWNlNGUxYzg3YmU4NTg1MF8xMC0xLTEtMS0x_e852ef06-8d37-4dca-a1e2-9f7f6563e92b">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_364a1241-d7a9-4e7c-98c2-25b02fba3fdb">http://fasb.org/us-gaap/2021-01-31#GrantMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_407c59a9-1a55-41e6-8ea4-62a5380e3581">http://fasb.org/us-gaap/2021-01-31#GrantMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_54ac70d5-5fa9-4988-b93c-d343cc9752bd">http://fasb.org/us-gaap/2021-01-31#GrantMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0wLTEtMS0x_7f901995-a856-4b16-b7c1-84ec51666bd0">http://fasb.org/us-gaap/2021-01-31#GrantMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7e25a08a7b8243698baceb726d714709_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI0NA_14cf129a-350a-4324-b668-9e3a5073d911">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTI1_a59fd105-be6e-4873-a4c4-198e9064115c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjcxODdkNGZjZDU1NGNiMDhjYzVmZTFiMGI1MDlmOGQvdGFibGVyYW5nZTo2NzE4N2Q0ZmNkNTU0Y2IwOGNjNWZlMWIwYjUwOWY4ZF8xLTAtMS0xLTE_08ef18e5-f6e7-4357-90ff-d61ef24614e6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjcxODdkNGZjZDU1NGNiMDhjYzVmZTFiMGI1MDlmOGQvdGFibGVyYW5nZTo2NzE4N2Q0ZmNkNTU0Y2IwOGNjNWZlMWIwYjUwOWY4ZF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjo2YmQxNTZiNmUzNDI0MTg4ODE1NWFlYWMxOWVlODYwNF8zNQ_a1383c0a-308f-4686-859c-12359fc9ff3f">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjcxODdkNGZjZDU1NGNiMDhjYzVmZTFiMGI1MDlmOGQvdGFibGVyYW5nZTo2NzE4N2Q0ZmNkNTU0Y2IwOGNjNWZlMWIwYjUwOWY4ZF80LTAtMS0xLTE_94d6cdf5-9770-4a06-a731-803f38d4f0ea">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xMTY_29f7b27a-855f-443f-a565-09f6960c1103">001-36812</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xMjA_a8d574ce-3f63-4b7a-a5db-859c2596bf42">SALARIUS PHARMACEUTICALS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjA0Njc2MThkMmExNDgxYTgwOGVhNjIzMDNmOTM4ZTkvdGFibGVyYW5nZTo2MDQ2NzYxOGQyYTE0ODFhODA4ZWE2MjMwM2Y5MzhlOV8wLTEtMS0xLTE_2079826a-fdf5-451b-b1de-a945231c925c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6NjA0Njc2MThkMmExNDgxYTgwOGVhNjIzMDNmOTM4ZTkvdGFibGVyYW5nZTo2MDQ2NzYxOGQyYTE0ODFhODA4ZWE2MjMwM2Y5MzhlOV8wLTMtMS0xLTE_f4632101-a23f-474d-95d4-d8d2ce0f805b">46-5087339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xODA_462f63ac-923d-4506-a4c9-9d90b608cda0">2450 Holcombe Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTI3_d8430af1-f29a-404a-8339-b5dc2b5d781a">Suite X</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTQ_b6af9f43-5592-4136-9359-47c12e6a1a25">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTg_58989376-290b-49dd-bed0-f34a07da851d">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8yMDE_62fdae51-3254-4216-a9a2-5810ac9fac8c">77021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8yNTg_d173e16f-8547-49eb-975a-9f03ccc24a41">832</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xOTI4_b0c0c426-b6fa-46c0-aad5-e2913d1a621e">834-6992</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MzQwMjZkZmExMTA3NGM3MWFiZGU0ZjFlYTY2NmQwNzQvdGFibGVyYW5nZTozNDAyNmRmYTExMDc0YzcxYWJkZTRmMWVhNjY2ZDA3NF8xLTAtMS0xLTE_78e4750a-0fa3-413b-9147-56e9638ed991">Common Stock, $ 0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MzQwMjZkZmExMTA3NGM3MWFiZGU0ZjFlYTY2NmQwNzQvdGFibGVyYW5nZTozNDAyNmRmYTExMDc0YzcxYWJkZTRmMWVhNjY2ZDA3NF8xLTItMS0xLTE_fc1b6fef-41eb-4e90-a116-b9bdb0b539a0">SLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MzQwMjZkZmExMTA3NGM3MWFiZGU0ZjFlYTY2NmQwNzQvdGFibGVyYW5nZTozNDAyNmRmYTExMDc0YzcxYWJkZTRmMWVhNjY2ZDA3NF8xLTQtMS0xLTE_019879f4-4441-48a5-be81-7bb42b9bfeb5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV84MTI_c9a5aa9d-2ed3-4069-b173-62e317ca5b8c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xMTMy_33965841-ee95-4d57-a701-34589ce750d0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MGVmZTVlMzk4YzI2NDE2MDljNjAzMTJiMTQ4MDM0YWEvdGFibGVyYW5nZTowZWZlNWUzOThjMjY0MTYwOWM2MDMxMmIxNDgwMzRhYV8wLTQtMS0xLTE_b9c77f3f-7e01-4171-a8e1-75230d8d245a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MGVmZTVlMzk4YzI2NDE2MDljNjAzMTJiMTQ4MDM0YWEvdGFibGVyYW5nZTowZWZlNWUzOThjMjY0MTYwOWM2MDMxMmIxNDgwMzRhYV8wLTctMS0xLTE_3273534b-2598-466d-aa6f-5ec874e0d8d0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGFibGU6MGVmZTVlMzk4YzI2NDE2MDljNjAzMTJiMTQ4MDM0YWEvdGFibGVyYW5nZTowZWZlNWUzOThjMjY0MTYwOWM2MDMxMmIxNDgwMzRhYV8wLTktMS0xLTE_c2db8700-9630-4618-876e-a71c7d79d048">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8xODU2_90a1e407-7577-4066-82c4-c0e81bccea88">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ieb85bd86da7243f5aa57922b11eff1e9_I20211101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xL2ZyYWc6NGM2OTIyZWIyMTU1NGZmMTk2NGJjZDViNGM4NmRjNDUvdGV4dHJlZ2lvbjo0YzY5MjJlYjIxNTU0ZmYxOTY0YmNkNWI0Yzg2ZGM0NV8yMTk5MDIzMjU3NTE2_dd16b589-65cd-4b8f-a6ce-e22d350c1ce4"
      unitRef="shares">45206135</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNC0xLTEtMS0x_e99ccaf8-7dbf-49ff-8f04-7f0373e036ea"
      unitRef="usd">31903727</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNC0zLTEtMS0x_3066ca21-7f91-4e4d-be0f-b0970b1bacbe"
      unitRef="usd">11118614</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNS0xLTEtMS0x_502b14f0-2a0d-4f48-9d97-154ccb211544"
      unitRef="usd">2086157</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNS0zLTEtMS0x_2698fa6d-6cd7-40df-9c48-bf61281979c1"
      unitRef="usd">3855996</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNy0xLTEtMS0x_75f750ef-bf31-4745-bc41-67572114ea1c"
      unitRef="usd">1194255</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfNy0zLTEtMS0x_3c2041ab-42e3-459b-b4f8-af0888ab42b2"
      unitRef="usd">822050</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOC0xLTEtMS0x_67a3f123-ddfa-4a3e-bec2-2b6b90740e9f"
      unitRef="usd">35184139</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOC0zLTEtMS0x_abf84753-7f62-4391-95c2-daf7ed5db39f"
      unitRef="usd">15796660</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOS0xLTEtMS0x_d11a6958-209d-4f99-9727-2321c03d5350"
      unitRef="usd">11570</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfOS0zLTEtMS0x_091522da-4c6c-4ebe-afe5-23509c88b9ce"
      unitRef="usd">22639</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTAtMS0xLTEtMQ_c78b909f-ec2a-441e-9ce2-10e693f55370"
      unitRef="usd">201389</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTAtMy0xLTEtMQ_d5eafff6-0a10-4a1f-9f81-85e86f4c232c"
      unitRef="usd">247113</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTEtMS0xLTEtMQ_0bcf99fb-9c5c-4424-90dd-3b9e150cdf0c"
      unitRef="usd">8865909</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTEtMy0xLTEtMQ_f23511b2-a2e2-4e20-9fda-f94aef30dec0"
      unitRef="usd">8865909</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTItMS0xLTEtMQ_5eebdb60-3a69-427c-806e-a74c608e7f3f"
      unitRef="usd">44263007</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTItMy0xLTEtMQ_c79540e3-0bf1-48fc-97a1-73976c48ff79"
      unitRef="usd">24932321</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTUtMS0xLTEtMQ_8269b532-4fac-45cf-88cc-c2b980ee74ad"
      unitRef="usd">1234922</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTUtMy0xLTEtMQ_a189649a-d710-415c-a9ef-64b46048c051"
      unitRef="usd">1853756</us-gaap:AccountsPayableCurrent>
    <flks:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTYtMS0xLTEtMQ_b91b854e-5f91-43e6-aab4-ae852608f0fa"
      unitRef="usd">323364</flks:AccruedExpensesAndOtherCurrentLiabilities>
    <flks:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTYtMy0xLTEtMQ_c6e5fc8e-5d56-4fc3-b71b-8495b08cdc92"
      unitRef="usd">383138</flks:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:NotesPayableCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTktMS0xLTEtMQ_c43f24be-05e6-469f-8109-36ad889e59c0"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMTktMy0xLTEtMQ_cfd559a3-1f97-47e9-a282-539496f0ae53"
      unitRef="usd">477028</us-gaap:NotesPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjAtMS0xLTEtMQ_4799be75-5c8b-4136-a18f-d93761c1ef53"
      unitRef="usd">54006</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjAtMy0xLTEtMQ_6b4b87cd-9f0d-4171-8f92-72f8b75c15fb"
      unitRef="usd">59211</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjEtMS0xLTEtMQ_8c93edae-d084-4868-b8ae-a8eecb87c97f"
      unitRef="usd">1612292</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjEtMy0xLTEtMQ_0ad7e3d2-bc31-4eaf-a77e-7627517b927a"
      unitRef="usd">2773133</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjUtMS0xLTEtMQ_2ba92ac0-29ff-46af-b621-e10a28d37196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjUtMy0xLTEtMQ_9762ba0d-0348-43eb-bb98-34d04f0c9891"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzIx_2fd5d993-af4a-4948-ac55-a29ad6ad6553"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzIx_ecae1d18-bda6-4a0b-8e19-5564047a23b9"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzM1_23b6b0fb-7a39-48d3-9fe8-883af56900c2"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzM1_c6ad3893-4551-43cd-82be-ccc3dbe2b6c5"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_000e87e6-ecee-4230-84e4-69e5c1a30226"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_02432825-ac4d-4b41-87c6-e53899cf6e8a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_78b859bc-cc06-45a9-b4ee-3732e132f517"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOmU2MTcyYzNiMTE4ZjQxNzVhNjc0M2M5YTBmMGI3NDNlXzU3_e00e4d6b-8ca5-4a79-8eb3-75225a316fb0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMS0xLTEtMQ_58617722-566f-470c-ba63-fe728feffe4d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjgtMy0xLTEtMQ_b1156c20-f8c9-4b7c-aef6-066786e46929"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzE4_2720fa02-99a6-49d6-a6a3-363f94d281f2"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzE4_97b55338-a671-44e3-b335-bcae772b3917"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzMy_282bd815-735a-490a-a9b7-26b7c9411f0b"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzMy_519baf24-9c0d-4887-bb64-9e5e9427aabd"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzU0_7cdbc24d-c838-4671-8ddf-359ebaee68c0"
      unitRef="shares">45172535</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzYx_0bfefd06-532e-4238-a278-3160d6075940"
      unitRef="shares">23810541</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzk2_f178f781-ea02-45c8-b64e-ec0a9c092889"
      unitRef="shares">45172535</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMC0xLTEtMS90ZXh0cmVnaW9uOjBmYjQ0N2EwY2FjMDQwZmNhNGQyYjA5NDQ0MWZlYWJmXzEwMw_0892232d-d145-4db8-94e7-ff178008ecd9"
      unitRef="shares">23808546</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMS0xLTEtMQ_6251525d-78a7-4d08-9825-8bc3a2953318"
      unitRef="usd">4517</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMjktMy0xLTEtMQ_f797052f-cb4a-4445-975c-1d26abc9d280"
      unitRef="usd">2381</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzAtMS0xLTEtMQ_d40bc5ea-7d95-4848-9fa3-aab929cca333"
      unitRef="usd">70738517</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzAtMy0xLTEtMQ_76805f9d-91c8-4d86-866e-6a5951b17a9a"
      unitRef="usd">41585761</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzItMS0xLTEtMQ_fb7a2e2a-6e99-46e0-816c-581bf89c1a1b"
      unitRef="usd">-28092319</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzItMy0xLTEtMQ_dbac701e-8a0f-4bee-9193-9482cc66b64b"
      unitRef="usd">-19428954</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzMtMS0xLTEtMQ_639d7f63-77e6-4f01-8c26-2a5aac35dcde"
      unitRef="usd">42650715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzMtMy0xLTEtMQ_db0ef43a-e33e-4361-a15d-9c9683c26c8b"
      unitRef="usd">22159188</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzQtMS0xLTEtMQ_e7b1a8f0-53e4-48d5-85cd-8d38819f8e81"
      unitRef="usd">44263007</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8xOS9mcmFnOjE1NDlmNmM1MThlZjQ1OTk4MzYxM2MzOWNmZWFjYTgwL3RhYmxlOjVjZmQxOTVmYjk5YzQ4Yjg4NTU0OWUxMmUyODNkMzM3L3RhYmxlcmFuZ2U6NWNmZDE5NWZiOTljNDhiODg1NTQ5ZTEyZTI4M2QzMzdfMzQtMy0xLTEtMQ_0ce77dd9-a565-4dba-adbd-c1a93f1abf04"
      unitRef="usd">24932321</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0xLTEtMS0x_fa8f1209-f73e-45ac-82a6-2e022871b54a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy0zLTEtMS0x_f4fd9689-d1e7-4d5e-bdc9-3ea00d023156"
      unitRef="usd">1378239</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy01LTEtMS0x_d53fefeb-43e2-4b0f-9412-c376f08f5cad"
      unitRef="usd">1840216</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMy03LTEtMS0x_b3832c5b-d720-40ff-9944-91f78d89548e"
      unitRef="usd">3754379</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS0xLTEtMS0x_30ea4270-c93e-4ef1-8eb9-04305ae7723b"
      unitRef="usd">2015930</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS0zLTEtMS0x_9299adb6-ad5d-4b9b-9b2d-84630370b65e"
      unitRef="usd">1803682</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS01LTEtMS0x_47b00c7f-1f4b-4bc2-897e-793dd2e6742a"
      unitRef="usd">5852887</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNS03LTEtMS0x_25c16507-e50e-4d91-bf55-5b46a017f7cc"
      unitRef="usd">4890375</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi0xLTEtMS0x_78301076-17d3-4da0-b0c4-e7bfc3188fa4"
      unitRef="usd">1730730</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi0zLTEtMS0x_8949f42a-051b-4668-957f-1ee2fbd877f9"
      unitRef="usd">1333062</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi01LTEtMS0x_535ce011-46a9-4485-aa08-52f95bb2b1ee"
      unitRef="usd">4655404</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNi03LTEtMS0x_9091e74a-a1fa-4a13-af3c-02ba395f4770"
      unitRef="usd">4893021</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy0xLTEtMS0x_badd8366-a770-46de-82c2-d5e57dc288d8"
      unitRef="usd">3746660</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy0zLTEtMS0x_2408af8b-53ef-463a-bf4f-2b63e0864940"
      unitRef="usd">3136744</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy01LTEtMS0x_4694a1e7-f450-4f69-b3fb-b9594f0a4cba"
      unitRef="usd">10508291</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfNy03LTEtMS0x_e6def2f2-d229-436a-a4c4-979f6dc8306b"
      unitRef="usd">9783396</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC0xLTEtMS0x_cf3d42e7-82c2-4f06-be8c-e98b68c3d894"
      unitRef="usd">-3746660</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC0zLTEtMS0x_610497fa-233b-4335-b723-2bf9fa23d334"
      unitRef="usd">-1758505</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC01LTEtMS0x_519bbcb8-b32c-4952-a257-869a0594256a"
      unitRef="usd">-8668075</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOC03LTEtMS0x_4bebdf7e-c689-45e2-9d5e-e5ead9e69667"
      unitRef="usd">-6029017</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS0xLTEtMS0x_d9a00ff3-f61e-4592-bf98-6a6131b88f27"
      unitRef="usd">-9073</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS0zLTEtMS0x_24f914a0-4061-49eb-b24a-f97d5b699446"
      unitRef="usd">-45103</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS01LTEtMS0x_c32a9839-1d7c-470b-a979-50590ee085b8"
      unitRef="usd">-5205</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfOS03LTEtMS0x_b45f8446-a4c9-4e59-85d1-c0f18cbe73c7"
      unitRef="usd">-265538</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtMS0xLTEtMQ_7447cada-d19c-4041-b72d-23fcf213ccfa"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtMy0xLTEtMQ_bdc0f3c1-46da-4ca8-afd4-3bd9437411f5"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtNS0xLTEtMQ_84f67498-6b5e-49f1-83bd-f0e3c2a3952c"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTAtNy0xLTEtMQ_3599b3e1-39ea-4cca-afeb-9a10005d267b"
      unitRef="usd">179027</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtMS0xLTEtMQ_358ee2e7-6b81-4175-bccf-87c38cedcef0"
      unitRef="usd">487</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtMy0xLTEtMQ_2bed848e-12e1-49eb-9ae5-931a4b5aab9c"
      unitRef="usd">-3230</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtNS0xLTEtMQ_7114096a-f9d0-4ee4-a481-dd75647adbbb"
      unitRef="usd">-495</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTEtNy0xLTEtMQ_4405cc4e-96eb-470a-8e2f-07819801e907"
      unitRef="usd">-254</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItMS0xLTEtMQ_ddc39591-2ad6-4738-a3a6-1e50c1f15431"
      unitRef="usd">-3737100</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItMy0xLTEtMQ_9f817d8d-f911-4a6b-9c49-4be27b0a186f"
      unitRef="usd">-1716632</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItNS0xLTEtMQ_50d9d937-02ce-4a88-8332-418743692638"
      unitRef="usd">-8663365</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTItNy0xLTEtMQ_6c1c2868-3a63-4996-ad46-332b5463eac0"
      unitRef="usd">-5584706</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:NetIncomeLoss
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtMS0xLTEtMQ_b07246b8-8e9f-48e0-80af-8a1776e74341"
      unitRef="usd">-3737100</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtMy0xLTEtMQ_277c38bf-3b6b-4104-9c92-dde951b5113a"
      unitRef="usd">-1716632</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtNS0xLTEtMQ_8c10e984-ac89-4beb-b26c-79fca0d4fcc4"
      unitRef="usd">-8663365</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTMtNy0xLTEtMQ_0cc84983-4565-40bf-a298-631c35e66838"
      unitRef="usd">-5584706</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMS0xLTEtMQ_09c0bb82-e3b4-4423-808a-d38c5bc34156"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMS0xLTEtMQ_4e5254fb-79c7-45d8-b052-acd646e912c7"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMy0xLTEtMQ_d43e3f27-59e2-4b6c-8c2c-1be3ea99e610"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtMy0xLTEtMQ_fc1fec73-0f61-46e5-ba41-fc35587e44e9"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNS0xLTEtMQ_47a14ada-f84b-4539-b981-2e0511728b17"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNS0xLTEtMQ_ac182478-c61b-46be-bf10-3a7b3d7642ab"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNy0xLTEtMQ_4c2ab2b7-bdba-4a9b-b794-0890f016ce6e"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTUtNy0xLTEtMQ_9fadea1c-c0e3-4871-8b5f-cdceedc583c0"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMS0xLTEtMQ_7254fdcd-4b82-47f3-b78b-c6bac9e8a979"
      unitRef="shares">44804741</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMS0xLTEtMQ_eb38ae60-d079-4d48-81d4-b3356647e172"
      unitRef="shares">44804741</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMy0xLTEtMQ_9e62452d-72a3-4725-9d13-28524cfd6010"
      unitRef="shares">17968664</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtMy0xLTEtMQ_d203ea4b-88f2-4193-96f1-2b63c07179a2"
      unitRef="shares">17968664</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNS0xLTEtMQ_33675986-0f75-48df-aef8-0ab8e6e98abc"
      unitRef="shares">40064119</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNS0xLTEtMQ_f25f91ec-2bfa-4e6c-8928-492c0476c1df"
      unitRef="shares">40064119</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNy0xLTEtMQ_8377a8db-edcb-445a-9eb3-ba957d77af6b"
      unitRef="shares">13833410</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yMi9mcmFnOmNkZDdiZDc3OWEzMzQ4NzM5OGIwMjBmNjIyNjllMGY4L3RhYmxlOmZkZjVmNzFlZGFhOTQyZTZhYTJhOTM5NmQzOWQ0MzY3L3RhYmxlcmFuZ2U6ZmRmNWY3MWVkYWE5NDJlNmFhMmE5Mzk2ZDM5ZDQzNjdfMTYtNy0xLTEtMQ_fd312662-cb3a-4095-80ad-9c06c39841e2"
      unitRef="shares">13833410</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMy0xLTEtMS0x_752a6126-2f98-4728-b3f7-6e5db243e849"
      unitRef="usd">-8663365</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMy0zLTEtMS0x_88cb9062-7aec-4b6f-bc69-71317bcf8b1f"
      unitRef="usd">-5584706</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNS0xLTEtMS0x_bb1b3636-5c24-4cdc-922f-3dff1451645c"
      unitRef="usd">14387</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNS0zLTEtMS0x_443a5226-e0b9-4ea4-86ca-1e479578afe3"
      unitRef="usd">12699</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNi0xLTEtMS0x_d7fa0ea5-9385-4279-85c8-0dc2681c74ba"
      unitRef="usd">413153</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfNi0zLTEtMS0x_11084c7a-3df4-438e-b683-3906111b2ad5"
      unitRef="usd">149660</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOC0xLTEtMS0x_083efb46-2d7c-431c-9624-8534d3d81adf"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOC0zLTEtMS0x_1f53c67e-5a06-43f4-8def-54e3ceac932e"
      unitRef="usd">25000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOS0xLTEtMS0x_a8eb16a9-9eb7-47d7-9ff7-119e00cce94f"
      unitRef="usd">-5205</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfOS0zLTEtMS0x_0a01995b-7d9a-4fcf-b7af-3b2fd290d22f"
      unitRef="usd">-265538</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTEtMS0xLTEtMQ_be57c212-dae8-41a6-b7ec-3e91ff456d37"
      unitRef="usd">-1769839</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTEtMy0xLTEtMQ_34004fe2-1895-4238-8d20-6a5e3fb99fee"
      unitRef="usd">3212678</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTItMS0xLTEtMQ_1dae9e60-d238-44be-a4e7-8a279e5c3e3f"
      unitRef="usd">329799</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTItMy0xLTEtMQ_eae0ec15-8a0b-4f99-b604-179d6e97c815"
      unitRef="usd">-799210</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTQtMS0xLTEtMQ_61acfc11-ae61-4af6-a707-9950bdba37f0"
      unitRef="usd">-618830</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTQtMy0xLTEtMQ_1ba58c1e-d2da-4029-a7e8-60ab8c0ac4e4"
      unitRef="usd">-607904</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTUtMS0xLTEtMQ_2d6dfd96-d4b8-4166-9b72-1dcd000ae708"
      unitRef="usd">-59774</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTUtMy0xLTEtMQ_5ce5a233-2683-4f72-b902-3e82d0b9a2ba"
      unitRef="usd">288079</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTYtMS0xLTEtMQ_9c23f398-b938-426d-bdb8-0e2c30499abb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTYtMy0xLTEtMQ_d56e5517-bac7-4f2a-b7d7-26cbf02f0ec9"
      unitRef="usd">-541701</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTctMS0xLTEtMQ_f709d8bb-4932-4176-abd9-e2c9acf0e4ef"
      unitRef="usd">-7479594</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMTctMy0xLTEtMQ_4808eaee-4aa5-41b8-acf5-8a0d4dcb9b2a"
      unitRef="usd">-8937879</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjEtMS0xLTEtMQ_5f19b8f4-a8a6-4696-b9cc-2fec5cc15e31"
      unitRef="usd">27256384</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjEtMy0xLTEtMQ_1c1cd086-666f-4387-97af-e75b0015dd17"
      unitRef="usd">14810945</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjItMS0xLTEtMQ_f225f7e3-191a-4235-a2cb-3fc3c5462d47"
      unitRef="usd">1485351</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjItMy0xLTEtMQ_d8abd9e9-0418-41e1-b484-7cef7296a2fc"
      unitRef="usd">636214</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjMtMS0xLTEtMQ_d1b0ea19-6a0b-4ba7-a19b-946ae47b7481"
      unitRef="usd">477028</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjMtMy0xLTEtMQ_4ace17aa-f0d9-483f-b8f0-09670304fd61"
      unitRef="usd">690367</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjUtMS0xLTEtMQ_b059a7b4-ded0-4aec-9bf8-7a38f3c5d03c"
      unitRef="usd">28264707</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjUtMy0xLTEtMQ_ed600fd6-aa79-488f-a142-293f8137c4ec"
      unitRef="usd">14756792</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjctMS0xLTEtMQ_11aad131-acd4-42ac-9297-daa9ba6cc0d4"
      unitRef="usd">20785113</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjctMy0xLTEtMQ_ad8d9561-c71b-4c2b-9a71-525df5d6197a"
      unitRef="usd">5818913</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjgtMS0xLTEtMQ_513acd17-1884-4edf-b4e2-ff349297107f"
      unitRef="usd">11118614</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjgtMy0xLTEtMQ_080a7ab6-8ccf-4a32-ac22-f380c311cd7b"
      unitRef="usd">3738900</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjktMS0xLTEtMQ_ef0f4482-f579-454d-a863-82e13cbcb31e"
      unitRef="usd">31903727</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMjktMy0xLTEtMQ_bc99b819-2652-41f0-88d6-8023d2072679"
      unitRef="usd">9557813</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzItMS0xLTEtMQ_ee077215-c427-43a5-baad-a67afdfec2f4"
      unitRef="usd">1468</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzItMy0xLTEtMQ_9fe0a7c2-148f-45ce-a826-0655a38a2cb5"
      unitRef="usd">6615</us-gaap:InterestPaidNet>
    <flks:StockIssuanceCostsAccruedAndAmortized
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzQtMS0xLTEtMQ_a72330b3-e8d8-47ea-af15-6943e770975a"
      unitRef="usd">0</flks:StockIssuanceCostsAccruedAndAmortized>
    <flks:StockIssuanceCostsAccruedAndAmortized
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzQtMy0xLTEtMQ_c15fcb44-b8dc-4d44-920d-0db72c5a7536"
      unitRef="usd">12001</flks:StockIssuanceCostsAccruedAndAmortized>
    <flks:PrepaidExpenseFinancedByNotePayable
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzUtMS0xLTEtMTAzNTg_8dab33ef-9ea1-49de-98f7-cc665d99af1d"
      unitRef="usd"
      xsi:nil="true"/>
    <flks:PrepaidExpenseFinancedByNotePayable
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yNS9mcmFnOjEzYTVmNTZiMmQyYTRmMTU5YzA5OTE4MTA3ZjcxM2VkL3RhYmxlOjFmOThiM2UwYWE2YjQ5YTVhNzc3NDRlNzExNzUyMjRmL3RhYmxlcmFuZ2U6MWY5OGIzZTBhYTZiNDlhNWE3Nzc0NGU3MTE3NTIyNGZfMzUtMy0xLTEtMTAzNTg_9b816508-a762-4a7c-b4be-1bdd1a3616b2"
      unitRef="usd">949131</flks:PrepaidExpenseFinancedByNotePayable>
    <us-gaap:SharesOutstanding
      contextRef="i8d20dc51e5fe4ea99139098eb7f83411_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0xLTEtMS0x_45862565-145c-45cf-9989-ff410f2f9b7e"
      unitRef="shares">4511174</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8d20dc51e5fe4ea99139098eb7f83411_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0zLTEtMS0x_86dbed16-4d72-42a8-a832-2dde8537ef81"
      unitRef="usd">451</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i91ac971072f1418a89a4376f024276cd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy01LTEtMS0x_b6b5e172-c0e6-4e94-86f8-1982bd279de8"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i91ac971072f1418a89a4376f024276cd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy03LTEtMS0x_77f909da-38a7-4d3f-8dce-01c8af682f35"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0024786ef67540f7ac2c0db72574744a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy05LTEtMS0x_9f45ad52-3edd-4ced-9c71-a9941d2eb265"
      unitRef="usd">22657103</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d2ac1c7ee44444cb491532bc41f23f5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0xMS0xLTEtMQ_4372b99d-baaa-4343-9524-ab26dbf0bdba"
      unitRef="usd">-12076700</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMy0xMy0xLTEtMQ_1a1f265e-0b6e-4745-84ac-bac62949b4e2"
      unitRef="usd">10580854</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC0xLTEtMS0x_b7480d57-6c80-4dcb-b399-fd8509340a88"
      unitRef="shares">8353480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC0zLTEtMS0x_0438ebbc-2f34-4a03-b164-278c25db20fc"
      unitRef="usd">835</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC01LTEtMS0x_4c6afe06-db06-49d0-b0f6-7d7a367ebd0d"
      unitRef="shares">1246519</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC03LTEtMS0x_208aee17-5db6-4966-a96a-86e059842744"
      unitRef="usd">125</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC05LTEtMS0x_a9393e5b-aac6-4520-af01-49c5ba203c0d"
      unitRef="usd">9466206</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNC0xMy0xLTEtMQ_2a316a09-d224-4d43-af3c-988cdc833380"
      unitRef="usd">9467166</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS0xLTEtMS0x_91455171-807d-466a-8269-bac6cf217fb6"
      unitRef="shares">777825</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS0zLTEtMS0x_a70b7e87-9baa-4f49-9d96-44291e38b5b4"
      unitRef="usd">78</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS01LTEtMS0x_d345ffc1-8ab8-4c3d-a06f-c6a385baeb9c"
      unitRef="shares">-777825</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i18254c89c4564a21a71a20589bc53179_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS03LTEtMS0x_fab3a20d-8f05-4bb3-b03a-922649935c5c"
      unitRef="usd">-78</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNS0xMy0xLTEtMQ_cbb144b2-32cd-4331-89cb-e5767283ee4c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia8d5368e253047c7b7edd6cf8bdb7919_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNi0xLTEtMS0x_e6876e9a-2f10-415c-ad22-5a626fb25209"
      unitRef="shares">3198</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNi05LTEtMS0x_b2fb1ecb-e0c3-4ca3-8947-2ade607e805c"
      unitRef="usd">38409</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNi0xMy0xLTEtMQ_5d17a589-c342-4d7e-a357-3bb7e0176c71"
      unitRef="usd">38409</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ieb03da10c8aa48f08dc0254a264659dd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNy0xMS0xLTEtMQ_08c0bdfc-17e8-4f1b-ab46-4a9440d5bf35"
      unitRef="usd">-2083816</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i501b5ccdf12d4f52ba251139220a2855_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfNy0xMy0xLTEtMQ_e97bf535-facc-46a1-ae58-14d0b3f2b7c0"
      unitRef="usd">-2083816</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifdadb645f0404a4d95746cc2ba5ff395_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0xLTEtMS0x_dd7731be-861f-4486-a24d-7463a0cb5bf4"
      unitRef="shares">13645677</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifdadb645f0404a4d95746cc2ba5ff395_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0zLTEtMS0x_6702704d-0568-4326-a1cd-e4f8525dc410"
      unitRef="usd">1364</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="id72958b2722c44979991d7838b0e41c5_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC01LTEtMS0x_242bfa5e-a2b1-44ea-a6b2-8f6eeb249a82"
      unitRef="shares">468694</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id72958b2722c44979991d7838b0e41c5_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC03LTEtMS0x_a2e30bea-8d00-44ba-a07e-722401ffdcf0"
      unitRef="usd">47</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i879f0c3963444b66916504729b1e3d17_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC05LTEtMS0x_04c421a9-3e96-43e8-9c72-85800835ffab"
      unitRef="usd">32161718</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf5af0205ac648a5a2afbfdf5f6e3274_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0xMS0xLTEtMQ_30f4978e-fb7c-478e-9476-089623b8da48"
      unitRef="usd">-14160516</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d5e105e076d46699489e811c97d2199_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOC0xMy0xLTEtMQ_4b2ad82b-230b-4c7c-b7e5-f4b20b155183"
      unitRef="usd">18002613</us-gaap:StockholdersEquity>
    <flks:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS0xLTEtMS0x_2a53ddf9-5346-4747-8a43-bb652a11e921"
      unitRef="shares">503230</flks:StockIssuedDuringPeriodSharesWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS0zLTEtMS0x_c583864a-a4f6-4ec6-8718-bfe89f0ed8e6"
      unitRef="usd">50</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if6ef3be74ccc4ed780f60aaea7b84cd6_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS05LTEtMS0x_1f34489a-3dcf-4048-b371-a16c750faea9"
      unitRef="usd">578664</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfOS0xMy0xLTEtMQ_5ab1a259-3121-4c57-a6ef-6168a0e51d7c"
      unitRef="usd">578714</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtMS0xLTEtMQ_a4ec229b-9173-4fd3-a6e1-1f5273c6800e"
      unitRef="shares">468694</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtMy0xLTEtMQ_519dd97f-7159-4ae3-ad9e-440affa64b9d"
      unitRef="usd">47</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="id883671275ee47f29805bc8d421e6c30_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtNS0xLTEtMQ_00b6aa82-f06d-4b23-9977-16ebac93dde1"
      unitRef="shares">-468694</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="id883671275ee47f29805bc8d421e6c30_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtNy0xLTEtMQ_38a03942-b9a2-45c5-b224-05dbc635f03c"
      unitRef="usd">-47</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTAtMTMtMS0xLTE_954d543a-02d9-4ea7-a1ce-87847e2454f9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i003d9dea81f546f5a31ad68118c0ea93_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTEtMS0xLTEtMQ_3b1e0028-5889-41db-954e-d19f3d8916aa"
      unitRef="shares">1843</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if6ef3be74ccc4ed780f60aaea7b84cd6_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTEtOS0xLTEtMQ_d51029ba-aedc-4a29-a468-c19dba3d6523"
      unitRef="usd">32905</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTEtMTMtMS0xLTE_50a6f730-f5ea-4170-a891-cb6dd1b06982"
      unitRef="usd">32905</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i89b959c132384760adfcad6637c903e0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItMS0xLTEtMQ_da7555dd-6055-4fa1-a6ac-c1df5e32bec4"
      unitRef="shares">18564</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i89b959c132384760adfcad6637c903e0_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItMy0xLTEtMQ_f336641b-c6ed-48b8-a431-94dd8f076c72"
      unitRef="usd">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i77cb73c0bc694074878b0432e6f254cf_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItOS0xLTEtMQ_30a02517-981b-4e3a-a35c-a190b29cf938"
      unitRef="usd">24998</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibf6b4d878dea4f218fc2f35d89ffb0c3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTItMTMtMS0xLTE_a71e00a4-8849-4e2b-996b-edf4a9b47f96"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ia4078d2163404318a25c07dba8baec76_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTMtMTEtMS0xLTE_b1d715b0-ddeb-4585-b7f1-cce9785b3bfa"
      unitRef="usd">-1784258</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i295f6fb2cd9b4a8599e90724c90524b7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTMtMTMtMS0xLTE_709815f7-fa57-42cb-859d-a38d631cfc58"
      unitRef="usd">-1784258</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i38e80edb414d4a79ae54153572f0e6eb_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMS0xLTEtMQ_085f0706-2665-4d18-97b2-b949f03ab89b"
      unitRef="shares">14638008</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i38e80edb414d4a79ae54153572f0e6eb_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMy0xLTEtMQ_b248b767-09c4-42c8-8856-8a8ddd7b2e53"
      unitRef="usd">1463</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i56344979fde94e63aa913f4a5e8723d0_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtNS0xLTEtMQ_2ab6813f-e950-430a-8966-057c779c5dd1"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i56344979fde94e63aa913f4a5e8723d0_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtNy0xLTEtMQ_26169be0-6086-43bd-aa54-732a0b31eb66"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a378992dd7b49d9a157ab15eab9f3ed_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtOS0xLTEtMQ_292669be-05c3-41e3-a6bc-9f5f2cb85a7e"
      unitRef="usd">32798285</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i494e149e02d3480995871fe3ca7e8497_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMTEtMS0xLTE_46f9c00a-112f-40c7-8eac-416a0c197b5a"
      unitRef="usd">-15944774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i008da512d397437a9cba8e4395f8379c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTQtMTMtMS0xLTE_1eafae7c-567c-4a92-947a-6598104f5d72"
      unitRef="usd">16854974</us-gaap:StockholdersEquity>
    <flks:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtMS0xLTEtMTAzNjI_ca3b5ddc-7af4-479b-b0f3-1ad5f493e649"
      unitRef="shares">50000</flks:StockIssuedDuringPeriodSharesWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtMy0xLTEtMTAzNjI_f614d092-2e82-4790-bad1-c3ab1dca61a7"
      unitRef="usd">5</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtOS0xLTEtMTAzNjI_56829544-508a-4de5-b75f-769d3234266c"
      unitRef="usd">57495</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTUtMTMtMS0xLTEwMzYy_96b203ee-9416-4350-bc66-1f4c44dba303"
      unitRef="usd">57500</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMS0xLTEtMTAzNjI_6ec77e9e-1d97-4772-abfe-289b20019e25"
      unitRef="shares">5130390</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMy0xLTEtMTAzNjI_9745d5a1-d0be-4ab5-83d7-d65b2ada4605"
      unitRef="usd">513</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtOS0xLTEtMTAzNjI_2997f7ee-ef7e-4bb9-828c-9194062c6343"
      unitRef="usd">5331265</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMTMtMS0xLTEwMzYy_2dda0bd3-cd83-4f6c-9b3c-ee54de2a840c"
      unitRef="usd">5331778</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie0ee8f8e7e244ab5b66399ac6663a4d4_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMS0xLTEtMTAzNjI_b48bd6ab-a58e-443b-b390-1651eaa155ca"
      unitRef="shares">514</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9e52d628b1ac43c3aca638cb2c80d569_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctOS0xLTEtMTAzNjI_e14a3939-256f-4271-a9ee-94b305db06da"
      unitRef="usd">78346</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMTMtMS0xLTEwMzYy_82d8fe60-312e-4ce8-8214-15aae187c83f"
      unitRef="usd">78346</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="iad60589c9a6a4dd7b40672b0faa48107_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMTEtMS0xLTEwMzYy_7191b8b4-8fc9-4570-8766-56b08069c1e6"
      unitRef="usd">-1716632</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMTMtMS0xLTEwMzYy_225a39d9-76f7-4cb6-8c02-91aae0d36496"
      unitRef="usd">-1716632</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i103946fb0b22442b9d8a5266ee347645_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMS0xLTEtMTAzNjI_255d53a3-bf54-4c22-8503-47f00193f2ee"
      unitRef="shares">19818912</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i103946fb0b22442b9d8a5266ee347645_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMy0xLTEtMTAzNjI_916401ce-3a4c-4537-83e9-967d37d2f761"
      unitRef="usd">1981</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i7b7745f01faa466f876bdd522070c58d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktNS0xLTEtMTAzNjQ_66816edd-068f-421a-ab2c-4955958d23c6"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7b7745f01faa466f876bdd522070c58d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktNy0xLTEtMTAzNjQ_ff1b5984-71c2-428d-a755-a9190ab5c18d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0db0f3b8635a4838b6ac72d40a6ecc06_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktOS0xLTEtMTAzNjI_4215054d-ebab-4ec1-917e-754dfb774549"
      unitRef="usd">38265391</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45f8c31eb4f14036be3bc5ad4af88834_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMTEtMS0xLTEwMzYy_0f5bdc91-900b-45a6-a208-2c92a8ad3caf"
      unitRef="usd">-17661406</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMTMtMS0xLTEwMzYy_c014285e-7384-428d-ab8c-55e5b196e2e3"
      unitRef="usd">20605966</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i11266e19063543088c03f4b86e4beca8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMS0xLTEtMQ_bde7fc2b-6205-4e64-9858-4f121d72c9f7"
      unitRef="shares">23808546</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i11266e19063543088c03f4b86e4beca8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMy0xLTEtMQ_c321b884-6216-4767-a606-667d9f2bd794"
      unitRef="usd">2381</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i177696ed3c044d74afa4d317d038fb4d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtNS0xLTEtMQ_84bfef17-89ca-4f5d-be4e-eb7d2ae02dad"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i177696ed3c044d74afa4d317d038fb4d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtNy0xLTEtMQ_ba4b11be-4c1a-4bfd-a8e1-8e75666fd37b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecdeccc9f1f44bff859e3f3fcc5cbdb0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtOS0xLTEtMQ_c750160c-4084-45b8-9edf-d764dcd9060e"
      unitRef="usd">41585761</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70f542a0e98d4604a00099497a1f1804_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMTEtMS0xLTE_2fbf2c63-465e-4424-b2cd-4c68c26e7ffa"
      unitRef="usd">-19428954</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTYtMTMtMS0xLTE_26fa1e42-21c7-40a4-a295-fdb52d110d8e"
      unitRef="usd">22159188</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMS0xLTEtMQ_509a8288-0497-427a-b34d-61383addf2e3"
      unitRef="shares">19627215</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMy0xLTEtMQ_4c1311b1-5600-430b-addb-07551a369562"
      unitRef="usd">1963</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4246855be8574284a65e3d4eba29df11_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctOS0xLTEtMQ_10cc8941-a4e1-4de1-a6f3-4e2d7352fb60"
      unitRef="usd">26848058</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTctMTMtMS0xLTE_db3aab85-e764-4e19-b33c-b94818c5d257"
      unitRef="usd">26850021</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <flks:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMS0xLTEtMQ_cf3a1f5b-c199-4c1c-9da9-e1e5be2f6ce9"
      unitRef="shares">1298567</flks:StockIssuedDuringPeriodSharesWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ib552ff1dbb674586b246269a7598461d_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMy0xLTEtMQ_89ca500e-e07a-4c43-9208-20b64966242f"
      unitRef="usd">129</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i4246855be8574284a65e3d4eba29df11_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtOS0xLTEtMQ_2a2bff5a-1851-473e-ba1e-e3b72586a00f"
      unitRef="usd">1485222</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <flks:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTgtMTMtMS0xLTE_298cca72-12d9-4356-a14e-3d3a0d27bb3b"
      unitRef="usd">1485351</flks:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4246855be8574284a65e3d4eba29df11_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktOS0xLTEtMQ_f6c7a30a-753d-4641-8a7b-1038b2547df1"
      unitRef="usd">135379</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMTktMTMtMS0xLTE_be6769f4-b71a-4698-8de1-4433be3a6cd7"
      unitRef="usd">135379</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i0b30b72e16c34ba3a2db567ae552cea6_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjAtMTEtMS0xLTE_78a271a6-21bf-4ce9-b233-8278ca54c056"
      unitRef="usd">-1851896</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i34255b6eeae14c00b5a8cd0c81776ef3_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjAtMTMtMS0xLTE_9d2b5966-cd21-4eab-812e-46ee27398fd8"
      unitRef="usd">-1851896</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i88143d34f36d418e965adf2e6fd1ec52_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMS0xLTEtMQ_cb44389e-12ca-48af-b473-bde452ef4224"
      unitRef="shares">44734328</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i88143d34f36d418e965adf2e6fd1ec52_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMy0xLTEtMQ_93a90ba0-975d-4edd-a88f-38e71ee27c41"
      unitRef="usd">4473</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i84baeb8b40334043b2e851612655fc30_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtNS0xLTEtMQ_7d975453-03f4-42c0-8a04-4d7df0e2c2b3"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i84baeb8b40334043b2e851612655fc30_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtNy0xLTEtMQ_752c0a15-2675-4093-8f8d-27e7cb837162"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58585740081444529b94b6645f75a15f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtOS0xLTEtMQ_2c2b8903-fff0-4cc5-8e33-bf1c459fa81a"
      unitRef="usd">70054420</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bdd980a35274061bc26ccaccf9623a7_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMTEtMS0xLTE_d8cf1429-c509-450e-a610-ff2f4d2468e9"
      unitRef="usd">-21280850</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic29d1e6d22804c40b7c53ce44db787ec_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjEtMTMtMS0xLTE_29c1d59f-f93f-40ee-8fa8-4f40063a022c"
      unitRef="usd">48778043</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7d02fc8d1b514c81839144c985474d09_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItMS0xLTEtMQ_5fee6dc6-d0fe-42b4-ac8b-18a27f57dc22"
      unitRef="shares">38278</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7d02fc8d1b514c81839144c985474d09_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItMy0xLTEtMQ_c37f226d-8ee6-4473-a747-9f3c2d78fbe9"
      unitRef="usd">4</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id8c23cfd88914796ae8bcfbb6182d920_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItOS0xLTEtMQ_43c6d7e8-abc0-407c-be53-8a14ffc3f396"
      unitRef="usd">147452</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibeb593881ffd4b39a7166b73ba48fad3_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjItMTMtMS0xLTE_6e8e14c6-e106-459d-90af-ccc8009bbbed"
      unitRef="usd">147456</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i70f8c9fa71354fb58629cf1202290260_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjMtMS0xLTEtMQ_8103df7d-2683-44c0-9bb9-9794b3ba3e91"
      unitRef="shares">6188</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ia256a575bccf481fa61288d8f7b235d1_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjQtMTEtMS0xLTE_99a7cfbd-ec48-4965-a8ac-c92b59b36c38"
      unitRef="usd">-3074369</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibeb593881ffd4b39a7166b73ba48fad3_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjQtMTMtMS0xLTE_2405d0fe-58b9-483e-a658-a78386d1bec0"
      unitRef="usd">-3074369</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib4486746847a436886263055e53f87f8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMS0xLTEtMQ_c52cdb40-3b18-4be7-b91e-ec4a7ddc2649"
      unitRef="shares">44778794</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib4486746847a436886263055e53f87f8_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMy0xLTEtMQ_20c09de8-318e-41ad-ad07-5efb257c3a81"
      unitRef="usd">4477</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i2408113d2df34fd08dad1aad2b45fc4d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtNS0xLTEtMQ_f9f549ce-f541-418a-b72d-9f1a059a5ceb"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2408113d2df34fd08dad1aad2b45fc4d_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtNy0xLTEtMQ_3346e605-64b3-43e0-be21-9dff79b43074"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf11851802384bfcb427ad4bdb517f9d_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtOS0xLTEtMQ_3a5c905e-5140-4325-bdfc-c4e3b002dd76"
      unitRef="usd">70201872</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80c8dcc9ab0b4b0ebdfe09ad48ecb9fb_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMTEtMS0xLTE_f5976e9b-07ac-4a66-af49-ddfeb60ab606"
      unitRef="usd">-24355219</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4adff28f56e841a08e131253d1872d50_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMjUtMTMtMS0xLTE_d2a127f6-4ca8-46d4-9976-1a0544e3cf55"
      unitRef="usd">45851130</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic64588aad3ec4f21aae0e0cd7fb960cf_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzEtOS0xLTEtMTAzNjY_93329f61-68af-4cac-abb6-20e5476fa63d"
      unitRef="usd">130322</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzEtMTMtMS0xLTEwMzY2_a0edc390-b18d-4474-9c8d-bf9b9a43f497"
      unitRef="usd">130322</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i88c667283927432092625abe5f346269_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItMS0xLTEtMTAzNjg_c9d75576-d092-47ac-8d59-2bd0f1026a67"
      unitRef="shares">393741</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i88c667283927432092625abe5f346269_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItMy0xLTEtMTAzNjg_4bac7ede-80db-4ab6-95a2-8d495cd3a65f"
      unitRef="usd">40</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic64588aad3ec4f21aae0e0cd7fb960cf_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItOS0xLTEtMTAzNjg_09e083ab-9c75-484d-b729-f35954830a37"
      unitRef="usd">406323</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzItMTMtMS0xLTEwMzY4_81b8269d-4c5c-4d94-a0ce-aba6c4307af3"
      unitRef="usd">406363</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ifc81e334348d4c79b3f31451ed65c6b1_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzMtMTEtMS0xLTEwMzY4_e794c6ef-731e-4fbc-9c03-98d9b6390687"
      unitRef="usd">-3737100</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzMtMTMtMS0xLTEwMzY4_a70d67da-2e54-4951-be85-91f431f11bbb"
      unitRef="usd">-3737100</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMS0xLTEtMTAzNjg_4ba8be54-6dd1-4a7a-8dd3-9e604b8babe5"
      unitRef="shares">45172535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMy0xLTEtMTAzNjg_4c880ea7-cfb4-4688-91a4-f7adc5ab3654"
      unitRef="usd">4517</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8d0a506d355e4b78bb7008211cbfe661_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtNS0xLTEtMTAzNjg_3e46cf43-6c15-48cd-a168-5eed1e561931"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8d0a506d355e4b78bb7008211cbfe661_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtNy0xLTEtMTAzNjg_53421554-54a6-4a94-9891-56d1ab1e8e79"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60f38b06e4284e2dad48030ae167ccec_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtOS0xLTEtMTAzNjg_e8479d90-4dc2-42db-a5d0-0ca6e7c86e23"
      unitRef="usd">70738517</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f8bf301820e43f0bbc64c6954a84ac1_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMTEtMS0xLTEwMzY4_58c8c443-d150-44ec-8f8d-d679779e3d2c"
      unitRef="usd">-28092319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8yOC9mcmFnOmJmOGQ2YzE3NWM1ODQwYmU4NDdjODJjMDhkMzBmZjk3L3RhYmxlOmMxOTQwYmZjZTY0ODQ5NWM4ZDA1ZThkZjY5NjJhODk4L3RhYmxlcmFuZ2U6YzE5NDBiZmNlNjQ4NDk1YzhkMDVlOGRmNjk2MmE4OThfMzQtMTMtMS0xLTEwMzY4_26d3b1c4-f7e1-4250-8628-49936412cbd2"
      unitRef="usd">42650715</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNC9mcmFnOmExMGY2YmFmMjdhOTQwNzdhOTM5ZjMyYzdmZDljMzliL3RleHRyZWdpb246YTEwZjZiYWYyN2E5NDA3N2E5MzlmMzJjN2ZkOWMzOWJfMTgzOQ_aa804e75-58ff-4ef3-b981-87bf390e9767">ORGANIZATION AND OPERATIONS&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Salarius Pharmaceuticals, Inc. (&#x201c;Salarius&#x201d; or the &#x201c;Company&#x201d;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, the Company is developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The field concerned with gene expression regulation is called &#x2018;epigenetics&#x2019;. As cancers are often diseases driven by gene dysregulation, epigenetics is an area of interest for cancer treatment. The Company's lead epigenetic based technology was licensed from the University of Utah Research Foundation in 2011. The Company is located in Houston, Texas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risks Related to Covid-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The COVID-19 pandemic is significantly affecting the United States, global economies, and businesses worldwide.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;While the potential magnitude and duration of the economic and social impact of the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may, in the future, reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. At this time we are experiencing minimal disruption to our clinical trials. However, our ongoing Phase 1/2 Ewing sarcoma clinical trial and Phase 1/2 AST clinical trial may encounter delays in enrolling new patients due to concerns or healthcare resource constraints because of the COVID-19 pandemic.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;In addition, although at this time we have experienced no disruptions to manufacturing capabilities, certain aspects of our supply chain may be disrupted as certain of our third party suppliers and manufacturers have paused their operations in response to the COVID-19 pandemic or have otherwise encountered delays in providing supplies and services. The COVID-19 pandemic could also have a material and negative impact on our liquidity, capital resources (including our ability to secure additional financing if and when needed), our business and operations, and our workforce, as well as those of the third parties with which we do business or upon which we rely. While the situation is fluid and we do not yet know the full extent of potential delays or impacts on us or on healthcare systems or the global economy in general, we have worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic. However, we may experience disruptions in the future that have and could further adversely impact our business operations as well as our preclinical studies and clinical trials.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDk_592f9fc8-0c3e-4419-b7c7-a37cd4494fb5">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2020 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 18, 2021. In the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September&#160;30, 2021 and the results of operations for the three and nine months ended September&#160;30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2020 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains several bank accounts including an interest-bearing account for funds received from Cancer Prevention and Research Institution of Texas ("CPRIT"). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.  There were no impairment charges related to long-lived assets for the three and nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment charge is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired. There was no impairment of goodwill during the three and nine months ended September&#160;30, 2021 or September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments and Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s preclinical and clinical trials are performed by third party contract research organizations (CROs) and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations (CMOs). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#x2019;s research and development expenses in future periods. To date the Company has had no significant adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grants Receivable and Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Salarius&#x2019; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option valuation model to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) unvested restricted stock, (iv) convertible preferred stock and (v) rights entitling holders to receive warrants to purchase the Company's common shares, which have been excluded from the computation of diluted loss per share, was 9,531,198 and 10,075,278 shares as of September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of September&#160;30, 2021 and December&#160;31, 2020, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Application of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDg_23496ed9-fab1-4248-acec-c93b2348f045">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTg_f2e5797a-bcd8-429f-ba5a-c679beb3a5b3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MjM_fb2b8f4b-83d3-43f3-bae3-fa2f57a5f981">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDI_d97981bf-2370-4b4a-9edb-2507fd28420e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. &lt;/span&gt;&lt;/div&gt;The Company maintains several bank accounts including an interest-bearing account for funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDM_cf771947-3c8e-4077-9736-5a2e0210644d">Impairment of Long-Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_8abc45e5-a14f-4137-8966-ba1e89795191"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_b0dc9509-c374-46da-8253-9d660693d5fa"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_dddcb87b-9fbd-4e39-a647-56fd4311b778"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMzEyNg_fa035990-d4be-49c6-88cd-673e820e15f4"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTA_89881b0c-4484-42ed-8c33-d40ef0669558">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. &lt;/span&gt;&lt;/div&gt;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment charge is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_1f4fc628-b398-49fe-8cb9-a9db9d580933"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_3a9ea0c7-c750-4df3-af0b-73388f13494c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic8bd7bce4c2e484eb722824b89354d16_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_3ba37ba0-1a2d-40cb-90fe-1bcedf6f048e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i928284c249a945d7b73742e4cc3089e5_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfNDA3Nw_91bf3612-eafe-4152-a21f-adef3b77889a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTk_341edcf2-6c1a-432a-a62b-bdf24d673a26">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments and Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDQ_13ca785c-b5ac-4c36-85f3-8100dec53c31">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust &lt;/span&gt;&lt;/div&gt;the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDU_7a990f07-77aa-4921-8e0b-da3bd5044808">Grants Receivable and Revenue Recognition Salarius&#x2019; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTU_d7bc9224-2d25-4bb2-8989-6522e954242e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTE_bc1316ef-2631-4c44-a76d-d2c1316b69f5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;The Company uses the Black-Scholes option valuation model to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDY_5b3eef41-0d6e-491e-81ba-e60efe78db0a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfOTExMQ_5b81104a-ae3f-42cb-ab40-a0430c5c1f88"
      unitRef="shares">9531198</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTA5OTUxMTYyOTAxNDI_4197c2cd-8b4d-4908-aac9-9a2fdcfc17e0"
      unitRef="shares">10075278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MDc_94b95750-0f9e-4117-96ae-4d589366ff28">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of September&#160;30, 2021 and December&#160;31, 2020, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MjI_7d2861cc-9cf9-47f8-9a50-356ec97c7a78">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV8zNy9mcmFnOjRkNTY2OTA1MmZiNDRhN2ViZGM2YTUwN2U5ODVhMDQ0L3RleHRyZWdpb246NGQ1NjY5MDUyZmI0NGE3ZWJkYzZhNTA3ZTk4NWEwNDRfMTE4MTc_a47acc42-bfd1-4f9f-976c-46cec413aa5f">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Application of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80My9mcmFnOjJhZmIxMzBmYjIyMjRjZjA4MTZjMmU0ZjA3OTU3ZGJiL3RleHRyZWdpb246MmFmYjEzMGZiMjIyNGNmMDgxNmMyZTRmMDc5NTdkYmJfMzI2_c653faff-113a-4e85-9f47-e167df42df9b">GRANTS RECEIVABLEGrants receivable represents qualifying costs incurred where there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $2.1 million and $3.9 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80My9mcmFnOjJhZmIxMzBmYjIyMjRjZjA4MTZjMmU0ZjA3OTU3ZGJiL3RleHRyZWdpb246MmFmYjEzMGZiMjIyNGNmMDgxNmMyZTRmMDc5NTdkYmJfMjcx_48774a0c-a095-4237-a5c7-238ba4c2faf3"
      unitRef="usd">2100000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80My9mcmFnOjJhZmIxMzBmYjIyMjRjZjA4MTZjMmU0ZjA3OTU3ZGJiL3RleHRyZWdpb246MmFmYjEzMGZiMjIyNGNmMDgxNmMyZTRmMDc5NTdkYmJfMjg2_df4b4d18-9b6a-4b26-9053-c89a4807d240"
      unitRef="usd">3900000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfNjIx_06b7039f-6220-43e2-a469-371a5b6b30e9">PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;Prepaid insurance is comprised of prepaid directors' and officers' insurance. In July 2020, the Company financed its directors' and officers' insurance premium with a short term note, the principal amount of which was approximately $0.9 million bearing interest at a rate of 2.49%. In July 2021, the Company paid the directors' and officers' insurance policy in full.</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfNjIy_f69aacf0-8d1d-4d89-a966-d69a7e28a791">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <flks:PrepaidClinicalTrialExpense
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMS0xLTEtMS0x_ffca9125-4849-4ba7-889e-9ea319723998"
      unitRef="usd">135227</flks:PrepaidClinicalTrialExpense>
    <flks:PrepaidClinicalTrialExpense
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMS0zLTEtMS0x_a4d04544-0793-46c0-a43d-f58906666fdc"
      unitRef="usd">0</flks:PrepaidClinicalTrialExpense>
    <us-gaap:PrepaidInsurance
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMi0xLTEtMS0x_729a893b-4974-4cc9-ae2c-5ddf16af61bd"
      unitRef="usd">963797</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfMi0zLTEtMS0x_bcd3d372-2a59-4418-af1a-ffa7b1038c59"
      unitRef="usd">684268</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNC0xLTEtMS0x_2ec019aa-4194-40b8-8948-3ed98ece04b1"
      unitRef="usd">95231</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNC0zLTEtMS0x_3e631ac3-4e75-4f76-8f83-a639439d0e27"
      unitRef="usd">137782</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNS0xLTEtMS0x_14fd45ad-13ab-4448-9362-7a2ab1f03922"
      unitRef="usd">1194255</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RhYmxlOjQwMGM5OWY4YmY3YzRmMWJiODQ4NGU3OGY3YzE4NjYyL3RhYmxlcmFuZ2U6NDAwYzk5ZjhiZjdjNGYxYmI4NDg0ZTc4ZjdjMTg2NjJfNS0zLTEtMS0x_0209adbe-2d10-4df9-acb5-8479c13440ce"
      unitRef="usd">822050</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3365ee0645e1428a8bf15e40c57c905e_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfMzgx_038e19d7-b203-40b3-b858-7ea1c914c401"
      unitRef="usd">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifdc107ab4ba649ca943e231ca67e264f_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfMzgx_dd4a9e8d-e381-4feb-bd15-03cc53e801e3"
      unitRef="usd">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3365ee0645e1428a8bf15e40c57c905e_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80Ni9mcmFnOmI3NDI4NmFmN2ViNTRlZWM4YTFkNjAwMDMwN2UwZWM0L3RleHRyZWdpb246Yjc0Mjg2YWY3ZWI1NGVlYzhhMWQ2MDAwMzA3ZTBlYzRfNDE0_3b3bc4bb-b481-4c6e-acde-4edfd2e3631e"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjc4Mw_3c3d4310-9113-4421-ae41-5902b87cbf70">COMMITMENTS AND CONTINGENCIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreement with the University of Utah Research Foundation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 ("LSD1"). In exchange for the license, the Company issued 2% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement subject to certain adjustments specified in the agreement, such as granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cancer Prevention and Research Institute of Texas&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant of up to $18.7 million, further modified to $16.1&#160;million, to fund the development of an LSD1 inhibitor. This is a 3-year grant award which originally expired on May 31, 2019. The grant now expires on May 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of a certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than 1% of net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CPRIT grant is subject to funding conditions including a matching funds requirement where the Company will match 50% of funding from the CPRIT grant. As of September&#160;30, 2021, the Company has expended all allowable funds under the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021 and December&#160;31, 2020, the Company had grants receivable of $2.1 million and $3.9 million, respectively, related to the CPRIT contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i75439519a47a4f6989cd2cd3b40b5195_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMzYx_d541bde7-5c2e-4be4-9d48-004a049162e2"
      unitRef="number">0.02</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <flks:RevenueFromGrantsMaximumAward
      contextRef="i12375731a1584f5db3722367e5d44b8b_D20160601-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfOTk5_ef862b42-e0c4-4e9a-9573-09964338d6f2"
      unitRef="usd">18700000</flks:RevenueFromGrantsMaximumAward>
    <flks:RevenueFromGrantsMaximumAward
      contextRef="i88ae7eac7ac445aebc542f0429384d0a_D20160701-20160701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMTAyMw_9c481cf8-f751-4369-914e-0bc3fc5f4866"
      unitRef="usd">16100000</flks:RevenueFromGrantsMaximumAward>
    <flks:RevenueFromGrantsAwardTerm
      contextRef="i12375731a1584f5db3722367e5d44b8b_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjc4NA_e3834d40-f4e6-406e-ab54-e05ba12d19db">P3Y</flks:RevenueFromGrantsAwardTerm>
    <flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjQxNg_176dfe4a-1174-4b13-943b-e916fb8e0d79"
      unitRef="number">0.01</flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales>
    <flks:RevenueFromGrantsMatchingFundsRequirement
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjU1MQ_0d3dec95-08ea-43b6-8994-f71e5b8def87"
      unitRef="number">0.50</flks:RevenueFromGrantsMatchingFundsRequirement>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjcxMg_48774a0c-a095-4237-a5c7-238ba4c2faf3"
      unitRef="usd">2100000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV80OS9mcmFnOjFmY2I2NDQxMjIwMjQ4NzVhOGFiMmIyNzU5YjZiZWYwL3RleHRyZWdpb246MWZjYjY0NDEyMjAyNDg3NWE4YWIyYjI3NTliNmJlZjBfMjcyNw_df4b4d18-9b6a-4b26-9053-c89a4807d240"
      unitRef="usd">3900000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RleHRyZWdpb246YjY0NGE4MGZiYzY0NGNlN2I2OTJhM2UwMDc0NGVjNjZfMTY4Ng_fe97ca04-cb54-4db2-b537-33bbda8685db">FAIR VALUE OF FINANCIAL INSTRUMENTS &lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Significant unobservable inputs including Salarius&#x2019; own assumptions in determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrants issued in connection with the Company's merger with Flex Pharma in 2019, which are measured at fair value on a recurring basis for the three and nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RleHRyZWdpb246YjY0NGE4MGZiYzY0NGNlN2I2OTJhM2UwMDc0NGVjNjZfMTY4Nw_25cb47b2-1dfa-4dc4-9f96-3c0a235c86ba">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrants issued in connection with the Company's merger with Flex Pharma in 2019, which are measured at fair value on a recurring basis for the three and nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i56f1fbc10f714bacb40851d5e79f0484_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RhYmxlOjM4ZDJjNDNiNmIwMjQ0ZTBhNzkxZmU5ZmUzYWI0YmRhL3RhYmxlcmFuZ2U6MzhkMmM0M2I2YjAyNDRlMGE3OTFmZTlmZTNhYjRiZGFfMS0xLTEtMS0x_5d016a74-6e39-4594-9e5d-9e3485722469"
      unitRef="usd">59211</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i509e2e173464488a8d80584086100e5c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RhYmxlOjM4ZDJjNDNiNmIwMjQ0ZTBhNzkxZmU5ZmUzYWI0YmRhL3RhYmxlcmFuZ2U6MzhkMmM0M2I2YjAyNDRlMGE3OTFmZTlmZTNhYjRiZGFfMS0zLTEtMS0x_5644ba85-412f-4127-9037-b148e0afc12e"
      unitRef="usd">5205</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ice74598ecb934cd4a025ee4792e6670d_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81Mi9mcmFnOmI2NDRhODBmYmM2NDRjZTdiNjkyYTNlMDA3NDRlYzY2L3RhYmxlOjM4ZDJjNDNiNmIwMjQ0ZTBhNzkxZmU5ZmUzYWI0YmRhL3RhYmxlcmFuZ2U6MzhkMmM0M2I2YjAyNDRlMGE3OTFmZTlmZTNhYjRiZGFfMS01LTEtMS0x_95f71860-4ac3-4705-bae4-df1704a77e22"
      unitRef="usd">54006</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTYzMw_26e8cb4b-88a8-4f81-a5b0-4a86895bde52">STOCKHOLDERS' EQUITY&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock and Common Stock  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 11, 2020, the Company completed a public offering with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase an additional 1,252,173 shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius (the &#x201c;February 2020 Offering&#x201d;). The February 2020 Offering was comprised of 7,101,307 Class A units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase one share of common stock with and exercise price of $1.15 per share. A total of 8,353,480 shares of common stock, 1,246,519 shares of Series A convertible preferred stock, and warrants to purchase up to 9,599,999 shares of common stock were issued in the offering, including the full exercise of the over-allotment option. The exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. All Series A preferred stock was converted to common stock prior to December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed above, in connection with the February 2020 Offering, the Company issued five-year warrants to purchase one share of common stock at an exercise price of $1.15 per share (each a "warrant"). On December 11, 2020, the Company entered into warrant exercise inducement offer letters (&#x201c;Inducement Letters&#x201d;) with certain holders of 3,964,065 Warrants (collectively, the &#x201c;Exercising Holders&#x201d;) pursuant to which such holders agreed to exercise on December 11, 2020 for cash, their Warrants to purchase 3,964,065 shares of Common Stock in exchange for the Company&#x2019;s agreement to (i) lower the exercise price of the Warrants held by the Exercising Holders to $0.90 and (ii) issue new warrants (the &#x201c;Inducement Warrants&#x201d;) to purchase up to 3,964,065 shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of $1.182 and expires on June 11, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 3, 2020, the Company completed a public offering of 5,130,390 shares of its common stock at a price to the public of $1.20 per share. Total gross proceeds from the offering were approximately $6.2 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 5, 2021, the Company entered into an At the Market Offering Agreement with Ladenburg Thalmann &amp;amp; Co. Inc. Under this agreement the Company is able to issue and sell, from time to time, shares of its common stock. On February 5, 2021 and July 2, 2021, the Company filed prospectus supplements with the SEC to register the offering and sale of Common Stock having an aggregate offering price of up to $6.3&#160;million and $25.0&#160;million, respectively. During the nine months ended September&#160;30, 2021, the Company issued 3,214,234 shares under the Sales Agreement for gross proceeds of $6.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2021, the Company completed a public offering of 16,806,722 shares of its common stock at a price to the public of $1.3685 per share. Total gross proceeds from the offering were approximately $23.0&#160;million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants Exercised for Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, the Company issued 1,298,567 common shares as a result of warrant exercises, and received cash proceeds of approximately $1.5 million. As of September&#160;30, 2021, 7,747,587 warrants remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Right to Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 3, 2019, Flex Pharma, Private Salarius and Merger Sub entered into the Merger Agreement. Pursuant to the Merger Agreement, Flex Pharma distributed one right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive a warrant to purchase the Company's common shares on January 20, 2020. These warrants were issued on July 1, 2021 and are exercisable in the aggregate, into 142,711 shares of the Company's common stock with a 5-year term from January 20, 2020, at an exercise price of $15.17 per share. The warrants are subject to a cashless exercise, at the option of the Company, at the closing of an issuance and sale of the Company&#x2019;s common stock in certain qualified financing, upon the closing of which the holders of warrants shall be entitled to receive a number of shares of common stock equal to the greater of two formulae defined by the Merger Agreement, which are based on the volume weighted average price of the Company's common stock during the 10 consecutive trading days ending on the trading day immediately preceding the date of exercise. As a result, the warrants have been classified as a liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for these warrants at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a Black-Scholes valuation model. Using this method, unobservable inputs included the Company&#x2019;s equity value, expected timing of possible outcomes, risk free interest rates and stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variables used in the Black-Scholes model are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.56%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Wedbush Warrant&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2019, upon the closing of the merger, the Company elected to issue warrants to purchase 42,928 common shares to Wedbush Securities Inc. ("Wedbush") to satisfy $0.5 million of the $1.0 million success fee payable to Wedbush at the closing of the merger. The remaining $0.5 million success fee was paid in cash. These warrants have an exercise price of $18.90 and a 5-year term. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021, all warrants issued to Wedbush were outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8980e464358d45fabde2cb82b652df91_D20200211-20200211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTc1_7b15c4b2-8459-4b64-aa54-e3203005a130"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8980e464358d45fabde2cb82b652df91_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjgx_70eec555-5ce0-4891-bf98-a9d83bfbfb04"
      unitRef="shares">1252173</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0d4f1866e1f849c489daf2e3e0a10e39_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDgw_617fcc53-df2a-4648-b477-e0c58a331644"
      unitRef="shares">7101307</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i03bc59929da24395880307913e87fb66_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTM1_15ec5fbb-e522-4363-bf5a-f0f1de093983"
      unitRef="usdPerShare">1.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTc3_1d081bc8-e5fb-42ab-8e5c-7b2ae862f6af"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0Ng_ff28f6b0-efca-4a5e-a5ef-c629a1006a0f">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNjM2_d58ea350-61d1-4c03-974a-38156cabeaf0"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNjg1_1c094e28-87f1-4efa-9133-1e7cf12627d5"
      unitRef="usdPerShare">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3725d493747d4bbe83005958d3ac6d23_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNzAz_3a0960e5-daba-4b4e-aa5a-31ef0df95d80"
      unitRef="shares">1246519</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1f88e0cf88b84bf9854e0bedf0607dd1_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNzU4_9b9e974d-ba96-469e-a793-8dec8b470810"
      unitRef="usdPerShare">1.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfODAw_0af7b36e-e73e-4421-870c-8d4ced069e11"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTYzOA_e9c6c7d8-dcca-47d5-b3c3-fa9c1b9e3dd3">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfODgz_439568a5-bc6b-428e-9b45-a3e6c8ead8e4"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6026e2ea63474bb6b5241d862bf6c303_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfOTM1_bbdd17e0-fcbf-403b-b9dd-f298e223c63f"
      unitRef="usdPerShare">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i507cbbf0634340df95b758b92062fb43_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfOTYw_07d91382-2f93-41f6-8308-c114760d7fd2"
      unitRef="shares">8353480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ieb060d868e36408ebdd36e2a2fe2658d_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfOTg3_c9be51ed-122e-4954-b815-ae4b70610778"
      unitRef="shares">1246519</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7fa8c9f6d7934dcaa6197a4ab35db643_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTA2OQ_e36816c4-fae8-4bf5-ab82-fc241986f785"
      unitRef="shares">9599999</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i9309e3d556bc49209dff4d4ae28bffc9_I20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0MQ_b1fbacb6-0d2f-41b0-9c42-5cdad4c0c2e3">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i9309e3d556bc49209dff4d4ae28bffc9_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTQzNA_f3c75054-d3e9-4c7b-bf5c-09c6a3cc2191"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i62ba6b78c05f44859360da199a2f4d38_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTQ4Mw_da6dac0f-45f8-41ce-af41-80e67d2e5a6b"
      unitRef="usdPerShare">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTY1Mg_677e39e6-94f3-4c81-883f-8b93d05fb518"
      unitRef="shares">3964065</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTgxMw_dce206d4-63c0-49ee-9683-4dadd7c2ef81"
      unitRef="shares">3964065</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idc44ad82e29143268254f26cd0b201a3_I20201211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMTk2MQ_b2281815-a45b-46d2-8515-65d337d8c6fd"
      unitRef="usdPerShare">0.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjAzOA_b388a208-a061-4cdb-bade-c4d3305a4bb1"
      unitRef="shares">3964065</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i154dce57782f49a0b2407f5f8b6c7819_I20201211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjEyOA_026310f2-bdbb-4611-b351-3ad581390e89"
      unitRef="usdPerShare">1.182</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8d324e00fd0449ada9306d7820e7650a_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjIyMw_7141ddc1-6890-421a-959d-af4089c1f84c"
      unitRef="shares">5130390</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i637b5066c13e46c8ad5054fcf7d9db91_I20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjI4MQ_4bf47f14-6a23-484f-b6d3-cc58fb50eb11"
      unitRef="usdPerShare">1.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i97060a95644a4253a9d97d1b2c868b7e_D20200803-20200803"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjM1Mw_af2beade-f067-4e5b-97ae-b878ea73d08d"
      unitRef="usd">6200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie1455af2bd3e48fbab07d23af33ccf27_D20210205-20210205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjg3MQ_244c6d58-a768-4554-8a85-eb07b9cb9f20"
      unitRef="shares">6300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8e0f9788dcba480c96b8fa31f68fb351_D20210702-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjg3OA_9a9ac783-e327-4e17-a409-4e5b44140cdf"
      unitRef="shares">25000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i22aba5a3e90e4e95a276ef89efe1ac98_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMjk0Ng_18cbb509-267f-4516-a61f-f4e0cc2dd25f"
      unitRef="shares">3214234</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i22aba5a3e90e4e95a276ef89efe1ac98_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzAwNA_e4297f86-7852-4f20-8195-91c747bf2d6f"
      unitRef="usd">6700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id5ae6026c59f4ec38c6949b4bef8d233_D20210308-20210308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzA3MA_f945e672-70bf-4d94-b1f5-08bf24dda9cc"
      unitRef="shares">16806722</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4075aa174dd346ae968ca14c8a84ba8a_I20210308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzEyOA_9b053e6e-bdbf-40fa-9c48-08085b8f973a"
      unitRef="usdPerShare">1.3685</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i38ec404e1c2a4fa19e8f881a89360a33_D20210308-20210308"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzIwMA_4d6e86cc-e814-46e8-bac4-d226bf89b107"
      unitRef="usd">23000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <flks:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i72d6648d8528478096111949d12cd28f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzM4NA_6c6ab96d-2ee2-445f-8401-583fb8710422"
      unitRef="shares">1298567</flks:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzQ3OQ_b9982be7-2746-4ae5-a48b-443527386eab"
      unitRef="usd">1500000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic7cf095f8f0646cfb8bfc0b7cde4699b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzUwMQ_d7055003-6f49-4b31-b03e-7e3994340a7a"
      unitRef="shares">7747587</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i9f29b4bffdb04060b79c90b287ec75ee_I20190718"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfMzcxOA_ad95a074-39f3-4382-bfa0-0141c6c76f65"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDAzMQ_09ec4958-57d3-42a5-99b2-3aa71e36d847"
      unitRef="shares">142711</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0MA_52c5e3d7-2c8c-403a-909d-fc8ddafc3fa5">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i59b462c5ddf64161a7ea7e84ae1097bc_I20210701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDEzOA_bc1ef736-59bf-4c8e-94d0-10987a701308"
      unitRef="usdPerShare">15.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flks:ClassOfWarrantOrRightThresholdConsecutiveTradingDays
      contextRef="i7b06abcc4a3c4d32837217db39cf0e29_D20190718-20190718"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNDYxMA_797b58c0-a533-464e-8fcd-3480ea551ca1"
      unitRef="day">10</flks:ClassOfWarrantOrRightThresholdConsecutiveTradingDays>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTYzNg_67627345-5e6c-4cec-a205-68229c72f30d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variables used in the Black-Scholes model are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.56%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="ic6b4f85b5e2f4b0da127ab2e310c28a8_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMS0yLTEtMS0x_fbcafcdc-fec1-451f-8b10-f8e25b4060fc"
      unitRef="number">0.0053</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="iefe55d006aa740d7bdb83434769e6cec_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMS00LTEtMS0x_85b14db7-171d-40a6-9e9b-54c3e24b89f8"
      unitRef="number">0.0027</flks:WarrantsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMi0yLTEtMS0x_55cd6b22-3316-4cc2-8db3-7814b91f234b">P3Y3M21D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMi00LTEtMS0x_02e5fc40-c90e-48ed-af4e-060d4ee5b5f7">P4Y21D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="i6b1e7939df33476493958c5474f1ec12_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMy0yLTEtMS0x_0313300d-72b8-479c-84ce-868e7bd5001e"
      unitRef="number">1.3023</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="if20fa72ce8b44760a27f5514b956d6a1_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfMy00LTEtMS0x_8445459d-9912-4771-b1e8-3c16be4e7b8f"
      unitRef="number">1.3056</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="ib3767d63d21841febd91f1664b87398c_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfNC0yLTEtMS0x_436bcb30-d03d-4d2b-9e09-f2d2d8ae085d"
      unitRef="number">0</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="ie27743a41234488c94ecdbae56d5030e_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RhYmxlOjBjY2ExZjE4YmVhNTRhYWNiZWEzMmIyYzQ5ZDMxZmM1L3RhYmxlcmFuZ2U6MGNjYTFmMThiZWE1NGFhY2JlYTMyYjJjNDlkMzFmYzVfNC00LTEtMS0x_3dde8c51-b1f9-4de5-a899-43af72229781"
      unitRef="number">0</flks:WarrantsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTI5OQ_9e2a5fca-b099-4649-9a1e-89c40433a98d"
      unitRef="shares">42928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTM2Ng_8f6dc8b1-49eb-407f-8302-fcaa9294c93f"
      unitRef="usd">500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTM4NA_be9fe3c9-5c4b-438d-8141-6070b49defe0"
      unitRef="usd">1000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i9de1973dc957478cb0bc2d769059d427_D20190719-20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTQ3MA_55643bbe-3731-48dd-9b1d-259a25543c17"
      unitRef="usd">500000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTU1Mg_4513aa02-2505-4e39-8b58-b5e7e7c8fcc3"
      unitRef="usdPerShare">18.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i39cc82ccd45243c7ad5b75bc43e08efb_I20190719"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81NS9mcmFnOjY1OTczMDExYzIyODQzMTA4YjYzNjQyNTU0NWVlMjVlL3RleHRyZWdpb246NjU5NzMwMTFjMjI4NDMxMDhiNjM2NDI1NTQ1ZWUyNWVfNTY0Mg_5f611747-a9fd-46da-b8ee-b56b3323d9a5">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU3OA_64c54756-0844-4020-a840-f79f64195a3f">EQUITY-BASED COMPENSATION &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of September&#160;30, 2021, there were 1,026,690 shares remaining available for the grant of stock awards under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine-month periods ended September&#160;30, 2021 and 2020, the Company awarded 79,000 and 182,000, respectively, stock options to its employees and directors, pursuant to the plan described above. Stock options generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI0NA_14cf129a-350a-4324-b668-9e3a5073d911"&gt;one&lt;/span&gt; to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants awarded during each of the nine month periods ended September&#160;30, 2021 and 2020 was $0.1 million and $0.7 million, respectively, which has been estimated with the following assumptions on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3/10/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6/16/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9/2/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for employees and non-employees for the nine months ended September&#160;30, 2021 and 2020: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$34.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743,118&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,613)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,766)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$37.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$175,770&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.04-$1.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$271,540&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,730&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$34,440&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and 2020, there was approximately $1.0 million and $0.4 million respectively of total unrecognized compensation cost related to unvested stock options. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 2.45 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id806215bb22c4a6bbb84c72994b31e52_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfOTU1_ec16a5eb-11e3-4258-9a6b-50cf382baebe"
      unitRef="shares">1026690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTEwMQ_d98d10e3-7a3b-485d-acff-ef3a355d5fa2"
      unitRef="shares">79000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9cd9bebb5d234611a3707cb6f311df80_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTEwOA_94cc8836-209e-4d2e-9385-c0a3cad64871"
      unitRef="shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i618536f8debf473cb0710a7c02b3140f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI1MA_88b443f6-5a85-4198-852e-e2e0ce9ae5e0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i28b2f8b8184949889f3aa6bcf52f8836_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI4NA_a60ae93f-f4ca-4abf-a189-a813266bd880">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU3Nw_9234e57c-cec3-4ff2-ac6b-2b0b9bebd986">The fair value of the option grants awarded during each of the nine month periods ended September&#160;30, 2021 and 2020 was $0.1 million and $0.7 million, respectively, which has been estimated with the following assumptions on the grant date.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3/10/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6/16/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9/2/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTk5Ng_c5063401-9aa0-4d5e-8512-e24cec6c887c"
      unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTA5OTUxMTYyODAzOTA_6d01847a-2de5-4742-ac93-15447bc86cca"
      unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMS0xLTEtMS0x_75027b64-0719-404e-bf2b-eccad6d901b0"
      unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMS0yLTEtMS0x_7a78aaca-2688-4769-bd93-8525ac926261"
      unitRef="number">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMS00LTEtMS0xMDM3Ng_3ce45de8-d614-4b84-9ee1-a50b086f4869"
      unitRef="number">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMi0xLTEtMS0x_028af1a1-6f90-40d1-be22-dac7c6913c62"
      unitRef="number">1.3335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMi0yLTEtMS0x_1823a53f-9f1b-4273-9efd-dc6960ee6c6d"
      unitRef="number">1.3106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMi00LTEtMS0xMDM3Ng_81e4e6b5-2062-4755-bcda-1ce539c1faae"
      unitRef="number">1.3044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMy0xLTEtMS0x_11bb73aa-1e22-4528-8688-d46a66c9cebb">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMy0yLTEtMS0x_d36aeb56-52b5-4f4f-bcd2-420a1ec88540">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfMy00LTEtMS0xMDM3Ng_a3e1e42a-a827-4b18-911f-31617c2242c2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie90e9dd01f7646fb918ea2921026108d_D20210310-20210310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfNC0xLTEtMS0x_e70278c5-5313-42cf-967f-750c8778e996"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7b6689afe5914caf854ee789d4cedf05_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfNC0yLTEtMS0x_e44c9e6b-b7fe-4f2e-93da-4d4c4cf4eaa5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjZiYmNmMDhiYTZjNDQwYzA4ODA5ODM0ZjgyZTRiYzY1L3RhYmxlcmFuZ2U6NmJiY2YwOGJhNmM0NDBjMDg4MDk4MzRmODJlNGJjNjVfNC00LTEtMS0xMDM3Ng_c5fd352f-c6e3-49ba-9c5a-99dc9d253d68"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU3Mw_cf41fbe9-6751-4ee4-9848-6c7a4722a6cb">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for employees and non-employees for the nine months ended September&#160;30, 2021 and 2020: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$34.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743,118&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,613)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,766)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$37.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$175,770&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.04-$1.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$271,540&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,730&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$34,440&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS0xLTEtMS0x_f10fcaa4-3b4f-4c08-bd1d-4c99a902dc6e"
      unitRef="shares">166233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS0zLTEtMS0x_a1a6f26e-3b0a-4bd3-8e8f-38ac35356966"
      unitRef="usdPerShare">34.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id634fbf36df7473db3bb7e070c784cad_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS01LTEtMS0x_fecb6402-ebd8-42c0-8259-13c0a5601c86">P6Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i306fd4a8b3a841e5ac70217bbe31abd7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMS03LTEtMS0x_1d40cea8-8643-455d-bf22-113fe042d3b4"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMi0xLTEtMS0x_2c0d32e9-2c61-4fcc-bbef-422266449ad3"
      unitRef="shares">743118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMi0zLTEtMS0x_abf9ec10-70a6-460e-b14b-75c24a950c09"
      unitRef="usdPerShare">0.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMy0xLTEtMS0x_042fe7cd-0590-4d50-b109-b13464411a00"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNC0xLTEtMS0x_d252ebba-6602-4532-8dab-386b0f5ac3a5"
      unitRef="shares">36613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNC0zLTEtMS0x_97411e2a-6b02-4624-a53c-42ccae31abd3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNS0xLTEtMS0x_c740fcde-132d-4386-9e56-7d306537e832"
      unitRef="shares">30766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi0xLTEtMS0x_20ab71f2-ed1a-484b-9919-0599a57e74dd"
      unitRef="shares">841972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi0zLTEtMS0x_db4d3313-caa5-42c4-8e3d-11e871f6708a"
      unitRef="usdPerShare">4.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi01LTEtMS0x_5ddcd007-1cb8-48e1-9255-ef6978f32e82">P9Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNi03LTEtMS0x_6787c5c2-aa73-4748-abd2-9281b2390d05"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy0xLTEtMS0x_40fd0772-c130-4f2a-b9b4-a9c07515e0fc"
      unitRef="shares">69813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy0zLTEtMS0x_37767c6b-b1bd-4b27-a06b-97be51deb31a"
      unitRef="usdPerShare">37.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i668f6d1a70e44d24ad1a0a975f0b6b53_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy01LTEtMS0x_8c79efa5-a2ed-4144-8e53-04520bf90b43">P5Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfNy03LTEtMS0x_057ceaf9-11d3-4862-a1b0-85cd7d07e303"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS0xLTEtMS0x_bbb394fa-0ce8-44ca-a284-cb0ac3851709"
      unitRef="shares">1563972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS0zLTEtMS0x_d0723bd7-6304-4b32-88df-58746714a7d4"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iab6f2c50c3e144b5b8f013949d188cfd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS01LTEtMS0x_bc896e04-b0f4-4435-8b1e-c097e63311f6">P9Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibc576fa0a40d46a09cde34e4add1d831_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfOS03LTEtMS0x_758c24fd-abe7-4a0f-b626-353564993821"
      unitRef="usd">175770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTAtMS0xLTEtMQ_d98d10e3-7a3b-485d-acff-ef3a355d5fa2"
      unitRef="shares">79000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if61674fa0744426bad5a356d5af164c9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTAtMy0xLTEtMS90ZXh0cmVnaW9uOjIxZTYwZThhNjU1OTQzZDVhYTVkNDMxNTA2ZGE4YmE4XzQ_4be82777-7ac2-4e15-a612-1d5438e2acde"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i01803b42cf2b4af6b7b175622f3970f8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTAtMy0xLTEtMS90ZXh0cmVnaW9uOjIxZTYwZThhNjU1OTQzZDVhYTVkNDMxNTA2ZGE4YmE4Xzc_6edd18d8-c287-4a2d-a118-febea3f6404c"
      unitRef="usdPerShare">1.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTEtMS0xLTEtMQ_0192362f-001c-44d7-a08d-2f47f7695ee0"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTItMS0xLTEtMQ_af4ed0fc-e60a-44db-a631-e93ad836f460"
      unitRef="shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTMtMS0xLTEtMQ_a394f7f3-8710-451b-9c50-5e52a565860e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtMS0xLTEtMQ_61283609-437f-4244-b481-d10a33023d36"
      unitRef="shares">1597972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtMy0xLTEtMQ_765ce476-ea24-4989-bbc8-4907f68cda5c"
      unitRef="usdPerShare">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtNS0xLTEtMQ_0229cdbf-a2ec-48ae-ba65-594eec662364">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTQtNy0xLTEtMQ_ab6c4222-b6ed-4c34-ace1-3693810d5808"
      unitRef="usd">271540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtMS0xLTEtMQ_2eaee187-61a2-4ccf-9202-41f891ec1182"
      unitRef="shares">323730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtMy0xLTEtMQ_0b62bb25-9389-4edb-b205-61214137bc30"
      unitRef="usdPerShare">9.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtNS0xLTEtMQ_3445c3f6-54cc-4048-8a8a-d2cd1a0a8fff">P7Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RhYmxlOjQwOWMzNmExZDhiMDRlOGRhZjIyMjgwMzFkMzhhNWRhL3RhYmxlcmFuZ2U6NDA5YzM2YTFkOGIwNGU4ZGFmMjIyODAzMWQzOGE1ZGFfMTUtNy0xLTEtMQ_ba3c3431-97e8-445c-84ce-58a9075b122e"
      unitRef="usd">34440</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjI1MQ_d92381f7-a518-4e47-83ba-7f8f65f94f2b"
      unitRef="usd">1000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ieeeac6ab2a224bf1872b2c69cfe254ff_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjI2Nw_7fd911e3-8a0b-45b4-af28-f9ef52f30e83"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMjU2Mw_84733612-ff57-4376-94d3-c4abeb65539a">P2Y5M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692048563576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SALARIUS PHARMACEUTICALS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5087339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2450 Holcombe Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite X<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">834-6992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $ 0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,206,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001615219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692052346152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,903,727<span></span>
</td>
<td class="nump">$ 11,118,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">2,086,157<span></span>
</td>
<td class="nump">3,855,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,194,255<span></span>
</td>
<td class="nump">822,050<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,184,139<span></span>
</td>
<td class="nump">15,796,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,570<span></span>
</td>
<td class="nump">22,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">201,389<span></span>
</td>
<td class="nump">247,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,865,909<span></span>
</td>
<td class="nump">8,865,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">44,263,007<span></span>
</td>
<td class="nump">24,932,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,234,922<span></span>
</td>
<td class="nump">1,853,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">323,364<span></span>
</td>
<td class="nump">383,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">477,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">54,006<span></span>
</td>
<td class="nump">59,211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,612,292<span></span>
</td>
<td class="nump">2,773,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 45,172,535 and 23,810,541 shares issued at September&#160;30, 2021 and December&#160;31, 2020, and 45,172,535 and 23,808,546 shares outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">4,517<span></span>
</td>
<td class="nump">2,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">70,738,517<span></span>
</td>
<td class="nump">41,585,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(28,092,319)<span></span>
</td>
<td class="num">(19,428,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">42,650,715<span></span>
</td>
<td class="nump">22,159,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 44,263,007<span></span>
</td>
<td class="nump">$ 24,932,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692052402888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">45,172,535<span></span>
</td>
<td class="nump">23,810,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">45,172,535<span></span>
</td>
<td class="nump">23,808,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692052376024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from contract with customer, product and service</a></td>
<td class="text">Grant [Member]<span></span>
</td>
<td class="text">Grant [Member]<span></span>
</td>
<td class="text">Grant [Member]<span></span>
</td>
<td class="text">Grant [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,378,239<span></span>
</td>
<td class="nump">$ 1,840,216<span></span>
</td>
<td class="nump">$ 3,754,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,015,930<span></span>
</td>
<td class="nump">1,803,682<span></span>
</td>
<td class="nump">5,852,887<span></span>
</td>
<td class="nump">4,890,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,730,730<span></span>
</td>
<td class="nump">1,333,062<span></span>
</td>
<td class="nump">4,655,404<span></span>
</td>
<td class="nump">4,893,021<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,746,660<span></span>
</td>
<td class="nump">3,136,744<span></span>
</td>
<td class="nump">10,508,291<span></span>
</td>
<td class="nump">9,783,396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss before other income (expense)</a></td>
<td class="num">(3,746,660)<span></span>
</td>
<td class="num">(1,758,505)<span></span>
</td>
<td class="num">(8,668,075)<span></span>
</td>
<td class="num">(6,029,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">9,073<span></span>
</td>
<td class="nump">45,103<span></span>
</td>
<td class="nump">5,205<span></span>
</td>
<td class="nump">265,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Government grants and other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">179,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">487<span></span>
</td>
<td class="num">(3,230)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations</a></td>
<td class="num">(3,737,100)<span></span>
</td>
<td class="num">(1,716,632)<span></span>
</td>
<td class="num">(8,663,365)<span></span>
</td>
<td class="num">(5,584,706)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,737,100)<span></span>
</td>
<td class="num">$ (1,716,632)<span></span>
</td>
<td class="num">$ (8,663,365)<span></span>
</td>
<td class="num">$ (5,584,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share, basic ( in dollar per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share, diluted ( in dollar per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic (in shares)</a></td>
<td class="nump">44,804,741<span></span>
</td>
<td class="nump">17,968,664<span></span>
</td>
<td class="nump">40,064,119<span></span>
</td>
<td class="nump">13,833,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted (in shares)</a></td>
<td class="nump">44,804,741<span></span>
</td>
<td class="nump">17,968,664<span></span>
</td>
<td class="nump">40,064,119<span></span>
</td>
<td class="nump">13,833,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692049224808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,663,365)<span></span>
</td>
<td class="num">$ (5,584,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairment</a></td>
<td class="nump">14,387<span></span>
</td>
<td class="nump">12,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">413,153<span></span>
</td>
<td class="nump">149,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(5,205)<span></span>
</td>
<td class="num">(265,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Grants receivable</a></td>
<td class="nump">1,769,839<span></span>
</td>
<td class="num">(3,212,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(329,799)<span></span>
</td>
<td class="nump">799,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(618,830)<span></span>
</td>
<td class="num">(607,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(59,774)<span></span>
</td>
<td class="nump">288,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(541,701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,479,594)<span></span>
</td>
<td class="num">(8,937,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from issuance of equity securities, net</a></td>
<td class="nump">27,256,384<span></span>
</td>
<td class="nump">14,810,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised for cash</a></td>
<td class="nump">1,485,351<span></span>
</td>
<td class="nump">636,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
<td class="num">(477,028)<span></span>
</td>
<td class="num">(690,367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">28,264,707<span></span>
</td>
<td class="nump">14,756,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">20,785,113<span></span>
</td>
<td class="nump">5,818,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">11,118,614<span></span>
</td>
<td class="nump">3,738,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">31,903,727<span></span>
</td>
<td class="nump">9,557,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuanceCostsAccruedAndAmortized', window );">Accrued issuance costs for public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_PrepaidExpenseFinancedByNotePayable', window );">Prepaid expense financed by note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 949,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_PrepaidExpenseFinancedByNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense Financed by Note Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_PrepaidExpenseFinancedByNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuanceCostsAccruedAndAmortized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Accrued and Amortized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuanceCostsAccruedAndAmortized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692040077768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Nonemployee</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Nonemployee</div>
</th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Nonemployee</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,511,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 10,580,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,657,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,076,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="nump">9,467,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">9,466,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Preferred shares converted to common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Preferred shares converted to common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation and services expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation and services expense</a></td>
<td class="nump">38,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,083,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,083,816)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,645,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">18,002,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">32,161,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,160,516)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,511,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">10,580,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,657,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,076,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,584,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,818,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">20,605,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,265,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,661,406)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,645,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">18,002,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">32,161,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,160,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised for cash, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised for cash, net</a></td>
<td class="nump">578,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Preferred shares converted to common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(468,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Preferred shares converted to common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation and services expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
<td class="nump">18,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation and services expense</a></td>
<td class="nump">32,905<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,905<span></span>
</td>
<td class="nump">$ 24,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,784,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,784,258)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,638,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">16,854,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">32,798,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,944,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,130,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="nump">5,331,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,331,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised for cash, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised for cash, net</a></td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation and services expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation and services expense</a></td>
<td class="nump">78,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,716,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,716,632)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,818,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">20,605,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,265,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,661,406)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,808,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">22,159,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41,585,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,428,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,627,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="nump">26,850,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,848,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised for cash, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,298,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised for cash, net</a></td>
<td class="nump">1,485,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,485,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation and services expense</a></td>
<td class="nump">135,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,851,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,851,896)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,734,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">48,778,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">70,054,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,280,850)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,808,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">22,159,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41,585,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,428,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised for cash, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,298,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,663,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,172,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">42,650,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">70,738,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,092,319)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,734,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">48,778,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">70,054,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,280,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation and services expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,278<span></span>
</td>
<td class="nump">6,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation and services expense</a></td>
<td class="nump">147,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,074,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,074,369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,778,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">45,851,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">70,201,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,355,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities, net</a></td>
<td class="nump">406,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation and services expense</a></td>
<td class="nump">130,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,737,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,737,100)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,172,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 42,650,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70,738,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,092,319)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692043937032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND OPERATIONS</a></td>
<td class="text">ORGANIZATION AND OPERATIONS<div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. Specifically, the Company is developing treatments for cancers caused by dysregulated gene expression, i.e., genes that are incorrectly turned on or off. The field concerned with gene expression regulation is called &#8216;epigenetics&#8217;. As cancers are often diseases driven by gene dysregulation, epigenetics is an area of interest for cancer treatment. The Company's lead epigenetic based technology was licensed from the University of Utah Research Foundation in 2011. The Company is located in Houston, Texas.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Covid-19 Pandemic</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic is significantly affecting the United States, global economies, and businesses worldwide.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the potential magnitude and duration of the economic and social impact of the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may, in the future, reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. At this time we are experiencing minimal disruption to our clinical trials. However, our ongoing Phase 1/2 Ewing sarcoma clinical trial and Phase 1/2 AST clinical trial may encounter delays in enrolling new patients due to concerns or healthcare resource constraints because of the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span>In addition, although at this time we have experienced no disruptions to manufacturing capabilities, certain aspects of our supply chain may be disrupted as certain of our third party suppliers and manufacturers have paused their operations in response to the COVID-19 pandemic or have otherwise encountered delays in providing supplies and services. The COVID-19 pandemic could also have a material and negative impact on our liquidity, capital resources (including our ability to secure additional financing if and when needed), our business and operations, and our workforce, as well as those of the third parties with which we do business or upon which we rely. While the situation is fluid and we do not yet know the full extent of potential delays or impacts on us or on healthcare systems or the global economy in general, we have worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic. However, we may experience disruptions in the future that have and could further adversely impact our business operations as well as our preclinical studies and clinical trials.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692043857208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2020 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 18, 2021. In the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2021 and the results of operations for the three and nine months ended September&#160;30, 2021 and 2020. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2020 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains several bank accounts including an interest-bearing account for funds received from Cancer Prevention and Research Institution of Texas ("CPRIT"). </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.  There were no impairment charges related to long-lived assets for the three and nine months ended September&#160;30, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment charge is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired. There was no impairment of goodwill during the three and nine months ended September&#160;30, 2021 or September&#160;30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s preclinical and clinical trials are performed by third party contract research organizations (CROs) and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations (CMOs). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#8217;s research and development expenses in future periods. To date the Company has had no significant adjustments.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants Receivable and Revenue Recognition </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option valuation model to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) unvested restricted stock, (iv) convertible preferred stock and (v) rights entitling holders to receive warrants to purchase the Company's common shares, which have been excluded from the computation of diluted loss per share, was 9,531,198 and 10,075,278 shares as of September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of September&#160;30, 2021 and December&#160;31, 2020, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Application of New Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692043967352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">GRANTS RECEIVABLE</a></td>
<td class="text">GRANTS RECEIVABLEGrants receivable represents qualifying costs incurred where there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $2.1 million and $3.9 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692043889848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text">PREPAID EXPENSES AND OTHER CURRENT ASSETS<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Prepaid insurance is comprised of prepaid directors' and officers' insurance. In July 2020, the Company financed its directors' and officers' insurance premium with a short term note, the principal amount of which was approximately $0.9 million bearing interest at a rate of 2.49%. In July 2021, the Company paid the directors' and officers' insurance policy in full.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692043981432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with the University of Utah Research Foundation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to an epigenetic enzyme lysine specific demethylase 1 ("LSD1"). In exchange for the license, the Company issued 2% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement subject to certain adjustments specified in the agreement, such as granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cancer Prevention and Research Institute of Texas</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant of up to $18.7 million, further modified to $16.1&#160;million, to fund the development of an LSD1 inhibitor. This is a 3-year grant award which originally expired on May 31, 2019. The grant now expires on May 31, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of a certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than 1% of net sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CPRIT grant is subject to funding conditions including a matching funds requirement where the Company will match 50% of funding from the CPRIT grant. As of September&#160;30, 2021, the Company has expended all allowable funds under the grant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021 and December&#160;31, 2020, the Company had grants receivable of $2.1 million and $3.9 million, respectively, related to the CPRIT contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692049156056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE OF FINANCIAL INSTRUMENTS <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrants issued in connection with the Company's merger with Flex Pharma in 2019, which are measured at fair value on a recurring basis for the three and nine months ended September&#160;30, 2021:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,211&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,205)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,006&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692045355736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS' EQUITY<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock and Common Stock  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, the Company completed a public offering with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase an additional 1,252,173 shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius (the &#8220;February 2020 Offering&#8221;). The February 2020 Offering was comprised of 7,101,307 Class A units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase one share of common stock with and exercise price of $1.15 per share. A total of 8,353,480 shares of common stock, 1,246,519 shares of Series A convertible preferred stock, and warrants to purchase up to 9,599,999 shares of common stock were issued in the offering, including the full exercise of the over-allotment option. The exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. All Series A preferred stock was converted to common stock prior to December 31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, in connection with the February 2020 Offering, the Company issued five-year warrants to purchase one share of common stock at an exercise price of $1.15 per share (each a "warrant"). On December 11, 2020, the Company entered into warrant exercise inducement offer letters (&#8220;Inducement Letters&#8221;) with certain holders of 3,964,065 Warrants (collectively, the &#8220;Exercising Holders&#8221;) pursuant to which such holders agreed to exercise on December 11, 2020 for cash, their Warrants to purchase 3,964,065 shares of Common Stock in exchange for the Company&#8217;s agreement to (i) lower the exercise price of the Warrants held by the Exercising Holders to $0.90 and (ii) issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to 3,964,065 shares of Common Stock. Each Inducement Warrant is exercisable at a price per share of $1.182 and expires on June 11, 2026.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2020, the Company completed a public offering of 5,130,390 shares of its common stock at a price to the public of $1.20 per share. Total gross proceeds from the offering were approximately $6.2 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2021, the Company entered into an At the Market Offering Agreement with Ladenburg Thalmann &amp; Co. Inc. Under this agreement the Company is able to issue and sell, from time to time, shares of its common stock. On February 5, 2021 and July 2, 2021, the Company filed prospectus supplements with the SEC to register the offering and sale of Common Stock having an aggregate offering price of up to $6.3&#160;million and $25.0&#160;million, respectively. During the nine months ended September&#160;30, 2021, the Company issued 3,214,234 shares under the Sales Agreement for gross proceeds of $6.7&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company completed a public offering of 16,806,722 shares of its common stock at a price to the public of $1.3685 per share. Total gross proceeds from the offering were approximately $23.0&#160;million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants Exercised for Cash </span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, the Company issued 1,298,567 common shares as a result of warrant exercises, and received cash proceeds of approximately $1.5 million. As of September&#160;30, 2021, 7,747,587 warrants remain outstanding. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Right to Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 3, 2019, Flex Pharma, Private Salarius and Merger Sub entered into the Merger Agreement. Pursuant to the Merger Agreement, Flex Pharma distributed one right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive a warrant to purchase the Company's common shares on January 20, 2020. These warrants were issued on July 1, 2021 and are exercisable in the aggregate, into 142,711 shares of the Company's common stock with a 5-year term from January 20, 2020, at an exercise price of $15.17 per share. The warrants are subject to a cashless exercise, at the option of the Company, at the closing of an issuance and sale of the Company&#8217;s common stock in certain qualified financing, upon the closing of which the holders of warrants shall be entitled to receive a number of shares of common stock equal to the greater of two formulae defined by the Merger Agreement, which are based on the volume weighted average price of the Company's common stock during the 10 consecutive trading days ending on the trading day immediately preceding the date of exercise. As a result, the warrants have been classified as a liability.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for these warrants at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a Black-Scholes valuation model. Using this method, unobservable inputs included the Company&#8217;s equity value, expected timing of possible outcomes, risk free interest rates and stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price volatility. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variables used in the Black-Scholes model are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:43.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.56%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wedbush Warrant</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, upon the closing of the merger, the Company elected to issue warrants to purchase 42,928 common shares to Wedbush Securities Inc. ("Wedbush") to satisfy $0.5 million of the $1.0 million success fee payable to Wedbush at the closing of the merger. The remaining $0.5 million success fee was paid in cash. These warrants have an exercise price of $18.90 and a 5-year term. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021, all warrants issued to Wedbush were outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692055976168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY-BASED COMPENSATION</a></td>
<td class="text">EQUITY-BASED COMPENSATION <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of September&#160;30, 2021, there were 1,026,690 shares remaining available for the grant of stock awards under the 2015 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine-month periods ended September&#160;30, 2021 and 2020, the Company awarded 79,000 and 182,000, respectively, stock options to its employees and directors, pursuant to the plan described above. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3MzU5NjdjYzljYjQxMDA4YjZlMWI2ZTc3YjhkNjRlL3NlYzozNzM1OTY3Y2M5Y2I0MTAwOGI2ZTFiNmU3N2I4ZDY0ZV81OC9mcmFnOmQ0YTYzNzI4N2JmNzQ5Yjk4ZmQzNGI1OGZjZjE1MjA3L3RleHRyZWdpb246ZDRhNjM3Mjg3YmY3NDliOThmZDM0YjU4ZmNmMTUyMDdfMTI0NA_14cf129a-350a-4324-b668-9e3a5073d911">one</span> to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants awarded during each of the nine month periods ended September&#160;30, 2021 and 2020 was $0.1 million and $0.7 million, respectively, which has been estimated with the following assumptions on the grant date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.467%"><tr><td style="width:1.0%"/><td style="width:36.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3/10/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/16/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/2/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for employees and non-employees for the nine months ended September&#160;30, 2021 and 2020: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:44.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$34.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743,118</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,613)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,766)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841,972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,813</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$175,770</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04-$1.49</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,000)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597,972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$271,540</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,730</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$34,440</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and 2020, there was approximately $1.0 million and $0.4 million respectively of total unrecognized compensation cost related to unvested stock options. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 2.45 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692053573624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. </span></div>The Company maintains several bank accounts including an interest-bearing account for funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. </span></div>Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment charge is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Financial Instruments and Credit Risks</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust </span></div>the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant. For warrants classified as equity contracts, the Company allocates the transaction proceeds to the warrants and any other free-standing instruments issued in the transaction based on an allowable allocation method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Grants Receivable and Revenue Recognition</a></td>
<td class="text">Grants Receivable and Revenue Recognition Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div>The Company uses the Black-Scholes option valuation model to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of September&#160;30, 2021 and December&#160;31, 2020, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Application of New Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Application of New Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692045510232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692045561608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrants issued in connection with the Company's merger with Flex Pharma in 2019, which are measured at fair value on a recurring basis for the three and nine months ended September&#160;30, 2021:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.532%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,211&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,205)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,006&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692045608024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Variables Used in Black-Scholes Model</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variables used in the Black-Scholes model are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:43.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.56%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692045571304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">The fair value of the option grants awarded during each of the nine month periods ended September&#160;30, 2021 and 2020 was $0.1 million and $0.7 million, respectively, which has been estimated with the following assumptions on the grant date.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.467%"><tr><td style="width:1.0%"/><td style="width:36.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3/10/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/16/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/2/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for employees and non-employees for the nine months ended September&#160;30, 2021 and 2020: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:44.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$34.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743,118</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,613)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,766)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841,972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,813</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$175,770</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.04-$1.49</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,000)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597,972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$271,540</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,730</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$34,440</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692048690872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,531,198<span></span>
</td>
<td class="nump">10,075,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692046070728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GRANTS RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">$ 2,086,157<span></span>
</td>
<td class="nump">$ 3,855,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692046287896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_PrepaidClinicalTrialExpense', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">$ 135,227<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">963,797<span></span>
</td>
<td class="nump">684,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">95,231<span></span>
</td>
<td class="nump">137,782<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,194,255<span></span>
</td>
<td class="nump">$ 822,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_PrepaidClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_PrepaidClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692045581192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details) - Note Payable - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692049143560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsAwardTerm', window );">Award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales', window );">Continued payments, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsMatchingFundsRequirement', window );">Matching funds requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,086,157<span></span>
</td>
<td class="nump">$ 3,855,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember', window );">University of Utah Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Award Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsMatchingFundsRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Matching Funds Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsMatchingFundsRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692046249352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value</a></td>
<td class="nump">$ 9,073<span></span>
</td>
<td class="nump">$ 45,103<span></span>
</td>
<td class="nump">$ 5,205<span></span>
</td>
<td class="nump">$ 265,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at September 30, 2021</a></td>
<td class="nump">$ 54,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140691965146280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 18, 2019 </div>
<div>day </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>Dec. 11, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406,363<span></span>
</td>
<td class="nump">$ 26,850,021<span></span>
</td>
<td class="nump">$ 5,331,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,467,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,964,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised for cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,485,351<span></span>
</td>
<td class="nump">$ 636,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays', window );">Consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flks_WedbushSecuritiesIncMember', window );">Wedbush | Satisfy Success Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related party | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Cash payment to related party | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=flks_AtTheMarketOfferingAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,214,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,806,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,130,390<span></span>
</td>
<td class="nump">8,353,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,741<span></span>
</td>
<td class="nump">19,627,215<span></span>
</td>
<td class="nump">5,130,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of rights per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,599,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised for cash, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,298,567<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">503,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,298,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,747,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,747,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of rights per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A | Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,101,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B | Preferred Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flks_WedbushSecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flks_WedbushSecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flks_SatisfySuccessFeeDueToRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flks_SatisfySuccessFeeDueToRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=flks_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=flks_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692053599192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_WarrantsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_WarrantsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">130.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_WarrantsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_WarrantsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Outstanding, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_WarrantsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692046171768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares)</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">743,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant of stock awards (in shares)</a></td>
<td class="nump">1,026,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member', window );">2015 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member', window );">2015 Plan | Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member', window );">2015 Plan | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692048674552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Sep. 02, 2021</div></th>
<th class="th"><div>Jun. 16, 2021</div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.93%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">130.44%<span></span>
</td>
<td class="nump">131.06%<span></span>
</td>
<td class="nump">133.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140692039796056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Summary of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,563,972<span></span>
</td>
<td class="nump">166,233<span></span>
</td>
<td class="nump">166,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">743,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(45,000)<span></span>
</td>
<td class="num">(36,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,597,972<span></span>
</td>
<td class="nump">841,972<span></span>
</td>
<td class="nump">1,563,972<span></span>
</td>
<td class="nump">166,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">323,730<span></span>
</td>
<td class="nump">69,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollar per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 34.42<span></span>
</td>
<td class="nump">$ 34.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollar per share)</a></td>
<td class="nump">2.75<span></span>
</td>
<td class="nump">4.55<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="nump">$ 34.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollar per share)</a></td>
<td class="nump">$ 9.27<span></span>
</td>
<td class="nump">$ 37.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term</a></td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">9 years 5 months 19 days<span></span>
</td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term</a></td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
<td class="text">5 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 271,540<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 175,770<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 34,440<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollar per share)</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollar per share)</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1)1=KCGSN=0?P/NE$.IPHW^@./D=_@=02P,$%     @ 885D4],=S?!6!0
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M>S&:(>^Y\?\;>A[\D85(,EBG%E9E/]8J7PIM?JL8TSX.%JHCA9!A#H'CSDK
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MK' A<>$2$WL$% &*$>XQQQ[(?KK7J@4ZD$J(RL)_K8JX+*2 5&""&M)U4S4
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M_BLH7]5N4B7++TDNF9TD5;;&F75=)G%9SLV'J_L DY"$"45H -*R]]?OT]T
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MV/JJ7P/;7*#$,&$$- "?Q6+M/2<5*+(W'"K(-3EA58Z4A_H20DM8R:L%670
MW8J8RMQ7QD!95$LEK$#<'A:-]EJ@AX8SD\Z' T!:O^3"E1BBQOK'X$:1"SQE
MN[+5ZBD1>.E(!HYQX!!/5:YAI$"BK>% ^E@4$J1AV0&UYI$Q_L<A_F?GZJV%
M4^0?K(1#',AW?'R*DG@(7V,O[H!\';" $S7"S0X&Q)C1[:6[L;3GSC1COUAQ
M^ '<UQR!$@QV=UI18*#X8%+NP<M@ELPOAA*Q$YF;<C"]V!^("\!'RE3"2YYE
M$<P]\GI@*#]EXF7258DRJ*"QA+%L:3GNPGIH"[K;)" 5RMIX1XF317&#-IZ
MS(YF8O9O.?>06]HN-5AC1RIS6)(]>U'!I@3L+@6 <]%[O/%*.@IQDI@)&7E[
MX#OV)(3Z6E1-U7,!&8 Y! G!Y//P=YB9<AY(<T3+9<@M=]1VW#2A)2734'S_
M X&'K;SEO#**01.X#938V*^&2S-PA2-,]FACA &",7<G<J#8WI!/Z["CDW);
MW7-X_Q><%V=[]!2>7+9IH?/]4*[/(!2@<6W#UU LL\4RULD&Y0U2"#LU6L[?
M*(N7:@:V*B'E02H73%7*O[MI,'9BX&(K'F[@?4S7EER?ZUOQV]JL4V,1<Z):
MF#K6,Q"T)Y#5;DVAO&+)8U)COX'+H*/]AV&YJ / ^C2 @(?=V9KCBW?]4L+V
M!Z&-&I-E*';,G(>/Q0E#[ 0__'296T%JOU&!)$*YW<X#D7P$<29QL4='H0Z\
MB_6,71MV6_P_&>E[I7-E2B$-NQPY2ID1A&=4):+;K\"I)NYEH,UAA:,:N_ V
MK1M:PJJ!&]J%Y>2B-$34M[:AHA. (ZMV#U-JQH:]XQUIO:42>>2=N5S<']4R
M/0J^&HEU"'.( M;5JJ?@KSY2"E$OH(Y-GVJUPLD+PA1Q?#UD[ED>TLS*(<T\
MI062Y//0U!!EBAHR&AB3QLHH[Z @B?/#,;&#%@N(UJY&M\M5$TV\:XK%"M$:
M@05OHYM1KU34T66\INQ+(&#$B-%#YZJO5/H#KW>.QAPDA2C=W&\,.UMC%X\T
M+$O(20X7%')2L:D\Q<#43#ZV$/++FH1EOJA!#7K7%+P&VAP"RG*=M.%MQ'WL
M]*C^&I<!' V1@V'PGAU!>N=O@Z5 9ZP:$"YIS7X +<;YH"";.T6H$XL2X""-
M-/VHHI'5?6)O[HVO+/5RGE1MA^:-2[IA!AKE_*;'B%/QV6DJON,VT)NKLML4
MHSPI&CA/NQT'HA"*K8Y]G$Q\2$FOEO'<$.TMH#9X1TF:(1I3+@FPY<-$41C.
MB!\.*6[6(.92PW[CXRS5HQH<Q9T\T4";6Z7E#)+T2T=[Q3>&?,^=J/4U.\F@
M'4HDTM(XO]0H)Z*S/IM=?PX\!3XB(R?2TM79I>Z<3]A,[T)/=C+"&'FG7U#3
M&1OZS&]XP4.>'::_@"EEFCMG*WJ?<!1,(;TUN9[AI-X\1 7W&W(GX^\LY8ZB
MUO'E@K5%C]DYBMM M47XJ\>NHTGK I @KM]2?BA(4&$Z5%<)IU0/]R&[R]@>
M.0[0%6 >:]2B0R%:3##=+;6VY<B%["%E!W0TW0N(8H#@.7M1K0/QF#I#$KF0
M;F%"GC<B/5</)#%"MQZ2>AQ;C'C2\%?S/*$\K$2G4.@ \=5$:*1&$T+%QBZ.
M(?;8*+(< 8*.:=.P0D87/*,N)H;15W=5D5'-4Q'*<&[#ILK6I'@E;:L$)V+F
M5"U5Z[A86&FNPLO+@4($-'L2)JYY@"">S;,"U,P(A==2I[-9T^0DRJF"ZWW%
M0=C'U;GL9<-KM>2PO#.;H"E#9)LWCGMK;K-^AZKM@E,*F4A@D:N>B$<?M^J
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M6I?/$*53')V9!W+#QVJ4:):V;;DN66#E )635Y/B0SI=QT:6DT#!.M4Y])G
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M&'P>@%A =#)ZNS](!-N]!%O%2]3<!ES)XF.!.[!TO '?%]:&[H4-]+?JHW\
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M5GE/A8J4:55D0)CJU$0L?;*K5WLO)_YEYMD4ZBY2"G6!DF#EMV"WA.V"939
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MH@QES5!?!H3QIV*^)B1_:2M\FEMSB]Q-3F)-N?71>.YIB_>>A]:.A;%PH0!
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M#5'XJ-C"O=[VB7,3S%"&2VGK-F]/VR$YJ6?#JWD]8:^8WG!I0.":H-'1CT$
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M5P/GPH&4+DC)]9U8?Z:UGJ[A2P17]A?6M:WG0%(J+;(:C!%D+*^>Y*7.PQ8
M>78#_!K@OP5T]@#:-:#]7@^=&M!YKX=N#;#2W4J[35Q(-!GVI5B#--;(9A8V
M^Q:-^6*YJ9-82WS+$*>'HR".8IA=P_QN$D^F]\%]-)M", TACFZFT74T#J;W
M$(S'LX?I?32]@?GL2S2.)C&<A%03QM4I?(*'.(23#Z=]5V-(AMA-:O>CRKV_
MQWT;;D6N5PHF>4K3'?CP,/[R -[%5#3Y\#?Y&/D'"6-:G$';^PB^Y[=VQ#-^
M/]S;)>?_O$_^V?NK9+2;XFA;OO8>OB!)1)EKEB]A+CA+&%7P/7A46N+]_G'
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M=W4*1'V\UA/%*WM"S;G2YYT=KO2-!,(8Z/T%YVH[,8=>>\<-_P%02P,$%
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M1(4V,JO J"!CXO0EWZM G '\_@5 4 &":P&]"M"[%M"O /UK 8,*,+@6$%:
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M#7 ^D=*\=.P]73\5I_\!4$L#!!0    ( &&%9%.!K[*E(@,  )P)   9
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M3$_%[G>LXDDL7RJ8<D_85;:!!VFAM,@KL/$@I[Q\DV]5'O8 AN<T(*H T5M
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MGU!: _-]*81^F5B!NB'K_0M02P,$%     @ 885D4[8R3&/Q!P  VBL  !D
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M#UFR+KYG=I]D61(5+U?,7S">"XC/ETF2;1_RKZ[MOLY[^C]02P,$%     @
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M^L<EBLJGZ"B>V5I@QI6N+&PST=4B"+- S\\Y5T\=4UY4]>?P'U!+ P04
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MN_*RP@)FC'XGB<S&UA<+)9#BBLH[MOT*C9^AUELS*LPOVM9C3P(+K2LA6=[
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M(?%X!H'%XY4L21AF2,*/?TO0464S4VR^G]%_S8,7P6PQ(\LD_!;X_' _FHR
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M4M431XG,ZE&XPPF-I-RK34W .\&4 1=$^;E$NAK5$&X)8900 %G Q^\RJ-5
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M&*N^L)KQ-#_\ESO\4[S[!U!+ P04    " !AA6139(35>E<!  "1$@  &@
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 8(5D4X8!Q$#N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 8(5D
M4YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !AA613DV$DP5T%   %%@  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 885D
M4],=S?!6!0  61,  !@              ("!H T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( &&%9%.2>[P*[ (  ,D)   8
M      " @2P3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !AA613U5OU\8P%  #J%0  &               @(%.%@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 885D4_AM!EPL!@  ^14  !@
M             ("!$!P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( &&%9%/QG;CK? H  #5    8              " @7(B  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !AA613&Q_"-S8%   .
M"P  &               @($D+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 885D4PYND40W$@  ;C,  !@              ("!D#(
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &&%9%.#(^8F
MCP(  *$%   8              " @?U$  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !AA613'W+_\\X"  !!!@  &0
M@('"1P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &&%
M9%/V%+9?D@8  &$/   9              " @<=*  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 885D4_BI:LL^!0  KPL  !D
M         ("!D%$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !AA613:LL"?AD*  "2'   &0              @($%5P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &&%9%.4AB@&C08  -(/
M   9              " @55A  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 885D4P%% /K,#0  &2D  !D              ("!&6@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !AA613DS_3
MFN,"   L!@  &0              @($<=@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( &&%9%.9%/VH^P(  $8&   9
M  " @39Y  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M885D4QL5PQR! @  3 4  !D              ("!:'P  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !AA613@T"RO$ $  !Z"0  &0
M            @($@?P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( &&%9%-ED/<*  ,  '$(   9              " @9>#  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 885D4S"EH&4, @
M6@0  !D              ("!SH8  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !AA613>J%>X\H"  #O!@  &0              @($1
MB0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &&%9%-]
M6[%70P(  !0%   9              " @1*,  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 885D4S%;Q]U? P  -@H  !D
M     ("!C(X  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M" !AA613@:^RI2(#  "<"0  &0              @($BD@  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &&%9%.V,DQC\0<  -HK   9
M              " @7N5  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ 885D4QX-)O#U @  BPH  !D              ("!HYT  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !AA613 _I".-<#
M  !##@  &0              @('/H   >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( &&%9%,=28E/J (  $L(   9              "
M@=VD  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 885D
M4ZZK9N5A!0  81<  !D              ("!O*<  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !AA613JIRR9"D#   R$P  #0
M        @ %4K0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &&%9%.7BKL<
MP    !,"   +              "  :BP  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( &&%9%-5@,8A,P,  -<4   /              "  9&Q  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !AA6139(35>E<!  "1$@  &@
M    @ 'QM   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !AA613.6DC=8(!  !,$P  $P              @ & M@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     )@ F $$*   SN      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>127</ContextCount>
  <ElementCount>244</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS</Role>
      <ShortName>ORGANIZATION AND OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - GRANTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/GRANTSRECEIVABLE</Role>
      <ShortName>GRANTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111105 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116107 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120108 - Disclosure - EQUITY-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION</Role>
      <ShortName>EQUITY-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - GRANTS RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails</Role>
      <ShortName>GRANTS RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/GRANTSRECEIVABLE</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="flks-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - EQUITY-BASED COMPENSATION - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="flks-20210930.htm">flks-20210930.htm</File>
    <File>flks-20210930.xsd</File>
    <File>flks-20210930_cal.xml</File>
    <File>flks-20210930_def.xml</File>
    <File>flks-20210930_lab.xml</File>
    <File>flks-20210930_pre.xml</File>
    <File>slrx20210930ex-311.htm</File>
    <File>slrx20210930ex-312.htm</File>
    <File>slrx20210930ex-321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "flks-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 127,
   "dts": {
    "calculationLink": {
     "local": [
      "flks-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "flks-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "flks-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "flks-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flks-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "flks-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 273,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 10
   },
   "keyCustom": 12,
   "keyStandard": 232,
   "memberCustom": 5,
   "memberStandard": 18,
   "nsprefix": "flks",
   "nsuri": "http://www.flex-pharma.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - COVER PAGE",
     "role": "http://www.flex-pharma.com/role/COVERPAGE",
     "shortName": "COVER PAGE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111105 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116107 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120108 - Disclosure - EQUITY-BASED COMPENSATION",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION",
     "shortName": "EQUITY-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - EQUITY-BASED COMPENSATION (Tables)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables",
     "shortName": "EQUITY-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i928284c249a945d7b73742e4cc3089e5_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i928284c249a945d7b73742e4cc3089e5_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - GRANTS RECEIVABLE (Details)",
     "role": "http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails",
     "shortName": "GRANTS RECEIVABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "flks:PrepaidClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "flks:PrepaidClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i3365ee0645e1428a8bf15e40c57c905e_I20200731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i3365ee0645e1428a8bf15e40c57c905e_I20200731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i88ae7eac7ac445aebc542f0429384d0a_D20160701-20160701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "flks:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i88ae7eac7ac445aebc542f0429384d0a_D20160701-20160701",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "flks:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i928284c249a945d7b73742e4cc3089e5_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i56f1fbc10f714bacb40851d5e79f0484_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i38ec404e1c2a4fa19e8f881a89360a33_D20210308-20210308",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i38ec404e1c2a4fa19e8f881a89360a33_D20210308-20210308",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ic6b4f85b5e2f4b0da127ab2e310c28a8_I20210930",
      "decimals": "4",
      "lang": "en-US",
      "name": "flks:WarrantsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ide8e9f771fc84abd8174ee9adf648b55_D20210902-20210902",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibd2d8321a77d4b7183c01e97fbd7fe12_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "ibc576fa0a40d46a09cde34e4add1d831_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - EQUITY-BASED COMPENSATION - Summary of Stock Option Activity (Details)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i928284c249a945d7b73742e4cc3089e5_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i928284c249a945d7b73742e4cc3089e5_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i8d20dc51e5fe4ea99139098eb7f83411_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i3c9a0133c9314c65b306d8c564cc536e_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND OPERATIONS",
     "role": "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS",
     "shortName": "ORGANIZATION AND OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - GRANTS RECEIVABLE",
     "role": "http://www.flex-pharma.com/role/GRANTSRECEIVABLE",
     "shortName": "GRANTS RECEIVABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20210930.htm",
      "contextRef": "i89fd4bdeae774541b418a364c3a450ac_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 23,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "flks_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the Market Offering Agreement",
        "label": "At the Market Offering Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Threshold Consecutive Trading Days",
        "label": "Class of Warrant or Right, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdConsecutiveTradingDays",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "flks_EquityIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2015 [Member]",
        "label": "Equity Incentive Plan 2015 [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2015Member",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_PrepaidClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical Trial Expense",
        "label": "Prepaid Clinical Trial Expense",
        "terseLabel": "Prepaid clinical trial expenses"
       }
      }
     },
     "localname": "PrepaidClinicalTrialExpense",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_PrepaidExpenseFinancedByNotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense Financed by Note Payable",
        "label": "Prepaid Expense Financed by Note Payable",
        "terseLabel": "Prepaid expense financed by note payable"
       }
      }
     },
     "localname": "PrepaidExpenseFinancedByNotePayable",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Award Term",
        "label": "Revenue From Grants, Award Term",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "RevenueFromGrantsAwardTerm",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "flks_RevenueFromGrantsMatchingFundsRequirement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Matching Funds Requirement",
        "label": "Revenue From Grants, Matching Funds Requirement",
        "terseLabel": "Matching funds requirement"
       }
      }
     },
     "localname": "RevenueFromGrantsMatchingFundsRequirement",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales",
        "label": "Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales",
        "terseLabel": "Continued payments, percent of net sales"
       }
      }
     },
     "localname": "RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_SatisfySuccessFeeDueToRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Satisfy Success Fee Due to Related Party",
        "label": "Satisfy Success Fee Due to Related Party [Member]",
        "verboseLabel": "Satisfy Success Fee"
       }
      }
     },
     "localname": "SatisfySuccessFeeDueToRelatedPartyMember",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_StockIssuanceCostsAccruedAndAmortized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs Accrued and Amortized",
        "label": "Stock Issuance Costs Accrued and Amortized",
        "terseLabel": "Accrued issuance costs for public offering"
       }
      }
     },
     "localname": "StockIssuanceCostsAccruedAndAmortized",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised for cash, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "flks_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised for cash, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_UniversityOfUtahResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Utah Research Foundation",
        "label": "University of Utah Research Foundation [Member]",
        "terseLabel": "University of Utah Research Foundation"
       }
      }
     },
     "localname": "UniversityOfUtahResearchFoundationMember",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_WarrantsOutstandingMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Outstanding, Measurement Input",
        "label": "Warrants Outstanding, Measurement Input",
        "terseLabel": "Warrants measurement input"
       }
      }
     },
     "localname": "WarrantsOutstandingMeasurementInput",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_WedbushSecuritiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wedbush Securities Inc.",
        "label": "Wedbush Securities Inc. [Member]",
        "terseLabel": "Wedbush"
       }
      }
     },
     "localname": "WedbushSecuritiesIncMember",
     "nsuri": "http://www.flex-pharma.com/20210930",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r162",
      "r172",
      "r208",
      "r209",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r341",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r162",
      "r172",
      "r208",
      "r209",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r341",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r162",
      "r172",
      "r198",
      "r208",
      "r209",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r341",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r162",
      "r172",
      "r198",
      "r208",
      "r209",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r340",
      "r341",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r242",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r239",
      "r240",
      "r241",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r66",
      "r111",
      "r114",
      "r120",
      "r127",
      "r147",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r255",
      "r259",
      "r280",
      "r294",
      "r296",
      "r323",
      "r331"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r34",
      "r66",
      "r127",
      "r147",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r255",
      "r259",
      "r280",
      "r294",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r214",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r23",
      "r56"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r50",
      "r56",
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r50",
      "r281"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r64",
      "r66",
      "r85",
      "r86",
      "r87",
      "r89",
      "r91",
      "r97",
      "r98",
      "r99",
      "r127",
      "r147",
      "r152",
      "r153",
      "r154",
      "r158",
      "r159",
      "r170",
      "r171",
      "r175",
      "r179",
      "r280",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of rights per share (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r145",
      "r326",
      "r336"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r146",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollar per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 45,172,535 and 23,810,541 shares issued at September\u00a030, 2021 and December\u00a031, 2020, and 45,172,535 and 23,808,546 shares outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r102",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments and Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r258",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r160",
      "r164",
      "r165",
      "r288",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r54",
      "r110"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation, amortization and impairment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r67",
      "r150",
      "r152",
      "r153",
      "r157",
      "r158",
      "r159",
      "r292",
      "r325",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r43",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r83",
      "r85",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r269",
      "r270",
      "r328",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share, basic ( in dollar per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r43",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r85",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r269",
      "r270",
      "r328",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share, diluted ( in dollar per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r39",
      "r40",
      "r41",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r96",
      "r128",
      "r186",
      "r193",
      "r239",
      "r240",
      "r241",
      "r252",
      "r253",
      "r268",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r342",
      "r343",
      "r344",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r54",
      "r166"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "negatedTerseLabel": "Change in Fair Value",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Variables Used in Black-Scholes Model"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r272",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r274",
      "r275",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r272",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at September 30, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r277",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r131",
      "r133",
      "r296",
      "r322"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r54",
      "r132",
      "r134",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r54",
      "r138",
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment charges of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r45",
      "r55",
      "r75",
      "r76",
      "r77",
      "r78",
      "r88",
      "r91",
      "r254"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r53",
      "r307"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Grants receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r49",
      "r51",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r66",
      "r115",
      "r127",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r256",
      "r259",
      "r260",
      "r280",
      "r294",
      "r295"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r66",
      "r127",
      "r280",
      "r296",
      "r324",
      "r333"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "GRANTS RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTSRECEIVABLE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owner"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r50",
      "r52",
      "r55"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r36",
      "r37",
      "r41",
      "r42",
      "r55",
      "r66",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r81",
      "r82",
      "r88",
      "r111",
      "r113",
      "r116",
      "r119",
      "r121",
      "r127",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r270",
      "r280",
      "r327",
      "r338"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Application of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Note Payable"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r111",
      "r113",
      "r116",
      "r119",
      "r121"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss before other income (expense)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r33",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other prepaid and current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Government grants and other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r214",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollar per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r6",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Proceeds from issuance of equity securities, net"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrants exercised for cash"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r139",
      "r296",
      "r329",
      "r335"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r14",
      "r20",
      "r296",
      "r334",
      "r347"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Grants receivable from CPRIT"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r206",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r206",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r206",
      "r291",
      "r293",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Payments on note payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "terseLabel": "Cash payment to related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r245",
      "r308",
      "r351"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r193",
      "r242",
      "r296",
      "r332",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r128",
      "r239",
      "r240",
      "r241",
      "r252",
      "r253",
      "r268",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r108",
      "r109",
      "r112",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124",
      "r195",
      "r196",
      "r309"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from contract with customer, product and service"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Grants Receivable and Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in dollar per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r214",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r220",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r31",
      "r64",
      "r97",
      "r98",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r179",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant of stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted-average exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r222",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollar per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r212",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted-average exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted-average exercise price (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r214",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r210",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r232",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r60",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r64",
      "r66",
      "r85",
      "r86",
      "r87",
      "r89",
      "r91",
      "r97",
      "r98",
      "r99",
      "r127",
      "r147",
      "r152",
      "r153",
      "r154",
      "r158",
      "r159",
      "r170",
      "r171",
      "r175",
      "r179",
      "r186",
      "r280",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r32",
      "r39",
      "r40",
      "r41",
      "r70",
      "r71",
      "r72",
      "r74",
      "r80",
      "r82",
      "r96",
      "r128",
      "r186",
      "r193",
      "r239",
      "r240",
      "r241",
      "r252",
      "r253",
      "r268",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r342",
      "r343",
      "r344",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r96",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Preferred shares converted to common shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r186",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of equity securities, net (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r186",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation and services expense (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r186",
      "r193",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Preferred shares converted to common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r186",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of equity securities, net",
        "verboseLabel": "Shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r213",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation and services expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r66",
      "r125",
      "r127",
      "r280",
      "r296"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r171",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r100",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r84",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r83",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r352": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r353": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r354": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r355": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r356": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r357": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r358": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001615219-21-000093-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001615219-21-000093-xbrl.zip
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MA/L+AGD+AF%(.@[2G6,#:H+A ! 2#,L%,9PJ%"A7^#491@@5A<=&HL"8)\S
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M#N&YTTD)EP&2&[5N%Y \U &:VZUFLB;K%UD R_(BVTJZ.9US\SUDZZ9K^CM
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ME'JKTPF=V\,:<F*AQ+.^&H/?X*7-[(_BYIOMI2KXQ0X#>#8T#\'GR JN[Y^
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M<BL=3B>>.8Z%$-:CI=4/;=/L9NV^H71E)_WHSS,VDLQ5WLH\99YHHHABCC#
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M^OSUP8NG.[_O=T="XL7NTUG(MV/D3_=VGSW?W7_^K(._[>_]_N+9S@'^L7^
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MSZ^E-$BM#'(7^$]EK1_L?-L]>/_.1.>%2)G8Y!@!&Q.Q)FL2@E(R6HOZ22S
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M..4Y,5FEY#E89_C6-BC35;8B[*&EU]W@5?M_+1U D^0-QY.@'F%C(J4(((\
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M);I*,$LA&)^5AXBT$I.#S)G)@6<AH[$Y>QIN$:9?":9-!#/MH'&ZG$,Z(,9
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M-R.-2?^?O3=O:B/9]D6_BH)X]YWN")*=4U5E=L=U!#;8E[XM\("['_Z'R*E
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M1%=/ 3LYE?)=L(1XZ=0:HB</3ZC>JGW-(IF)/OX(ZU+AGYN@A^:@1CPS!0W
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M;P\'<:SOL(]CF](EC\<<?G 9^'T/'"14+CX4)',<C& ;)-%>*D*I-%1JEO/
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MX#YU@[6=_;.AWP,9,Z[F3KIA+#"+XB 9,JA:FRF\O:9%;6KXL3/CPVH0,_R
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M&H['">DH^-3_>VO@;*45#> MB4QYF94&2)L[J[C-,^Y+S:(LH2!%HBR)/_P
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MUX5GECN5*UN$*\3)L@_^3NFGRT"8F)+;@*972?."R  VORY,(%85*IA">*K
MW,_7%FC/IA'^'IN16YKM'D:]_GQ-WF3;LD73<*<"H["J]=/X<3=-$6HZK-<;
M!S[&._^&XQS8L]%!9_?0](_-8-#Y?\WQR9]P6YRY[M8Z'ZLANKTIYW]ZS'L\
M 7AL<N7PH'"*^VHE%'K'24' _ZY>HD]B]'?V'>/-_CH#V<$7O739Z\?A3,,X
M^_(,1U.?@$63AK0W:<H/FZ]P :-PT!N?5M&*AI+B:DT]#*45#CDT7]+G\-[P
MX@<XGF.^[C^YG1<+ML45.4QF&7*3!TT'HM=8G/$I3"F$<R4O*KP@3C-2__"
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MX61DUPWC9+$@YJ=.4[JU55M3+8B#X.L@1H-^R1Y-X=3#F[N?L^V#?9?17.#
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M/1 #/:_?\AN>'/1&PZ WDEZ3\C4>7:$_I ;?AMW_9K/[KM<$5;TQJ+5;/1Q
MU&[7ANV^5PN\AFBU&LU6T.I2<O"@=VB*]9#)P;<BP$-R\+Y0X,)08*_;\66[
MUZU)T6S7VH/^H#8<^GWXJ=$;=?M^(#H^I0<?VF+==7KPK8R<0WKPGM/>!RM
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MYL$.)\"J0/TH;!)SYN=>86(M&65Z$0L.J\'],DQ,GIF^@?> PLHZ:]+757?
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M94#H-P%!8/OL.BJ,"Z\/F\$1W(#MM /&\[&@>#B (R39?F1MAOV,1GC!"K6
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MSEWDI R\A\A)V;?TDR>::7*KI)*M\^&W6/?>0XE$*>=GOWPXN?CR^<WY=YY
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M@\!*7GBB#EH<+R_E^T%_^^7_ 5!+ P04    " !AA613GMLF].<C  !7@ $
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M<A:(34D19B@Z""DPK]>PS%["V=CN2V?&ON-GKZKT*B'9+5#3@&(>6%7W9&8
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M!1*\2R0:S2'XJ V;*Q-X>\PZXX2QGE4746'7FTN?AOWV<J3)^4'^-/$GA]
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MMBI6.H^?!>FI+*C=ZKY"!=_UBF1_BK]>JT#^WAGO4815MU,>Q[BAO95NC/I
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MO[_)__A3,7Y]F\CESUYRJ0X_=I+G6T\U*(E!&:8&Y;\>,_;#&? ]X9WO8_4
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MYGQ<R$>MEG(4*IFBB'"89E$$]=\PI()0&#&><8D)9<AOCA;/#@Q-YE;G>:[
M[S5L2"O<0-; P9M!7BX@B=ED0G/P)O-J+<GW4I+OU\73$M,%7X(!+#TUA^&<
M.C5T!994@)H+L"0#E&STN"S543OVNUSEVXEA+6-UU$3.RUM=X1A0W,#?9WI8
M8*+HW\L=Y2B)24(3 =,0QQ"AA$!,I4E_AF,]UN=88+=PU.XQ#ZTW7:,;0+C
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MCX,6+U/AH\GYHY4]&F\Z<S3]85SPR<R(6K'*?1M*%*981M D%S9'/Q)(:91
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M%G%J\LMB12 2/(8D8!*2I,PRJW_C5L_]E,'!2<IW,W+00YS)6.D9R+NDN6O
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M .Y@=].>'[_G*D^;[?< I34->R<E[>]LOSMJLL=LKP+OIE0CL9:4.&$01Y)
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M%XOO!Z-)@?B>+0^81&U3!Z.Z\I.)XHK,YX)_>KLF[.G]L[. )HB$JI^3&*<
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M2Z.%?A\U8#?N^_@#/9.'Z:2TC^K=<L^-Q D)DE0"JN_P(P+53X)A0)3[(H1
M&,615;*PW=:GYG24RGE:.ZM=RN/(F<WFO?%P/!+-H;#/\'7,Y&$S>KV3,&X&
MKV/&'63L.OI0C_S/ORXR-?"+;/5V*W]=D:=[40C5PM/GY7I135!-2 61L8QH
M"D@<4X"DWF[ D /L)[Z4OL08,>/TSZ92IS:\MWIK7U!K[C6J>UO=+7(3&\/?
MS07.0'7,$69XG@[R. -8BYS/+@ >*>7SF1^N7:IG6YPZ,ST;-S9>HF=;^][E
M>;9^N7=(JQ1YKA83NG) _:T3F, @0A3$/N$ 89B")(4Q("&)0QGYH?"M2ID<
M$S(URM[H6)7*L YL/431S"T[%QO'S+L'BX,TK%T #!WK>BAH['C75E./Q+RV
M/SMD2O>=T*2B+J?V:;^<VFU50:TZG[U9W(D\6_*_"WTQ7_!+Q5/DF[C^0^0L
M*\1=GC&AW$!(*9$!B 7V 8I8 BB#(0A90B.!(TD2J]7<B+I/C9E*S06_\+[7
M2@-2:>V)6FWO1>M=)C[AR_F<Y-Z+R*L<*'TJ;H[TB9CQXT0[WC'MFM3D+$X4
MY;QMJG#6817JZZ@PN/ :%+P:!J_!P2N!<)V1WVGOC9#FWXW^$Z@=X+1CS H2
MN%6AW\3Y\W+)OV?S^2Q,],55GP.?(0P0U&F ?1J %/O2YR*D"$J;6:UI>')3
M3JV7W>2Q@<F,V?L8[YAV3]IM38#[1@[*3IO&1Z6.?9/VQ_7!OSOR5D^PP^UZ
M5>A;U=GBV\UBE6>+(F-52GL!41*G@0 I%!% ,M*5>FD$>!I&,(DICRUS3KC2
M=&JTL*/HA4>^?<O+T%#E6-1*>Z^=^?)'[N:!_,LQ.F\"WJ2I,_GN&]A8/'2E
M!.>],JZ7V%O;:?F$YX)N[0&>+?!CII[K/UZRO'QGXYW.9)@&,6$01"0IS\5\
MD.@:\9!&+ UA% B$>\3Z.U#5B+C&OQQ0:JJ(J7=Z5Q>].LX<T[>3_OUFEQU+
MM_L5TYE6.CIB4A/*,3W_K::2#J"'GD2Z1/6;/G;NWMTL7M:K3:".SX,08H)!
M&C()$!9J.. 4 18C&L% ZCUSFX5'FZ"IK1MV+R.6BO:/?&K%UHR)AT#,,9WV
M \N:"D\A,2B?M0H;E91.F;S/+">?[YL!<\G^];2<JS>*JK#P#!(A",$)"$B,
M 4IC#@@E'/@T2J!(& T1L;FC=2C"BA)&NZI5[.CYY[*2H6EFZBXP(X@YB@4@
M@?0!XCP 1-($I''LXT1P7:1Z]E(2_<.*Y*LQ(-T7YP[83^);MECHW'>4S.U3
M=!W!,TZ0C]2'"2)!H,(SPLJ)P[[Z5E.AX$R%2&6-Y_6"CX=F(\SADJ-<6@X&
MI.%BX2QH7/OZ[P9LI9YWN5)K;[I>Z:L%WFI9WY 9,IMK&R(#9W0]$#-R5M<V
M,P\SN[8^.8S'6AZ:_;:<*[=XKEIOPL)B3IG  L PT/OF,0.IWL((<,H8HARF
MR"HLS$CJU'Q97;2>Z:/SUXVBYWFPQ['NY\Z>C>#8ONU%%7#@;75V$&%FA9)3
MO_>XY ]U@CO!..41=[_<CXL^DRPO-W&KK/.7B]WJ7+4"_'9QKPM0Y&IZ5@]\
M72[RYJ]JF9\5^OUR2?\HV-,B^[^U*,J+;]M$R&F 1(A@!!+*%)<%5 *BLR*P
MB/G(IV&H?F/#9:-H/34N?&!/@J^K>BJ_D3PK4U=XO^H-OFSA?9H3]B^@GEGJ
MW_ZRY,(RGF"<+\&,:2?7OXZ96MM;'>IY!Z1=%9+<6.-MS:EO.KO)JSUJ%PPZ
M#8RC^:C3R*B=L3\-C2O\C%V>FZ)8"_[36DNMMI;+K>BB^OWG9?X@\E<UA18S
MM9:.(Y]SD!*< @35S$2BB #)8X1I0@F-K7QK._%3FUBVMPZ:,H_+Q:O(M=NM
MUI=L^?R\; X!SS@/M.LAB]6[$]S'6-E[E89>I?HF7+C2_J+Y5[G,O<:"@5?Y
MUL@-OP-@KL+XNP/6\!S=.;!OI6^R(SU.2Y&[ F9Q%+ D%@'@H0R5[XU2D @>
M 1J')($TD@&UJNS6(F=JI'95TY;6\Z)AKZP:4OUKUK9@;,96 R#GF)9JT!XJ
MT-X3T9#Y=#IQ&#@;SG%9(^>RZ33X,!--]^-#W#U]]_F2.$$IDA@H'P@#1'T$
M2)!2( ,81RR(0QDD_6^@3IDE=ER?08FB VPSKA@&0L=TL7==M6&,P0GC-!@.
MKZY^'&V<-KO[&NN Y+%-G-X=]D-;PW[*^T%ZR?<^=C28P9 2@8,0A!Q+@$C*
M 65I"&@:$RYE&H2I;WT_P(FJ4R.O'4V'O2#@IJ,-EW23Z#[7R[]!@SAWO@*W
M5P2<=LOP(9UNU!T_LM,I[$<#/-U*[)F_CO]S7:S*FZJ/RWNA <SFXJM8W2S8
M\EE\61;J]U>D>+K+EZ\9%_S3FSX;N5G<O@@=<;KX=LE6V6NY:[E)J<B3!-,X
MPD!--#Y OJZ;FL8)8 CB% F9P, H?Y9+):<V[>S8J/<'\\9*;R%6WGQ9E+_5
M/S-EI[>NSZ>6C8$>V5CX%\L\?"Z^ +-9Z:/[U?%\M->E&P/+?+J5B=X/VL@?
M]3]K.[W&4#U-_5 ?0O[H;<SUMO8Z*<'DLD.&S5GH0M%Q4Q\ZA/H@@Z)+64,%
M$&^X(R0TB*&  "(4 802!$B$*6 <<DBEX#*R"FMH%S6U.>!]9&(52FS)YAVX
M6AS^G(W6& <]9B&<3GCR-$B.HSH_AK-.FWTZRG,@_OBZ7(E".<JZLZ_6N>[I
M6<@HQ!A2$$@8*^*0'% )(R!PP-,4*1?4QS;$<43&U!A#J^B]5"K:$<4Q ,T8
MXDQ8'%-#J9U7JW?AU0H.-_0[K!]TS!^3,VY]^W9##TK8=SS:(T_SO7@5B[7X
MK%2JTB/5O] K9'W<6Q>9O%HNE&NRWE:=O%-K9%U"0"K/YH'H4FF42K4050X$
M3"0!B BN%J*2 A2E":)AB /$C1,Y#Z;6U$ADH[%FDE+E"YU\3RNMHR+UHK,@
M7=777'9A-R=]7,<XIK':!$\;52>_N_#J7X*B,JS9O%3_LNW"[>_NMEVH%YP/
M']:%%FFG/Z0K1\I+/7:7VB6R'ASYSDS7PTD;+Q7VX B]RY4]?.L]\P1JX587
M>';>F!"!EEHYN(ASQ-IA\^'MM#]N2KQ#PPZRXAUYI.TKVT7\B_KIKW]J?J/^
MIX\Y_OJG_P=02P,$%     @ 885D4QM:9:.M1@  Y"(# !4   !F;&MS+3(P
M,C$P.3,P7W!R92YX;6SE?6EWF[ERYO?\BIX[7P>WL2\Y2>;(LMQ7)V[)D=2W
MD_G"@Z5@<YHB?4G*;>773X$BK5WF\D(OZ+DG<<N23-3RH% %U/(O__OKY>BG
M+S"=#2?C?_T+^RO]RT\PCI,T''_\U[_\=O&.V+_\[W_[IW_ZE_]!R'^^.7O_
MT]M)O+J$\?RGPRGX.:2?_AS./_WT>X+9'S_EZ>3RI]\GTS^&7SPA_[;X1X>3
MS]?3X<=/\Y\XY>SA3Z?_[(0(8*TB&2(E4DA-K 5!G,XI.*6Y!?N_/OZS\%18
MQPP),F4BK<[$9OPJ2Y88C3QF:Q8?.AJ.__CG\D?P,_@)F1O/%G_]U[]\FL\_
M__///__YYY]__1JFH[].IA]_YI2*GU>__9?EKW]]]/M_BL5O,^?<SXN??OO5
MV?"I7\2/93__YZ_OS^,GN/1D.)[-_3B6!6;#?YXMOOE^$OU\(?/OTO73L[]1
M_D96OT;*MPCC1+"_?IVEO_S;/_WTTXTXII,1G$'^J?SWM[/C>TOF$7PEGS_Y
MZ:7_:YQ<_EQ^Y^?#T[\?G7TX^.4(*5Y\POSZ,_SK7V;#R\\C6'WOTQ3RO_XE
MC_Z8D:):Z@0MZ_[/VW_\\RT)GZ<P0]0L6'Z/WUA^1EEM:W+@ZQS&"6XX72TT
MFL1[OS0J<IY,5_]RY .,%M\=)!@.#B<(_8,PFT]]G ^,<"9R",3EQ(@$,,0Z
M'XFEQO$0M9;1WN>^4#Y#TA=JF4'\Z\?)EY_Q@W\N$BE?+$2S$,NCY6[$LQW=
MJUUX@;\[\"8Z)A0C*@4DVP,0RP4GU!@7(BBJ>-Z)[+NKW:?ZKEH/IO&GR33!
M%,W(:CD_C8]4?!_"R]_X^;.?X@>1^&DX2JM_7>Q)%[J:3SJ0W(U:D-R__(1<
M9YA.(;V_T<JSS"TXFZ-QA<5O=J'Q_[CR4_S$T?49?)Y,40X&[6<RCAAET7YJ
M*4B(*1+0PM!L@Q+*=*+\!PNOA0/>/@YVD6<CD/@ T^$D'8W36SR0!]9X",$S
MXE3$DS(IA0Q(26S \U, @ #="2#N+;L6'$3[<-A>EHV X6+JQ[-A$?P2T,(@
M_XFA"(1WR(,$$E*01-D / )'/ZL;/#Q<>2U(R/8AL9-$>T;%T7@^G%^_&X[@
MY.HRP'00(+*@#2):)\ 3SW-BT<B13%-QNS-U=+?CXN&*:Z% M8N"G238A/;/
MX..P"&$\/_&7:-.8CRQQ/-NXEWC ,4<<>$%BL-E*Z;S:T6%X:M6U4*!;1\$.
MDFP""<<8V$_1A"T$?X[RA\/)U7@^O3Z<)!C$;(+47"$[-!!I("'$450)4&3.
MLQAXZ  8+Q*Q%DY,ZSCI3LY-P.;"?SU.*+YA'M[<62PMH=?1>LXR 6:1&VJ
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MJ/54W !^7\[BBL8S(<KP @:12)XC\;0D=5%MA*)).M-J+EV]6;6MX;,[%3:
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M1<^[2"QGCG@1%(^9\1CK'-<O4;7?P<8F.'O^JF='735PA-_G /_1P=?A;)#
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M9'K#1(]!SFPZ'WQC:G%]&6V&X'P@N5P428!,G,/H+'#TQ)7@.:BU7O;QD^\
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M-V?FHQ% Q&+:@<J66.DYX=9&G;U,+JZ5Z+?6P)QOR_;K#G?MPFPOT19@L H
MN? 2J"6%?"*CUL12)DC@)OH,V4C6,1#ZGH^SI<H>*GT+^?6L]E^'X](.?TFX
MXM10J]!.!82]Y#P0EQB&_U)'+:))GJ_U7+:6XN\MW;/JMU'<I LI-N RW/;2
M+3V][]Y81S1R+FD\Q3@KV8U@B(M)$4<C#1&T5;'2T^)S)/7;SKU:O-N)!EJ
MTBWY)_X2O[R8^O',QZ*@I:N5@P?+,'[3Z$NCOY48L:4[*>/(D+<Z19OJ8.J[
MM/4<!7<#@H?0ZE8C#6#L] M,#T:CR4U9P^<[(^>LSU($%XAPIG2!I^F&$1D$
M-<8$-.RV"K2>):EG1'6L^TD-1?0]%>)@?O$)?O73/V!^FG'YDGCV<0J+^ZA5
MHQSJ1-# 2 HR$"F5(SZ4V@.?/671R[CF5)/OK]7S?6X=P-20<P.&Z Q&I<3I
M@Y_.K^\(:O;F^NY/%A:<1\%,=)9H ;@-LL\D*$-)")Z6YB607)U#;WT:^YU
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M+BBJWUAP^8/R1^'EW_[I_P%02P,$%     @ 885D4Q=]F2CP!P  CB(  !8
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MW$0:**B [2[*.YJT7XV58>_K8P4=VA7ZE3'9SN?F3SNV264CX97=?PKE[UC
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M"&Y9^NTA[_BBH/J-WS>$+RTN_@M02P,$%     @ 885D4P,"^  "!0  OA@
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MZI])(=5P(W1_(]OBS4C!Q7+X8D]Q(EYT-<Z.IYGBLZ99\[\8AHJNW>.BR62
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MQC#Y&U!+ 0(4 Q0    ( &&%9%-"_Q=#"3 ! #+""P 1              "
M 0    !F;&MS+3(P,C$P.3,P+FAT;5!+ 0(4 Q0    ( &&%9%,Z#!73>@D
M .!/   1              "  3@P 0!F;&MS+3(P,C$P.3,P+GAS9%!+ 0(4
M Q0    ( &&%9%-ZZY2O+@X  .UU   5              "  >$Y 0!F;&MS
M+3(P,C$P.3,P7V-A;"YX;6Q02P$"% ,4    " !AA613GMLF].<C  !7@ $
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G,#(Q,#DS,&5X+3,R,2YH=&U02P4&      D "0!6 @  9$,"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
